id	sid	tid	token	lemma	pos
cord-335140-njg0ln33	1	1	key	key	NN
cord-335140-njg0ln33	1	2	:	:	:
cord-335140-njg0ln33	1	3	cord-335140-njg0ln33	cord-335140-njg0ln33	NN
cord-335140-njg0ln33	1	4	authors	author	NNS
cord-335140-njg0ln33	1	5	:	:	:
cord-335140-njg0ln33	1	6	Freeman	Freeman	NNP
cord-335140-njg0ln33	1	7	,	,	,
cord-335140-njg0ln33	1	8	Ciara	Ciara	NNP
cord-335140-njg0ln33	1	9	L	L	NNP
cord-335140-njg0ln33	1	10	;	;	:
cord-335140-njg0ln33	1	11	Mikhael	Mikhael	NNP
cord-335140-njg0ln33	1	12	,	,	,
cord-335140-njg0ln33	1	13	Joseph	Joseph	NNP
cord-335140-njg0ln33	1	14	title	title	NN
cord-335140-njg0ln33	1	15	:	:	:
cord-335140-njg0ln33	1	16	Covid‐19	covid‐19	NN
cord-335140-njg0ln33	1	17	and	and	CC
cord-335140-njg0ln33	1	18	Myeloma	Myeloma	NNP
cord-335140-njg0ln33	2	1	:	:	:
cord-335140-njg0ln33	2	2	what	what	WP
cord-335140-njg0ln33	2	3	are	be	VBP
cord-335140-njg0ln33	2	4	the	the	DT
cord-335140-njg0ln33	2	5	implications	implication	NNS
cord-335140-njg0ln33	2	6	for	for	IN
cord-335140-njg0ln33	2	7	now	now	RB
cord-335140-njg0ln33	2	8	and	and	CC
cord-335140-njg0ln33	2	9	in	in	IN
cord-335140-njg0ln33	2	10	the	the	DT
cord-335140-njg0ln33	2	11	future	future	NN
cord-335140-njg0ln33	2	12	?	?	.
cord-335140-njg0ln33	3	1	date	date	NN
cord-335140-njg0ln33	3	2	:	:	:
cord-335140-njg0ln33	3	3	2020	2020	CD
cord-335140-njg0ln33	3	4	-	-	HYPH
cord-335140-njg0ln33	3	5	05	05	CD
cord-335140-njg0ln33	3	6	-	-	HYPH
cord-335140-njg0ln33	3	7	19	19	CD
cord-335140-njg0ln33	3	8	journal	journal	NN
cord-335140-njg0ln33	3	9	:	:	:
cord-335140-njg0ln33	4	1	Br	br	CC
cord-335140-njg0ln33	4	2	J	J	NNP
cord-335140-njg0ln33	4	3	Haematol	Haematol	NNP
cord-335140-njg0ln33	4	4	DOI	DOI	NNP
cord-335140-njg0ln33	4	5	:	:	:
cord-335140-njg0ln33	5	1	10.1111	10.1111	CD
cord-335140-njg0ln33	5	2	/	/	SYM
cord-335140-njg0ln33	5	3	bjh.16815	bjh.16815	NNP
cord-335140-njg0ln33	5	4	sha	sha	NNP
cord-335140-njg0ln33	5	5	:	:	:
cord-335140-njg0ln33	6	1	700558e4e630211dbcc8d6cfe73ee58674e5661a	700558e4e630211dbcc8d6cfe73ee58674e5661a	NNP
cord-335140-njg0ln33	6	2	doc_id	doc_id	CD
cord-335140-njg0ln33	6	3	:	:	:
cord-335140-njg0ln33	6	4	335140	335140	CD
cord-335140-njg0ln33	6	5	cord_uid	cord_uid	NNS
cord-335140-njg0ln33	6	6	:	:	:
cord-335140-njg0ln33	7	1	njg0ln33	njg0ln33	NNP
cord-335140-njg0ln33	8	1	The	the	DT
cord-335140-njg0ln33	8	2	pandemic	pandemic	NN
cord-335140-njg0ln33	8	3	has	have	VBZ
cord-335140-njg0ln33	8	4	affected	affect	VBN
cord-335140-njg0ln33	8	5	every	every	DT
cord-335140-njg0ln33	8	6	aspect	aspect	NN
cord-335140-njg0ln33	8	7	of	of	IN
cord-335140-njg0ln33	8	8	myeloma	myeloma	NN
cord-335140-njg0ln33	8	9	care	care	NN
cord-335140-njg0ln33	8	10	.	.	.
cord-335140-njg0ln33	9	1	Immediate	immediate	JJ
cord-335140-njg0ln33	9	2	focus	focus	NN
cord-335140-njg0ln33	9	3	is	be	VBZ
cord-335140-njg0ln33	9	4	minimizing	minimize	VBG
cord-335140-njg0ln33	9	5	risk	risk	NN
cord-335140-njg0ln33	9	6	of	of	IN
cord-335140-njg0ln33	9	7	contracting	contract	VBG
cord-335140-njg0ln33	9	8	COVID‐19	covid‐19	NN
cord-335140-njg0ln33	9	9	and	and	CC
cord-335140-njg0ln33	9	10	the	the	DT
cord-335140-njg0ln33	9	11	sequelae	sequela	NNS
cord-335140-njg0ln33	9	12	of	of	IN
cord-335140-njg0ln33	9	13	infection	infection	NN
cord-335140-njg0ln33	9	14	.	.	.
cord-335140-njg0ln33	10	1	However	however	RB
cord-335140-njg0ln33	10	2	,	,	,
cord-335140-njg0ln33	10	3	what	what	WP
cord-335140-njg0ln33	10	4	does	do	VBZ
cord-335140-njg0ln33	10	5	the	the	DT
cord-335140-njg0ln33	10	6	future	future	JJ
cord-335140-njg0ln33	10	7	hold	hold	NN
cord-335140-njg0ln33	10	8	for	for	IN
cord-335140-njg0ln33	10	9	our	-PRON-	PRP$
cord-335140-njg0ln33	10	10	patients	patient	NNS
cord-335140-njg0ln33	10	11	?	?	.
cord-335140-njg0ln33	11	1	What	what	WDT
cord-335140-njg0ln33	11	2	lessons	lesson	NNS
cord-335140-njg0ln33	11	3	will	will	MD
cord-335140-njg0ln33	11	4	be	be	VB
cord-335140-njg0ln33	11	5	taken	take	VBN
cord-335140-njg0ln33	11	6	forward	forward	RB
cord-335140-njg0ln33	11	7	to	to	TO
cord-335140-njg0ln33	11	8	tackle	tackle	VB
cord-335140-njg0ln33	11	9	myeloma	myeloma	NN
cord-335140-njg0ln33	11	10	in	in	IN
cord-335140-njg0ln33	11	11	the	the	DT
cord-335140-njg0ln33	11	12	fiscally	fiscally	RB
cord-335140-njg0ln33	11	13	constrained	constrained	JJ
cord-335140-njg0ln33	11	14	future	future	NN
cord-335140-njg0ln33	11	15	?	?	.
cord-335140-njg0ln33	12	1	If	if	IN
cord-335140-njg0ln33	12	2	we	-PRON-	PRP
cord-335140-njg0ln33	12	3	embrace	embrace	VBP
cord-335140-njg0ln33	12	4	the	the	DT
cord-335140-njg0ln33	12	5	challenges	challenge	NNS
cord-335140-njg0ln33	12	6	that	that	WDT
cord-335140-njg0ln33	12	7	will	will	MD
cord-335140-njg0ln33	12	8	emerge	emerge	VB
cord-335140-njg0ln33	12	9	in	in	IN
cord-335140-njg0ln33	12	10	the	the	DT
cord-335140-njg0ln33	12	11	post‐pandemic	post‐pandemic	JJ
cord-335140-njg0ln33	12	12	environment	environment	NN
cord-335140-njg0ln33	12	13	,	,	,
cord-335140-njg0ln33	12	14	the	the	DT
cord-335140-njg0ln33	12	15	treatment	treatment	NN
cord-335140-njg0ln33	12	16	delivered	deliver	VBN
cord-335140-njg0ln33	12	17	to	to	IN
cord-335140-njg0ln33	12	18	patients	patient	NNS
cord-335140-njg0ln33	12	19	could	could	MD
cord-335140-njg0ln33	12	20	be	be	VB
cord-335140-njg0ln33	12	21	more	more	RBR
cord-335140-njg0ln33	12	22	cost	cost	NN
cord-335140-njg0ln33	12	23	effective	effective	JJ
cord-335140-njg0ln33	12	24	and	and	CC
cord-335140-njg0ln33	12	25	better	well	RBR
cord-335140-njg0ln33	12	26	tailored	tailor	VBN
cord-335140-njg0ln33	12	27	than	than	IN
cord-335140-njg0ln33	12	28	before	before	RB
cord-335140-njg0ln33	12	29	.	.	.
cord-335140-njg0ln33	13	1	Healthcare	healthcare	NN
cord-335140-njg0ln33	13	2	delivery	delivery	NN
cord-335140-njg0ln33	14	1	post‐COVID	post‐COVID	NNP
cord-335140-njg0ln33	14	2	will	will	MD
cord-335140-njg0ln33	14	3	not	not	RB
cord-335140-njg0ln33	14	4	return	return	VB
cord-335140-njg0ln33	14	5	to	to	IN
cord-335140-njg0ln33	14	6	how	how	WRB
cord-335140-njg0ln33	14	7	it	-PRON-	PRP
cord-335140-njg0ln33	14	8	was	be	VBD
cord-335140-njg0ln33	14	9	,	,	,
cord-335140-njg0ln33	14	10	and	and	CC
cord-335140-njg0ln33	14	11	now	now	RB
cord-335140-njg0ln33	14	12	is	be	VBZ
cord-335140-njg0ln33	14	13	the	the	DT
cord-335140-njg0ln33	14	14	time	time	NN
cord-335140-njg0ln33	14	15	to	to	TO
cord-335140-njg0ln33	14	16	invest	invest	VB
cord-335140-njg0ln33	14	17	in	in	IN
cord-335140-njg0ln33	14	18	novel	novel	JJ
cord-335140-njg0ln33	14	19	strategies	strategy	NNS
cord-335140-njg0ln33	14	20	to	to	TO
cord-335140-njg0ln33	14	21	deliver	deliver	VB
cord-335140-njg0ln33	14	22	the	the	DT
cord-335140-njg0ln33	14	23	best	good	JJS
cord-335140-njg0ln33	14	24	possible	possible	JJ
cord-335140-njg0ln33	14	25	outcomes	outcome	NNS
cord-335140-njg0ln33	14	26	for	for	IN
cord-335140-njg0ln33	14	27	patients	patient	NNS
cord-335140-njg0ln33	14	28	.	.	.
cord-335140-njg0ln33	15	1	At	at	IN
cord-335140-njg0ln33	15	2	the	the	DT
cord-335140-njg0ln33	15	3	time	time	NN
cord-335140-njg0ln33	15	4	of	of	IN
cord-335140-njg0ln33	15	5	writing	writing	NN
cord-335140-njg0ln33	15	6	,	,	,
cord-335140-njg0ln33	15	7	the	the	DT
cord-335140-njg0ln33	15	8	outbreak	outbreak	NN
cord-335140-njg0ln33	15	9	of	of	IN
cord-335140-njg0ln33	15	10	the	the	DT
cord-335140-njg0ln33	15	11	highly	highly	RB
cord-335140-njg0ln33	15	12	infectious	infectious	JJ
cord-335140-njg0ln33	15	13	novel	novel	NN
cord-335140-njg0ln33	15	14	coronavirus	coronavirus	NN
cord-335140-njg0ln33	15	15	2019	2019	CD
cord-335140-njg0ln33	15	16	(	(	-LRB-
cord-335140-njg0ln33	15	17	COVID-	COVID-	NNP
cord-335140-njg0ln33	15	18	19	19	CD
cord-335140-njg0ln33	15	19	)	)	-RRB-
cord-335140-njg0ln33	15	20	has	have	VBZ
cord-335140-njg0ln33	15	21	swept	sweep	VBN
cord-335140-njg0ln33	15	22	across	across	IN
cord-335140-njg0ln33	15	23	all	all	DT
cord-335140-njg0ln33	15	24	5	5	CD
cord-335140-njg0ln33	15	25	continents	continent	NNS
cord-335140-njg0ln33	15	26	,	,	,
cord-335140-njg0ln33	15	27	with	with	IN
cord-335140-njg0ln33	15	28	over	over	IN
cord-335140-njg0ln33	15	29	4	4	CD
cord-335140-njg0ln33	15	30	million	million	CD
cord-335140-njg0ln33	15	31	confirmed	confirm	VBN
cord-335140-njg0ln33	15	32	cases	case	NNS
cord-335140-njg0ln33	15	33	globally	globally	RB
cord-335140-njg0ln33	15	34	(	(	-LRB-
cord-335140-njg0ln33	15	35	May	May	NNP
cord-335140-njg0ln33	15	36	9	9	CD
cord-335140-njg0ln33	15	37	,	,	,
cord-335140-njg0ln33	15	38	2020	2020	CD
cord-335140-njg0ln33	15	39	)	)	-RRB-
cord-335140-njg0ln33	15	40	(	(	-LRB-
cord-335140-njg0ln33	15	41	1	1	CD
cord-335140-njg0ln33	15	42	)	)	-RRB-
cord-335140-njg0ln33	15	43	.	.	.
cord-335140-njg0ln33	16	1	This	this	DT
cord-335140-njg0ln33	16	2	pandemic	pandemic	NN
cord-335140-njg0ln33	16	3	has	have	VBZ
cord-335140-njg0ln33	16	4	led	lead	VBN
cord-335140-njg0ln33	16	5	to	to	IN
cord-335140-njg0ln33	16	6	significant	significant	JJ
cord-335140-njg0ln33	16	7	changes	change	NNS
cord-335140-njg0ln33	16	8	in	in	IN
cord-335140-njg0ln33	16	9	the	the	DT
cord-335140-njg0ln33	16	10	way	way	NN
cord-335140-njg0ln33	16	11	physicians	physician	NNS
cord-335140-njg0ln33	16	12	interact	interact	VBP
cord-335140-njg0ln33	16	13	with	with	IN
cord-335140-njg0ln33	16	14	all	all	PDT
cord-335140-njg0ln33	16	15	our	-PRON-	PRP$
cord-335140-njg0ln33	16	16	patients	patient	NNS
cord-335140-njg0ln33	16	17	-and	-and	``
cord-335140-njg0ln33	16	18	how	how	WRB
cord-335140-njg0ln33	16	19	our	-PRON-	PRP$
cord-335140-njg0ln33	16	20	patients	patient	NNS
cord-335140-njg0ln33	16	21	interact	interact	VBP
cord-335140-njg0ln33	16	22	with	with	IN
cord-335140-njg0ln33	16	23	us	-PRON-	PRP
cord-335140-njg0ln33	16	24	.	.	.
cord-335140-njg0ln33	17	1	In	in	IN
cord-335140-njg0ln33	17	2	the	the	DT
cord-335140-njg0ln33	17	3	short	short	JJ
cord-335140-njg0ln33	17	4	term	term	NN
cord-335140-njg0ln33	17	5	,	,	,
cord-335140-njg0ln33	17	6	the	the	DT
cord-335140-njg0ln33	17	7	focus	focus	NN
cord-335140-njg0ln33	17	8	has	have	VBZ
cord-335140-njg0ln33	17	9	been	be	VBN
cord-335140-njg0ln33	17	10	on	on	IN
cord-335140-njg0ln33	17	11	liberating	liberate	VBG
cord-335140-njg0ln33	17	12	much	much	RB
cord-335140-njg0ln33	17	13	-	-	HYPH
cord-335140-njg0ln33	17	14	needed	need	VBN
cord-335140-njg0ln33	17	15	capacity	capacity	NN
cord-335140-njg0ln33	17	16	in	in	IN
cord-335140-njg0ln33	17	17	our	-PRON-	PRP$
cord-335140-njg0ln33	17	18	facilities	facility	NNS
cord-335140-njg0ln33	17	19	as	as	RB
cord-335140-njg0ln33	17	20	well	well	RB
cord-335140-njg0ln33	17	21	as	as	IN
cord-335140-njg0ln33	17	22	minimizing	minimize	VBG
cord-335140-njg0ln33	17	23	risk	risk	NN
cord-335140-njg0ln33	17	24	to	to	IN
cord-335140-njg0ln33	17	25	patients	patient	NNS
cord-335140-njg0ln33	17	26	and	and	CC
cord-335140-njg0ln33	17	27	other	other	JJ
cord-335140-njg0ln33	17	28	essential	essential	JJ
cord-335140-njg0ln33	17	29	care	care	NN
cord-335140-njg0ln33	17	30	providers	provider	NNS
cord-335140-njg0ln33	17	31	by	by	IN
cord-335140-njg0ln33	17	32	eliminating	eliminate	VBG
cord-335140-njg0ln33	17	33	all	all	DT
cord-335140-njg0ln33	17	34	non	non	JJ
cord-335140-njg0ln33	17	35	-	-	JJ
cord-335140-njg0ln33	17	36	critical	critical	JJ
cord-335140-njg0ln33	17	37	in	in	IN
cord-335140-njg0ln33	17	38	-	-	HYPH
cord-335140-njg0ln33	17	39	person	person	NN
cord-335140-njg0ln33	17	40	interactions	interaction	NNS
cord-335140-njg0ln33	17	41	.	.	.
cord-335140-njg0ln33	18	1	In	in	IN
cord-335140-njg0ln33	18	2	addition	addition	NN
cord-335140-njg0ln33	18	3	,	,	,
cord-335140-njg0ln33	18	4	we	-PRON-	PRP
cord-335140-njg0ln33	18	5	are	be	VBP
cord-335140-njg0ln33	18	6	choosing	choose	VBG
cord-335140-njg0ln33	18	7	alternative	alternative	JJ
cord-335140-njg0ln33	18	8	management	management	NN
cord-335140-njg0ln33	18	9	wherever	wherever	WRB
cord-335140-njg0ln33	18	10	possible	possible	JJ
cord-335140-njg0ln33	18	11	to	to	TO
cord-335140-njg0ln33	18	12	reduce	reduce	VB
cord-335140-njg0ln33	18	13	individual	individual	JJ
cord-335140-njg0ln33	18	14	patient	patient	JJ
cord-335140-njg0ln33	18	15	susceptibility	susceptibility	NN
cord-335140-njg0ln33	18	16	.	.	.
cord-335140-njg0ln33	19	1	Elective	elective	JJ
cord-335140-njg0ln33	19	2	procedures	procedure	NNS
cord-335140-njg0ln33	19	3	,	,	,
cord-335140-njg0ln33	19	4	anything	anything	NN
cord-335140-njg0ln33	19	5	deemed	deem	VBN
cord-335140-njg0ln33	19	6	non	non	JJ
cord-335140-njg0ln33	19	7	-	-	JJ
cord-335140-njg0ln33	19	8	essential	essential	JJ
cord-335140-njg0ln33	19	9	and	and	CC
cord-335140-njg0ln33	19	10	even	even	RB
cord-335140-njg0ln33	19	11	clinical	clinical	JJ
cord-335140-njg0ln33	19	12	trials	trial	NNS
cord-335140-njg0ln33	19	13	are	be	VBP
cord-335140-njg0ln33	19	14	,	,	,
cord-335140-njg0ln33	19	15	for	for	IN
cord-335140-njg0ln33	19	16	the	the	DT
cord-335140-njg0ln33	19	17	most	most	JJS
cord-335140-njg0ln33	19	18	part	part	NN
cord-335140-njg0ln33	19	19	,	,	,
cord-335140-njg0ln33	19	20	on	on	IN
cord-335140-njg0ln33	19	21	hold	hold	NN
cord-335140-njg0ln33	19	22	.	.	.
cord-335140-njg0ln33	20	1	Patients	patient	NNS
cord-335140-njg0ln33	20	2	with	with	IN
cord-335140-njg0ln33	20	3	underlying	underlie	VBG
cord-335140-njg0ln33	20	4	plasma	plasma	NN
cord-335140-njg0ln33	20	5	cell	cell	NN
cord-335140-njg0ln33	20	6	dyscrasias	dyscrasia	NNS
cord-335140-njg0ln33	20	7	are	be	VBP
cord-335140-njg0ln33	20	8	understandably	understandably	RB
cord-335140-njg0ln33	20	9	anxious	anxious	JJ
cord-335140-njg0ln33	20	10	,	,	,
cord-335140-njg0ln33	20	11	concerned	concerned	JJ
cord-335140-njg0ln33	20	12	about	about	IN
cord-335140-njg0ln33	20	13	progression	progression	NN
cord-335140-njg0ln33	20	14	of	of	IN
cord-335140-njg0ln33	20	15	their	-PRON-	PRP$
cord-335140-njg0ln33	20	16	disease	disease	NN
cord-335140-njg0ln33	20	17	during	during	IN
cord-335140-njg0ln33	20	18	this	this	DT
cord-335140-njg0ln33	20	19	time	time	NN
cord-335140-njg0ln33	20	20	of	of	IN
cord-335140-njg0ln33	20	21	crisis	crisis	NN
cord-335140-njg0ln33	20	22	but	but	CC
cord-335140-njg0ln33	20	23	equally	equally	RB
cord-335140-njg0ln33	20	24	not	not	RB
cord-335140-njg0ln33	20	25	wishing	wish	VBG
cord-335140-njg0ln33	20	26	to	to	TO
cord-335140-njg0ln33	20	27	undergo	undergo	VB
cord-335140-njg0ln33	20	28	immunosuppressive	immunosuppressive	JJ
cord-335140-njg0ln33	20	29	therapy	therapy	NN
cord-335140-njg0ln33	20	30	while	while	IN
cord-335140-njg0ln33	20	31	the	the	DT
cord-335140-njg0ln33	20	32	pandemic	pandemic	NN
cord-335140-njg0ln33	20	33	continues	continue	VBZ
cord-335140-njg0ln33	20	34	unchecked	unchecked	JJ
cord-335140-njg0ln33	20	35	.	.	.
cord-335140-njg0ln33	21	1	Our	-PRON-	PRP$
cord-335140-njg0ln33	21	2	immediate	immediate	JJ
cord-335140-njg0ln33	21	3	response	response	NN
cord-335140-njg0ln33	21	4	is	be	VBZ
cord-335140-njg0ln33	21	5	critical	critical	JJ
cord-335140-njg0ln33	21	6	to	to	TO
cord-335140-njg0ln33	21	7	reassure	reassure	VB
cord-335140-njg0ln33	21	8	and	and	CC
cord-335140-njg0ln33	21	9	optimise	optimise	VB
cord-335140-njg0ln33	21	10	each	each	DT
cord-335140-njg0ln33	21	11	patient	patient	NN
cord-335140-njg0ln33	21	12	to	to	IN
cord-335140-njg0ln33	21	13	the	the	DT
cord-335140-njg0ln33	21	14	best	good	JJS
cord-335140-njg0ln33	21	15	of	of	IN
cord-335140-njg0ln33	21	16	our	-PRON-	PRP$
cord-335140-njg0ln33	21	17	ability	ability	NN
cord-335140-njg0ln33	21	18	.	.	.
cord-335140-njg0ln33	22	1	We	-PRON-	PRP
cord-335140-njg0ln33	22	2	also	also	RB
cord-335140-njg0ln33	22	3	need	need	VBP
cord-335140-njg0ln33	22	4	to	to	TO
cord-335140-njg0ln33	22	5	consider	consider	VB
cord-335140-njg0ln33	22	6	that	that	IN
cord-335140-njg0ln33	22	7	the	the	DT
cord-335140-njg0ln33	22	8	way	way	NN
cord-335140-njg0ln33	22	9	we	-PRON-	PRP
cord-335140-njg0ln33	22	10	deliver	deliver	VBP
cord-335140-njg0ln33	22	11	care	care	NN
cord-335140-njg0ln33	22	12	to	to	IN
cord-335140-njg0ln33	22	13	myeloma	myeloma	NN
cord-335140-njg0ln33	22	14	patients	patient	NNS
cord-335140-njg0ln33	22	15	may	may	MD
cord-335140-njg0ln33	22	16	forever	forever	RB
cord-335140-njg0ln33	22	17	be	be	VB
cord-335140-njg0ln33	22	18	changed	change	VBN
cord-335140-njg0ln33	22	19	as	as	IN
cord-335140-njg0ln33	22	20	a	a	DT
cord-335140-njg0ln33	22	21	result	result	NN
cord-335140-njg0ln33	22	22	of	of	IN
cord-335140-njg0ln33	22	23	the	the	DT
cord-335140-njg0ln33	22	24	outbreak	outbreak	NN
cord-335140-njg0ln33	22	25	of	of	IN
cord-335140-njg0ln33	22	26	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	22	27	.	.	.
cord-335140-njg0ln33	23	1	This	this	DT
cord-335140-njg0ln33	23	2	global	global	JJ
cord-335140-njg0ln33	23	3	crisis	crisis	NN
cord-335140-njg0ln33	23	4	could	could	MD
cord-335140-njg0ln33	23	5	force	force	VB
cord-335140-njg0ln33	23	6	the	the	DT
cord-335140-njg0ln33	23	7	myeloma	myeloma	NN
cord-335140-njg0ln33	23	8	Accepted	Accepted	NNP
cord-335140-njg0ln33	23	9	Article	Article	NNP
cord-335140-njg0ln33	23	10	community	community	NN
cord-335140-njg0ln33	23	11	to	to	TO
cord-335140-njg0ln33	23	12	scrutinise	scrutinise	VB
cord-335140-njg0ln33	23	13	our	-PRON-	PRP$
cord-335140-njg0ln33	23	14	practices	practice	NNS
cord-335140-njg0ln33	23	15	and	and	CC
cord-335140-njg0ln33	23	16	ask	ask	VB
cord-335140-njg0ln33	23	17	whether	whether	IN
cord-335140-njg0ln33	23	18	every	every	DT
cord-335140-njg0ln33	23	19	test	test	NN
cord-335140-njg0ln33	23	20	,	,	,
cord-335140-njg0ln33	23	21	every	every	DT
cord-335140-njg0ln33	23	22	treatment	treatment	NN
cord-335140-njg0ln33	23	23	and	and	CC
cord-335140-njg0ln33	23	24	every	every	DT
cord-335140-njg0ln33	23	25	patient	patient	JJ
cord-335140-njg0ln33	23	26	interaction	interaction	NN
cord-335140-njg0ln33	23	27	is	be	VBZ
cord-335140-njg0ln33	23	28	truly	truly	RB
cord-335140-njg0ln33	23	29	delivering	deliver	VBG
cord-335140-njg0ln33	23	30	value	value	NN
cord-335140-njg0ln33	23	31	to	to	IN
cord-335140-njg0ln33	23	32	our	-PRON-	PRP$
cord-335140-njg0ln33	23	33	vulnerable	vulnerable	JJ
cord-335140-njg0ln33	23	34	population	population	NN
cord-335140-njg0ln33	23	35	,	,	,
cord-335140-njg0ln33	23	36	both	both	CC
cord-335140-njg0ln33	23	37	in	in	IN
cord-335140-njg0ln33	23	38	the	the	DT
cord-335140-njg0ln33	23	39	immediate	immediate	JJ
cord-335140-njg0ln33	23	40	-	-	HYPH
cord-335140-njg0ln33	23	41	term	term	NN
cord-335140-njg0ln33	23	42	and	and	CC
cord-335140-njg0ln33	23	43	also	also	RB
cord-335140-njg0ln33	23	44	in	in	IN
cord-335140-njg0ln33	23	45	the	the	DT
cord-335140-njg0ln33	23	46	future	future	NN
cord-335140-njg0ln33	23	47	.	.	.
cord-335140-njg0ln33	24	1	This	this	DT
cord-335140-njg0ln33	24	2	can	can	MD
cord-335140-njg0ln33	24	3	,	,	,
cord-335140-njg0ln33	24	4	and	and	CC
cord-335140-njg0ln33	24	5	should	should	MD
cord-335140-njg0ln33	24	6	serve	serve	VB
cord-335140-njg0ln33	24	7	as	as	IN
cord-335140-njg0ln33	24	8	an	an	DT
cord-335140-njg0ln33	24	9	opportunity	opportunity	NN
cord-335140-njg0ln33	24	10	to	to	TO
cord-335140-njg0ln33	24	11	do	do	VB
cord-335140-njg0ln33	24	12	better	well	JJR
cord-335140-njg0ln33	24	13	,	,	,
cord-335140-njg0ln33	24	14	delivering	deliver	VBG
cord-335140-njg0ln33	24	15	more	more	JJR
cord-335140-njg0ln33	24	16	value	value	NN
cord-335140-njg0ln33	24	17	for	for	IN
cord-335140-njg0ln33	24	18	patients	patient	NNS
cord-335140-njg0ln33	24	19	in	in	IN
cord-335140-njg0ln33	24	20	the	the	DT
cord-335140-njg0ln33	24	21	face	face	NN
cord-335140-njg0ln33	24	22	of	of	IN
cord-335140-njg0ln33	24	23	global	global	JJ
cord-335140-njg0ln33	24	24	economic	economic	JJ
cord-335140-njg0ln33	24	25	recession	recession	NN
cord-335140-njg0ln33	24	26	.	.	.
cord-335140-njg0ln33	25	1	Immediate	immediate	JJ
cord-335140-njg0ln33	25	2	changes	change	NNS
cord-335140-njg0ln33	25	3	to	to	IN
cord-335140-njg0ln33	25	4	myeloma	myeloma	NN
cord-335140-njg0ln33	25	5	care	care	VB
cord-335140-njg0ln33	25	6	in	in	IN
cord-335140-njg0ln33	25	7	response	response	NN
cord-335140-njg0ln33	25	8	to	to	TO
cord-335140-njg0ln33	25	9	COVID-19	covid-19	VB
cord-335140-njg0ln33	25	10	The	the	DT
cord-335140-njg0ln33	25	11	basics	basic	NNS
cord-335140-njg0ln33	25	12	-limit	-limit	''
cord-335140-njg0ln33	25	13	,	,	,
cord-335140-njg0ln33	25	14	isolate	isolate	VBP
cord-335140-njg0ln33	25	15	and	and	CC
cord-335140-njg0ln33	25	16	protect	protect	VB
cord-335140-njg0ln33	26	1	There	there	EX
cord-335140-njg0ln33	26	2	are	be	VBP
cord-335140-njg0ln33	26	3	now	now	RB
cord-335140-njg0ln33	26	4	many	many	JJ
cord-335140-njg0ln33	26	5	resources	resource	NNS
cord-335140-njg0ln33	26	6	that	that	WDT
cord-335140-njg0ln33	26	7	document	document	VBP
cord-335140-njg0ln33	26	8	the	the	DT
cord-335140-njg0ln33	26	9	key	key	JJ
cord-335140-njg0ln33	26	10	steps	step	NNS
cord-335140-njg0ln33	26	11	necessary	necessary	JJ
cord-335140-njg0ln33	26	12	to	to	TO
cord-335140-njg0ln33	26	13	protect	protect	VB
cord-335140-njg0ln33	26	14	cancer	cancer	NN
cord-335140-njg0ln33	26	15	patients	patient	NNS
cord-335140-njg0ln33	26	16	,	,	,
cord-335140-njg0ln33	26	17	and	and	CC
cord-335140-njg0ln33	26	18	centres	centre	NNS
cord-335140-njg0ln33	26	19	in	in	IN
cord-335140-njg0ln33	26	20	affected	affected	JJ
cord-335140-njg0ln33	26	21	countries	country	NNS
cord-335140-njg0ln33	26	22	have	have	VBP
cord-335140-njg0ln33	26	23	largely	largely	RB
cord-335140-njg0ln33	26	24	adopted	adopt	VBN
cord-335140-njg0ln33	26	25	these	these	DT
cord-335140-njg0ln33	26	26	approaches	approach	NNS
cord-335140-njg0ln33	26	27	(	(	-LRB-
cord-335140-njg0ln33	26	28	2	2	CD
cord-335140-njg0ln33	26	29	,	,	,
cord-335140-njg0ln33	26	30	3	3	CD
cord-335140-njg0ln33	26	31	)	)	-RRB-
cord-335140-njg0ln33	26	32	.	.	.
cord-335140-njg0ln33	27	1	In	in	IN
cord-335140-njg0ln33	27	2	brief	brief	JJ
cord-335140-njg0ln33	27	3	-patient	-patient	JJ
cord-335140-njg0ln33	27	4	visits	visit	NNS
cord-335140-njg0ln33	27	5	that	that	WDT
cord-335140-njg0ln33	27	6	can	can	MD
cord-335140-njg0ln33	27	7	be	be	VB
cord-335140-njg0ln33	27	8	postponed	postpone	VBN
cord-335140-njg0ln33	27	9	or	or	CC
cord-335140-njg0ln33	27	10	conducted	conduct	VBN
cord-335140-njg0ln33	27	11	via	via	IN
cord-335140-njg0ln33	27	12	telemedicine	telemedicine	NN
cord-335140-njg0ln33	27	13	(	(	-LRB-
cord-335140-njg0ln33	27	14	see	see	VB
cord-335140-njg0ln33	27	15	below	below	RB
cord-335140-njg0ln33	27	16	)	)	-RRB-
cord-335140-njg0ln33	27	17	should	should	MD
cord-335140-njg0ln33	27	18	be	be	VB
cord-335140-njg0ln33	27	19	changed	change	VBN
cord-335140-njg0ln33	27	20	.	.	.
cord-335140-njg0ln33	28	1	Wherever	wherever	WRB
cord-335140-njg0ln33	28	2	possible	possible	JJ
cord-335140-njg0ln33	28	3	,	,	,
cord-335140-njg0ln33	28	4	geographical	geographical	JJ
cord-335140-njg0ln33	28	5	separation	separation	NN
cord-335140-njg0ln33	28	6	of	of	IN
cord-335140-njg0ln33	28	7	low	low	JJ
cord-335140-njg0ln33	28	8	versus	versus	IN
cord-335140-njg0ln33	28	9	high	high	JJ
cord-335140-njg0ln33	28	10	risk	risk	NN
cord-335140-njg0ln33	28	11	patients	patient	NNS
cord-335140-njg0ln33	28	12	should	should	MD
cord-335140-njg0ln33	28	13	be	be	VB
cord-335140-njg0ln33	28	14	aggressively	aggressively	RB
cord-335140-njg0ln33	28	15	pursued	pursue	VBN
cord-335140-njg0ln33	28	16	as	as	IN
cord-335140-njg0ln33	28	17	per	per	IN
cord-335140-njg0ln33	28	18	the	the	DT
cord-335140-njg0ln33	28	19	infectious	infectious	JJ
cord-335140-njg0ln33	28	20	control	control	NN
cord-335140-njg0ln33	28	21	guidance	guidance	NN
cord-335140-njg0ln33	28	22	found	find	VBN
cord-335140-njg0ln33	28	23	on	on	IN
cord-335140-njg0ln33	28	24	the	the	DT
cord-335140-njg0ln33	28	25	WHO	WHO	NNP
cord-335140-njg0ln33	28	26	and	and	CC
cord-335140-njg0ln33	28	27	Centers	Centers	NNPS
cord-335140-njg0ln33	28	28	for	for	IN
cord-335140-njg0ln33	28	29	Disease	Disease	NNP
cord-335140-njg0ln33	28	30	Control	Control	NNP
cord-335140-njg0ln33	28	31	and	and	CC
cord-335140-njg0ln33	28	32	Prevention	Prevention	NNP
cord-335140-njg0ln33	28	33	(	(	-LRB-
cord-335140-njg0ln33	28	34	CDC	CDC	NNP
cord-335140-njg0ln33	28	35	)	)	-RRB-
cord-335140-njg0ln33	28	36	websites	website	NNS
cord-335140-njg0ln33	28	37	(	(	-LRB-
cord-335140-njg0ln33	28	38	4	4	CD
cord-335140-njg0ln33	28	39	,	,	,
cord-335140-njg0ln33	28	40	5	5	CD
cord-335140-njg0ln33	28	41	)	)	-RRB-
cord-335140-njg0ln33	28	42	.	.	.
cord-335140-njg0ln33	29	1	All	all	DT
cord-335140-njg0ln33	29	2	patients	patient	NNS
cord-335140-njg0ln33	29	3	should	should	MD
cord-335140-njg0ln33	29	4	be	be	VB
cord-335140-njg0ln33	29	5	screened	screen	VBN
cord-335140-njg0ln33	29	6	prior	prior	RB
cord-335140-njg0ln33	29	7	to	to	IN
cord-335140-njg0ln33	29	8	attending	attend	VBG
cord-335140-njg0ln33	29	9	(	(	-LRB-
cord-335140-njg0ln33	29	10	ideally	ideally	RB
cord-335140-njg0ln33	29	11	by	by	IN
cord-335140-njg0ln33	29	12	telephone	telephone	NN
cord-335140-njg0ln33	29	13	the	the	DT
cord-335140-njg0ln33	29	14	day	day	NN
cord-335140-njg0ln33	29	15	before	before	IN
cord-335140-njg0ln33	29	16	)	)	-RRB-
cord-335140-njg0ln33	29	17	the	the	DT
cord-335140-njg0ln33	29	18	chemotherapy	chemotherapy	NN
cord-335140-njg0ln33	29	19	unit	unit	NN
cord-335140-njg0ln33	29	20	or	or	CC
cord-335140-njg0ln33	29	21	outpatient	outpatient	NN
cord-335140-njg0ln33	29	22	settings	setting	NNS
cord-335140-njg0ln33	29	23	,	,	,
cord-335140-njg0ln33	29	24	and	and	CC
cord-335140-njg0ln33	29	25	again	again	RB
cord-335140-njg0ln33	29	26	(	(	-LRB-
cord-335140-njg0ln33	29	27	in	in	IN
cord-335140-njg0ln33	29	28	person	person	NN
cord-335140-njg0ln33	29	29	)	)	-RRB-
cord-335140-njg0ln33	29	30	at	at	IN
cord-335140-njg0ln33	29	31	designated	designate	VBN
cord-335140-njg0ln33	29	32	,	,	,
cord-335140-njg0ln33	29	33	restricted	restrict	VBN
cord-335140-njg0ln33	29	34	entry	entry	NN
cord-335140-njg0ln33	29	35	points	point	NNS
cord-335140-njg0ln33	29	36	.	.	.
cord-335140-njg0ln33	30	1	Patients	patient	NNS
cord-335140-njg0ln33	30	2	felt	feel	VBD
cord-335140-njg0ln33	30	3	to	to	TO
cord-335140-njg0ln33	30	4	be	be	VB
cord-335140-njg0ln33	30	5	at	at	IN
cord-335140-njg0ln33	30	6	risk	risk	NN
cord-335140-njg0ln33	30	7	can	can	MD
cord-335140-njg0ln33	30	8	then	then	RB
cord-335140-njg0ln33	30	9	be	be	VB
cord-335140-njg0ln33	30	10	identified	identify	VBN
cord-335140-njg0ln33	30	11	early	early	RB
cord-335140-njg0ln33	30	12	and	and	CC
cord-335140-njg0ln33	30	13	appropriate	appropriate	JJ
cord-335140-njg0ln33	30	14	referral	referral	NN
cord-335140-njg0ln33	30	15	either	either	RB
cord-335140-njg0ln33	30	16	to	to	IN
cord-335140-njg0ln33	30	17	a	a	DT
cord-335140-njg0ln33	30	18	dedicated	dedicated	JJ
cord-335140-njg0ln33	30	19	area	area	NN
cord-335140-njg0ln33	30	20	for	for	IN
cord-335140-njg0ln33	30	21	further	further	JJ
cord-335140-njg0ln33	30	22	assessment	assessment	NN
cord-335140-njg0ln33	30	23	or	or	CC
cord-335140-njg0ln33	30	24	to	to	IN
cord-335140-njg0ln33	30	25	an	an	DT
cord-335140-njg0ln33	30	26	acute	acute	JJ
cord-335140-njg0ln33	30	27	care	care	NN
cord-335140-njg0ln33	30	28	/	/	SYM
cord-335140-njg0ln33	30	29	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	30	30	assessment	assessment	NN
cord-335140-njg0ln33	30	31	centre	centre	NN
cord-335140-njg0ln33	30	32	can	can	MD
cord-335140-njg0ln33	30	33	be	be	VB
cord-335140-njg0ln33	30	34	 	 	_SP
cord-335140-njg0ln33	30	35	One	one	CD
cord-335140-njg0ln33	30	36	of	of	IN
cord-335140-njg0ln33	30	37	the	the	DT
cord-335140-njg0ln33	30	38	first	first	JJ
cord-335140-njg0ln33	30	39	and	and	CC
cord-335140-njg0ln33	30	40	easiest	easy	JJS
cord-335140-njg0ln33	30	41	changes	change	NNS
cord-335140-njg0ln33	30	42	in	in	IN
cord-335140-njg0ln33	30	43	practice	practice	NN
cord-335140-njg0ln33	30	44	for	for	IN
cord-335140-njg0ln33	30	45	many	many	JJ
cord-335140-njg0ln33	30	46	was	be	VBD
cord-335140-njg0ln33	30	47	to	to	TO
cord-335140-njg0ln33	30	48	switch	switch	VB
cord-335140-njg0ln33	30	49	in	in	IN
cord-335140-njg0ln33	30	50	-	-	HYPH
cord-335140-njg0ln33	30	51	person	person	NN
cord-335140-njg0ln33	30	52	visits	visit	NNS
cord-335140-njg0ln33	30	53	to	to	IN
cord-335140-njg0ln33	30	54	telemedicine	telemedicine	NN
cord-335140-njg0ln33	30	55	(	(	-LRB-
cord-335140-njg0ln33	30	56	6	6	CD
cord-335140-njg0ln33	30	57	)	)	-RRB-
cord-335140-njg0ln33	30	58	.	.	.
cord-335140-njg0ln33	31	1	For	for	IN
cord-335140-njg0ln33	31	2	myeloma	myeloma	NN
cord-335140-njg0ln33	31	3	patients	patient	NNS
cord-335140-njg0ln33	31	4	,	,	,
cord-335140-njg0ln33	31	5	who	who	WP
cord-335140-njg0ln33	31	6	are	be	VBP
cord-335140-njg0ln33	31	7	frequently	frequently	RB
cord-335140-njg0ln33	31	8	elderly	elderly	JJ
cord-335140-njg0ln33	31	9	,	,	,
cord-335140-njg0ln33	31	10	may	may	MD
cord-335140-njg0ln33	31	11	have	have	VB
cord-335140-njg0ln33	31	12	co	co	NNS
cord-335140-njg0ln33	31	13	-	-	NNS
cord-335140-njg0ln33	31	14	morbidities	morbidity	NNS
cord-335140-njg0ln33	31	15	,	,	,
cord-335140-njg0ln33	31	16	variable	variable	JJ
cord-335140-njg0ln33	31	17	frailty	frailty	NN
cord-335140-njg0ln33	31	18	or	or	CC
cord-335140-njg0ln33	31	19	mobility	mobility	NN
cord-335140-njg0ln33	31	20	issues	issue	NNS
cord-335140-njg0ln33	31	21	this	this	DT
cord-335140-njg0ln33	31	22	is	be	VBZ
cord-335140-njg0ln33	31	23	probably	probably	RB
cord-335140-njg0ln33	31	24	one	one	CD
cord-335140-njg0ln33	31	25	of	of	IN
cord-335140-njg0ln33	31	26	the	the	DT
cord-335140-njg0ln33	31	27	most	most	RBS
cord-335140-njg0ln33	31	28	welcome	welcome	JJ
cord-335140-njg0ln33	31	29	strategies	strategy	NNS
cord-335140-njg0ln33	31	30	that	that	WDT
cord-335140-njg0ln33	31	31	has	have	VBZ
cord-335140-njg0ln33	31	32	been	be	VBN
cord-335140-njg0ln33	31	33	employed	employ	VBN
cord-335140-njg0ln33	31	34	-and	-and	''
cord-335140-njg0ln33	31	35	perhaps	perhaps	RB
cord-335140-njg0ln33	31	36	will	will	MD
cord-335140-njg0ln33	31	37	be	be	VB
cord-335140-njg0ln33	31	38	one	one	CD
cord-335140-njg0ln33	31	39	of	of	IN
cord-335140-njg0ln33	31	40	the	the	DT
cord-335140-njg0ln33	31	41	most	most	RBS
cord-335140-njg0ln33	31	42	positive	positive	JJ
cord-335140-njg0ln33	31	43	changes	change	NNS
cord-335140-njg0ln33	31	44	to	to	TO
cord-335140-njg0ln33	31	45	emerge	emerge	VB
cord-335140-njg0ln33	31	46	from	from	IN
cord-335140-njg0ln33	31	47	this	this	DT
cord-335140-njg0ln33	31	48	pandemic	pandemic	NN
cord-335140-njg0ln33	31	49	(	(	-LRB-
cord-335140-njg0ln33	31	50	7	7	CD
cord-335140-njg0ln33	31	51	)	)	-RRB-
cord-335140-njg0ln33	31	52	(	(	-LRB-
cord-335140-njg0ln33	31	53	8)	8)	NNP
cord-335140-njg0ln33	31	54	(	(	-LRB-
cord-335140-njg0ln33	31	55	9	9	CD
cord-335140-njg0ln33	31	56	)	)	-RRB-
cord-335140-njg0ln33	31	57	.	.	.
cord-335140-njg0ln33	32	1	It	-PRON-	PRP
cord-335140-njg0ln33	32	2	goes	go	VBZ
cord-335140-njg0ln33	32	3	without	without	IN
cord-335140-njg0ln33	32	4	saying	say	VBG
cord-335140-njg0ln33	32	5	that	that	IN
cord-335140-njg0ln33	32	6	some	some	DT
cord-335140-njg0ln33	32	7	patients	patient	NNS
cord-335140-njg0ln33	32	8	will	will	MD
cord-335140-njg0ln33	32	9	continue	continue	VB
cord-335140-njg0ln33	32	10	to	to	TO
cord-335140-njg0ln33	32	11	require	require	VB
cord-335140-njg0ln33	32	12	a	a	DT
cord-335140-njg0ln33	32	13	direct	direct	JJ
cord-335140-njg0ln33	32	14	clinical	clinical	JJ
cord-335140-njg0ln33	32	15	assessment	assessment	NN
cord-335140-njg0ln33	32	16	and	and	CC
cord-335140-njg0ln33	32	17	examination	examination	NN
cord-335140-njg0ln33	32	18	.	.	.
cord-335140-njg0ln33	33	1	However	however	RB
cord-335140-njg0ln33	33	2	,	,	,
cord-335140-njg0ln33	33	3	limiting	limit	VBG
cord-335140-njg0ln33	33	4	interaction	interaction	NN
cord-335140-njg0ln33	33	5	to	to	IN
cord-335140-njg0ln33	33	6	this	this	DT
cord-335140-njg0ln33	33	7	group	group	NN
cord-335140-njg0ln33	33	8	of	of	IN
cord-335140-njg0ln33	33	9	patients	patient	NNS
cord-335140-njg0ln33	33	10	only	only	RB
cord-335140-njg0ln33	33	11	will	will	MD
cord-335140-njg0ln33	33	12	liberate	liberate	VB
cord-335140-njg0ln33	33	13	clinical	clinical	JJ
cord-335140-njg0ln33	33	14	space	space	NN
cord-335140-njg0ln33	33	15	,	,	,
cord-335140-njg0ln33	33	16	allow	allow	VB
cord-335140-njg0ln33	33	17	better	well	JJR
cord-335140-njg0ln33	33	18	distancing	distancing	NN
cord-335140-njg0ln33	33	19	and	and	CC
cord-335140-njg0ln33	33	20	reduce	reduce	VB
cord-335140-njg0ln33	33	21	the	the	DT
cord-335140-njg0ln33	33	22	number	number	NN
cord-335140-njg0ln33	33	23	of	of	IN
cord-335140-njg0ln33	33	24	patients	patient	NNS
cord-335140-njg0ln33	33	25	This	this	DT
cord-335140-njg0ln33	33	26	article	article	NN
cord-335140-njg0ln33	33	27	is	be	VBZ
cord-335140-njg0ln33	33	28	protected	protect	VBN
cord-335140-njg0ln33	33	29	by	by	IN
cord-335140-njg0ln33	33	30	copyright	copyright	NN
cord-335140-njg0ln33	33	31	.	.	.
cord-335140-njg0ln33	34	1	All	all	DT
cord-335140-njg0ln33	34	2	rights	right	NNS
cord-335140-njg0ln33	34	3	reserved	reserve	VBN
cord-335140-njg0ln33	34	4	attending	attend	VBG
cord-335140-njg0ln33	34	5	outpatient	outpatient	NN
cord-335140-njg0ln33	34	6	centres	centre	NNS
cord-335140-njg0ln33	34	7	.	.	.
cord-335140-njg0ln33	35	1	There	there	EX
cord-335140-njg0ln33	35	2	is	be	VBZ
cord-335140-njg0ln33	35	3	reassurance	reassurance	NN
cord-335140-njg0ln33	35	4	out	out	RB
cord-335140-njg0ln33	35	5	there	there	RB
cord-335140-njg0ln33	35	6	that	that	DT
cord-335140-njg0ln33	35	7	telemedicine	telemedicine	NN
cord-335140-njg0ln33	35	8	has	have	VBZ
cord-335140-njg0ln33	35	9	been	be	VBN
cord-335140-njg0ln33	35	10	shown	show	VBN
cord-335140-njg0ln33	35	11	to	to	TO
cord-335140-njg0ln33	35	12	be	be	VB
cord-335140-njg0ln33	35	13	at	at	IN
cord-335140-njg0ln33	35	14	least	least	JJS
cord-335140-njg0ln33	35	15	equivalent	equivalent	JJ
cord-335140-njg0ln33	35	16	to	to	IN
cord-335140-njg0ln33	35	17	in	in	IN
cord-335140-njg0ln33	35	18	-	-	HYPH
cord-335140-njg0ln33	35	19	person	person	NN
cord-335140-njg0ln33	35	20	care	care	NN
cord-335140-njg0ln33	35	21	and	and	CC
cord-335140-njg0ln33	35	22	is	be	VBZ
cord-335140-njg0ln33	35	23	associated	associate	VBN
cord-335140-njg0ln33	35	24	with	with	IN
cord-335140-njg0ln33	35	25	high	high	JJ
cord-335140-njg0ln33	35	26	levels	level	NNS
cord-335140-njg0ln33	35	27	of	of	IN
cord-335140-njg0ln33	35	28	patient	patient	JJ
cord-335140-njg0ln33	35	29	satisfaction	satisfaction	NN
cord-335140-njg0ln33	35	30	(	(	-LRB-
cord-335140-njg0ln33	35	31	10	10	CD
cord-335140-njg0ln33	35	32	)	)	-RRB-
cord-335140-njg0ln33	35	33	.	.	.
cord-335140-njg0ln33	36	1	The	the	DT
cord-335140-njg0ln33	36	2	urgency	urgency	NN
cord-335140-njg0ln33	36	3	of	of	IN
cord-335140-njg0ln33	36	4	the	the	DT
cord-335140-njg0ln33	36	5	situation	situation	NN
cord-335140-njg0ln33	36	6	created	create	VBN
cord-335140-njg0ln33	36	7	by	by	IN
cord-335140-njg0ln33	36	8	the	the	DT
cord-335140-njg0ln33	36	9	pandemic	pandemic	NN
cord-335140-njg0ln33	36	10	has	have	VBZ
cord-335140-njg0ln33	36	11	forced	force	VBN
cord-335140-njg0ln33	36	12	the	the	DT
cord-335140-njg0ln33	36	13	regulatory	regulatory	JJ
cord-335140-njg0ln33	36	14	bodies	body	NNS
cord-335140-njg0ln33	36	15	and	and	CC
cord-335140-njg0ln33	36	16	those	those	DT
cord-335140-njg0ln33	36	17	responsible	responsible	JJ
cord-335140-njg0ln33	36	18	for	for	IN
cord-335140-njg0ln33	36	19	re	re	NN
cord-335140-njg0ln33	36	20	-	-	NN
cord-335140-njg0ln33	36	21	imbursement	imbursement	NN
cord-335140-njg0ln33	36	22	to	to	TO
cord-335140-njg0ln33	36	23	finally	finally	RB
cord-335140-njg0ln33	36	24	address	address	VB
cord-335140-njg0ln33	36	25	existing	exist	VBG
cord-335140-njg0ln33	36	26	barriers	barrier	NNS
cord-335140-njg0ln33	36	27	to	to	IN
cord-335140-njg0ln33	36	28	the	the	DT
cord-335140-njg0ln33	36	29	delivery	delivery	NN
cord-335140-njg0ln33	36	30	of	of	IN
cord-335140-njg0ln33	36	31	telemedicine	telemedicine	NN
cord-335140-njg0ln33	36	32	that	that	WDT
cord-335140-njg0ln33	36	33	will	will	MD
cord-335140-njg0ln33	36	34	likely	likely	RB
cord-335140-njg0ln33	36	35	benefit	benefit	VB
cord-335140-njg0ln33	36	36	myeloma	myeloma	NN
cord-335140-njg0ln33	36	37	patients	patient	NNS
cord-335140-njg0ln33	36	38	for	for	IN
cord-335140-njg0ln33	36	39	years	year	NNS
cord-335140-njg0ln33	36	40	to	to	TO
cord-335140-njg0ln33	36	41	come	come	VB
cord-335140-njg0ln33	36	42	(	(	-LRB-
cord-335140-njg0ln33	36	43	11	11	CD
cord-335140-njg0ln33	36	44	)	)	-RRB-
cord-335140-njg0ln33	36	45	.	.	.
cord-335140-njg0ln33	37	1	Patients	patient	NNS
cord-335140-njg0ln33	37	2	with	with	IN
cord-335140-njg0ln33	37	3	myeloma	myeloma	NN
cord-335140-njg0ln33	37	4	are	be	VBP
cord-335140-njg0ln33	37	5	already	already	RB
cord-335140-njg0ln33	37	6	an	an	DT
cord-335140-njg0ln33	37	7	at	at	IN
cord-335140-njg0ln33	37	8	-	-	HYPH
cord-335140-njg0ln33	37	9	risk	risk	NN
cord-335140-njg0ln33	37	10	group	group	NN
cord-335140-njg0ln33	37	11	for	for	IN
cord-335140-njg0ln33	37	12	infectious	infectious	JJ
cord-335140-njg0ln33	37	13	complications	complication	NNS
cord-335140-njg0ln33	37	14	,	,	,
cord-335140-njg0ln33	37	15	in	in	IN
cord-335140-njg0ln33	37	16	particular	particular	JJ
cord-335140-njg0ln33	37	17	viral	viral	JJ
cord-335140-njg0ln33	37	18	infections	infection	NNS
cord-335140-njg0ln33	37	19	and	and	CC
cord-335140-njg0ln33	37	20	pneumonia	pneumonia	NN
cord-335140-njg0ln33	37	21	(	(	-LRB-
cord-335140-njg0ln33	37	22	12	12	CD
cord-335140-njg0ln33	37	23	)	)	-RRB-
cord-335140-njg0ln33	37	24	.	.	.
cord-335140-njg0ln33	38	1	Minimising	minimise	VBG
cord-335140-njg0ln33	38	2	immunosuppressive	immunosuppressive	JJ
cord-335140-njg0ln33	38	3	therapy	therapy	NN
cord-335140-njg0ln33	38	4	wherever	wherever	WRB
cord-335140-njg0ln33	38	5	possible	possible	JJ
cord-335140-njg0ln33	38	6	has	have	VBZ
cord-335140-njg0ln33	38	7	become	become	VBN
cord-335140-njg0ln33	38	8	a	a	DT
cord-335140-njg0ln33	38	9	key	key	JJ
cord-335140-njg0ln33	38	10	strategy	strategy	NN
cord-335140-njg0ln33	38	11	in	in	IN
cord-335140-njg0ln33	38	12	the	the	DT
cord-335140-njg0ln33	38	13	face	face	NN
cord-335140-njg0ln33	38	14	of	of	IN
cord-335140-njg0ln33	38	15	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	38	16	.	.	.
cord-335140-njg0ln33	39	1	There	there	EX
cord-335140-njg0ln33	39	2	will	will	MD
cord-335140-njg0ln33	39	3	remain	remain	VB
cord-335140-njg0ln33	39	4	a	a	DT
cord-335140-njg0ln33	39	5	number	number	NN
cord-335140-njg0ln33	39	6	of	of	IN
cord-335140-njg0ln33	39	7	critically	critically	RB
cord-335140-njg0ln33	39	8	unwell	unwell	JJ
cord-335140-njg0ln33	39	9	,	,	,
cord-335140-njg0ln33	39	10	or	or	CC
cord-335140-njg0ln33	39	11	high	high	JJ
cord-335140-njg0ln33	39	12	-	-	HYPH
cord-335140-njg0ln33	39	13	risk	risk	NN
cord-335140-njg0ln33	39	14	patients	patient	NNS
cord-335140-njg0ln33	39	15	for	for	IN
cord-335140-njg0ln33	39	16	whom	whom	WP
cord-335140-njg0ln33	39	17	this	this	DT
cord-335140-njg0ln33	39	18	strategy	strategy	NN
cord-335140-njg0ln33	39	19	can	can	MD
cord-335140-njg0ln33	39	20	not	not	RB
cord-335140-njg0ln33	39	21	be	be	VB
cord-335140-njg0ln33	39	22	employed	employ	VBN
cord-335140-njg0ln33	39	23	.	.	.
cord-335140-njg0ln33	40	1	Myeloma	myeloma	NN
cord-335140-njg0ln33	40	2	can	can	MD
cord-335140-njg0ln33	40	3	be	be	VB
cord-335140-njg0ln33	40	4	very	very	RB
cord-335140-njg0ln33	40	5	aggressive	aggressive	JJ
cord-335140-njg0ln33	40	6	and	and	CC
cord-335140-njg0ln33	40	7	if	if	IN
cord-335140-njg0ln33	40	8	patients	patient	NNS
cord-335140-njg0ln33	40	9	have	have	VBP
cord-335140-njg0ln33	40	10	very	very	RB
cord-335140-njg0ln33	40	11	active	active	JJ
cord-335140-njg0ln33	40	12	disease	disease	NN
cord-335140-njg0ln33	40	13	limiting	limit	VBG
cord-335140-njg0ln33	40	14	their	-PRON-	PRP$
cord-335140-njg0ln33	40	15	ideal	ideal	JJ
cord-335140-njg0ln33	40	16	care	care	NN
cord-335140-njg0ln33	40	17	is	be	VBZ
cord-335140-njg0ln33	40	18	not	not	RB
cord-335140-njg0ln33	40	19	advisable	advisable	JJ
cord-335140-njg0ln33	40	20	.	.	.
cord-335140-njg0ln33	41	1	However	however	RB
cord-335140-njg0ln33	41	2	,	,	,
cord-335140-njg0ln33	41	3	for	for	IN
cord-335140-njg0ln33	41	4	those	those	DT
cord-335140-njg0ln33	41	5	that	that	WDT
cord-335140-njg0ln33	41	6	can	can	MD
cord-335140-njg0ln33	41	7	,	,	,
cord-335140-njg0ln33	41	8	many	many	JJ
cord-335140-njg0ln33	41	9	are	be	VBP
cord-335140-njg0ln33	41	10	considering	consider	VBG
cord-335140-njg0ln33	41	11	the	the	DT
cord-335140-njg0ln33	41	12	early	early	JJ
cord-335140-njg0ln33	41	13	reduction	reduction	NN
cord-335140-njg0ln33	41	14	or	or	CC
cord-335140-njg0ln33	41	15	elimination	elimination	NN
cord-335140-njg0ln33	41	16	of	of	IN
cord-335140-njg0ln33	41	17	corticosteroids	corticosteroid	NNS
cord-335140-njg0ln33	41	18	once	once	RB
cord-335140-njg0ln33	41	19	patient	patient	NN
cord-335140-njg0ln33	41	20	's	's	POS
cord-335140-njg0ln33	41	21	disease	disease	NN
cord-335140-njg0ln33	41	22	appears	appear	VBZ
cord-335140-njg0ln33	41	23	to	to	TO
cord-335140-njg0ln33	41	24	have	have	VB
cord-335140-njg0ln33	41	25	stabilized	stabilize	VBN
cord-335140-njg0ln33	41	26	(	(	-LRB-
cord-335140-njg0ln33	41	27	13	13	CD
cord-335140-njg0ln33	41	28	,	,	,
cord-335140-njg0ln33	41	29	14	14	CD
cord-335140-njg0ln33	41	30	)	)	-RRB-
cord-335140-njg0ln33	41	31	.	.	.
cord-335140-njg0ln33	42	1	A	a	DT
cord-335140-njg0ln33	42	2	shift	shift	NN
cord-335140-njg0ln33	42	3	in	in	IN
cord-335140-njg0ln33	42	4	focus	focus	NN
cord-335140-njg0ln33	42	5	in	in	IN
cord-335140-njg0ln33	42	6	favour	favour	NN
cord-335140-njg0ln33	42	7	of	of	IN
cord-335140-njg0ln33	42	8	dose	dose	NN
cord-335140-njg0ln33	42	9	reductions	reduction	NNS
cord-335140-njg0ln33	42	10	(	(	-LRB-
cord-335140-njg0ln33	42	11	especially	especially	RB
cord-335140-njg0ln33	42	12	in	in	IN
cord-335140-njg0ln33	42	13	the	the	DT
cord-335140-njg0ln33	42	14	maintenance	maintenance	NN
cord-335140-njg0ln33	42	15	setting	setting	NN
cord-335140-njg0ln33	42	16	)	)	-RRB-
cord-335140-njg0ln33	42	17	to	to	TO
cord-335140-njg0ln33	42	18	minimize	minimize	VB
cord-335140-njg0ln33	42	19	neutropenia	neutropenia	NN
cord-335140-njg0ln33	42	20	(	(	-LRB-
cord-335140-njg0ln33	42	21	15	15	CD
cord-335140-njg0ln33	42	22	)	)	-RRB-
cord-335140-njg0ln33	42	23	,	,	,
cord-335140-njg0ln33	42	24	more	more	RBR
cord-335140-njg0ln33	42	25	liberal	liberal	JJ
cord-335140-njg0ln33	42	26	use	use	NN
cord-335140-njg0ln33	42	27	of	of	IN
cord-335140-njg0ln33	42	28	GCSF	GCSF	NNP
cord-335140-njg0ln33	42	29	support	support	NN
cord-335140-njg0ln33	42	30	and	and	CC
cord-335140-njg0ln33	42	31	drug	drug	NN
cord-335140-njg0ln33	42	32	"	"	``
cord-335140-njg0ln33	42	33	holidays	holiday	NNS
cord-335140-njg0ln33	42	34	"	"	''
cord-335140-njg0ln33	42	35	may	may	MD
cord-335140-njg0ln33	42	36	be	be	VB
cord-335140-njg0ln33	42	37	carefully	carefully	RB
cord-335140-njg0ln33	42	38	considered	consider	VBN
cord-335140-njg0ln33	42	39	for	for	IN
cord-335140-njg0ln33	42	40	some	some	DT
cord-335140-njg0ln33	42	41	if	if	IN
cord-335140-njg0ln33	42	42	deemed	deem	VBN
cord-335140-njg0ln33	42	43	appropriate	appropriate	JJ
cord-335140-njg0ln33	42	44	.	.	.
cord-335140-njg0ln33	43	1	Careful	careful	JJ
cord-335140-njg0ln33	43	2	discussion	discussion	NN
cord-335140-njg0ln33	43	3	with	with	IN
cord-335140-njg0ln33	43	4	each	each	DT
cord-335140-njg0ln33	43	5	patient	patient	NN
cord-335140-njg0ln33	43	6	is	be	VBZ
cord-335140-njg0ln33	43	7	required	require	VBN
cord-335140-njg0ln33	43	8	to	to	TO
cord-335140-njg0ln33	43	9	establish	establish	VB
cord-335140-njg0ln33	43	10	the	the	DT
cord-335140-njg0ln33	43	11	risk	risk	NN
cord-335140-njg0ln33	43	12	vs	vs	IN
cord-335140-njg0ln33	43	13	benefit	benefit	NN
cord-335140-njg0ln33	43	14	of	of	IN
cord-335140-njg0ln33	43	15	treatment	treatment	NN
cord-335140-njg0ln33	43	16	modifications	modification	NNS
cord-335140-njg0ln33	43	17	in	in	IN
cord-335140-njg0ln33	43	18	the	the	DT
cord-335140-njg0ln33	43	19	light	light	NN
cord-335140-njg0ln33	43	20	of	of	IN
cord-335140-njg0ln33	43	21	the	the	DT
cord-335140-njg0ln33	43	22	ongoing	ongoing	JJ
cord-335140-njg0ln33	43	23	pandemic	pandemic	NN
cord-335140-njg0ln33	43	24	.	.	.
cord-335140-njg0ln33	44	1	Potential	potential	JJ
cord-335140-njg0ln33	44	2	adaptations	adaptation	NNS
cord-335140-njg0ln33	44	3	in	in	IN
cord-335140-njg0ln33	44	4	appropriately	appropriately	RB
cord-335140-njg0ln33	44	5	selected	select	VBN
cord-335140-njg0ln33	44	6	patients	patient	NNS
cord-335140-njg0ln33	44	7	the	the	DT
cord-335140-njg0ln33	44	8	face	face	NN
cord-335140-njg0ln33	44	9	of	of	IN
cord-335140-njg0ln33	44	10	this	this	DT
cord-335140-njg0ln33	44	11	crisis	crisis	NN
cord-335140-njg0ln33	44	12	could	could	MD
cord-335140-njg0ln33	44	13	include	include	VB
cord-335140-njg0ln33	44	14	:	:	:
cord-335140-njg0ln33	44	15			NFP
cord-335140-njg0ln33	44	16	Temporary	temporary	JJ
cord-335140-njg0ln33	44	17	substitution	substitution	NN
cord-335140-njg0ln33	44	18	of	of	IN
cord-335140-njg0ln33	44	19	ixazomib	ixazomib	NNP
cord-335140-njg0ln33	44	20	for	for	IN
cord-335140-njg0ln33	44	21	bortezomib	bortezomib	NNP
cord-335140-njg0ln33	44	22	,	,	,
cord-335140-njg0ln33	44	23	especially	especially	RB
cord-335140-njg0ln33	44	24	in	in	IN
cord-335140-njg0ln33	44	25	patients	patient	NNS
cord-335140-njg0ln33	44	26	with	with	IN
cord-335140-njg0ln33	44	27	good	good	JJ
cord-335140-njg0ln33	44	28	disease	disease	NN
cord-335140-njg0ln33	44	29	control	control	NN
cord-335140-njg0ln33	44	30	on	on	IN
cord-335140-njg0ln33	44	31	combination	combination	NN
cord-335140-njg0ln33	44	32	therapy	therapy	NN
cord-335140-njg0ln33	44	33	or	or	CC
cord-335140-njg0ln33	44	34	maintenance	maintenance	NN
cord-335140-njg0ln33	44	35	(	(	-LRB-
cord-335140-njg0ln33	44	36	16	16	CD
cord-335140-njg0ln33	44	37	,	,	,
cord-335140-njg0ln33	44	38	17	17	CD
cord-335140-njg0ln33	44	39	)	)	-RRB-
cord-335140-njg0ln33	44	40			NFP
cord-335140-njg0ln33	44	41	Moving	move	VBG
cord-335140-njg0ln33	44	42	more	more	RBR
cord-335140-njg0ln33	44	43	quickly	quickly	RB
cord-335140-njg0ln33	44	44	to	to	IN
cord-335140-njg0ln33	44	45	monthly	monthly	JJ
cord-335140-njg0ln33	44	46	administration	administration	NN
cord-335140-njg0ln33	44	47	of	of	IN
cord-335140-njg0ln33	44	48	daratumumab	daratumumab	NNP
cord-335140-njg0ln33	44	49	once	once	RB
cord-335140-njg0ln33	44	50	tumor	tumor	NN
cord-335140-njg0ln33	44	51	burden	burden	NN
cord-335140-njg0ln33	44	52	has	have	VBZ
cord-335140-njg0ln33	44	53	been	be	VBN
cord-335140-njg0ln33	44	54	reduced	reduce	VBN
cord-335140-njg0ln33	44	55	(	(	-LRB-
cord-335140-njg0ln33	44	56	18	18	CD
cord-335140-njg0ln33	44	57	)	)	-RRB-
cord-335140-njg0ln33	44	58			.
cord-335140-njg0ln33	45	1	For	for	IN
cord-335140-njg0ln33	45	2	many	many	JJ
cord-335140-njg0ln33	45	3	,	,	,
cord-335140-njg0ln33	45	4	once	once	RB
cord-335140-njg0ln33	45	5	-	-	HYPH
cord-335140-njg0ln33	45	6	weekly	weekly	NN
cord-335140-njg0ln33	45	7	dosing	dosing	NN
cord-335140-njg0ln33	45	8	of	of	IN
cord-335140-njg0ln33	45	9	bortezomib	bortezomib	NNP
cord-335140-njg0ln33	45	10	and	and	CC
cord-335140-njg0ln33	45	11	carfilzomib	carfilzomib	NNP
cord-335140-njg0ln33	45	12	has	have	VBZ
cord-335140-njg0ln33	45	13	already	already	RB
cord-335140-njg0ln33	45	14	become	become	VBN
cord-335140-njg0ln33	45	15	standard	standard	NN
cord-335140-njg0ln33	45	16	of	of	IN
cord-335140-njg0ln33	45	17	care	care	NN
cord-335140-njg0ln33	45	18	,	,	,
cord-335140-njg0ln33	45	19	and	and	CC
cord-335140-njg0ln33	45	20	if	if	IN
cord-335140-njg0ln33	45	21	not	not	RB
cord-335140-njg0ln33	45	22	,	,	,
cord-335140-njg0ln33	45	23	we	-PRON-	PRP
cord-335140-njg0ln33	45	24	would	would	MD
cord-335140-njg0ln33	45	25	advocate	advocate	VB
cord-335140-njg0ln33	45	26	in	in	IN
cord-335140-njg0ln33	45	27	favour	favour	NN
cord-335140-njg0ln33	45	28	of	of	IN
cord-335140-njg0ln33	45	29	reducing	reduce	VBG
cord-335140-njg0ln33	45	30	the	the	DT
cord-335140-njg0ln33	45	31	schedule	schedule	NN
cord-335140-njg0ln33	45	32	to	to	IN
cord-335140-njg0ln33	45	33	This	this	DT
cord-335140-njg0ln33	45	34	article	article	NN
cord-335140-njg0ln33	45	35	is	be	VBZ
cord-335140-njg0ln33	45	36	protected	protect	VBN
cord-335140-njg0ln33	45	37	by	by	IN
cord-335140-njg0ln33	45	38	copyright	copyright	NN
cord-335140-njg0ln33	45	39	.	.	.
cord-335140-njg0ln33	46	1	All	all	DT
cord-335140-njg0ln33	46	2	rights	right	NNS
cord-335140-njg0ln33	46	3	reserved	reserve	VBD
cord-335140-njg0ln33	46	4	this	this	DT
cord-335140-njg0ln33	46	5	at	at	IN
cord-335140-njg0ln33	46	6	minimum	minimum	NN
cord-335140-njg0ln33	46	7	(	(	-LRB-
cord-335140-njg0ln33	46	8	19	19	CD
cord-335140-njg0ln33	46	9	)	)	-RRB-
cord-335140-njg0ln33	46	10	(	(	-LRB-
cord-335140-njg0ln33	46	11	20	20	CD
cord-335140-njg0ln33	46	12	)	)	-RRB-
cord-335140-njg0ln33	46	13	(	(	-LRB-
cord-335140-njg0ln33	46	14	21	21	CD
cord-335140-njg0ln33	46	15	)	)	-RRB-
cord-335140-njg0ln33	47	1	In	in	IN
cord-335140-njg0ln33	47	2	select	select	JJ
cord-335140-njg0ln33	47	3	patients	patient	NNS
cord-335140-njg0ln33	47	4	with	with	IN
cord-335140-njg0ln33	47	5	responsive	responsive	JJ
cord-335140-njg0ln33	47	6	,	,	,
cord-335140-njg0ln33	47	7	controlled	controlled	JJ
cord-335140-njg0ln33	47	8	disease	disease	NN
cord-335140-njg0ln33	47	9	with	with	IN
cord-335140-njg0ln33	47	10	low	low	JJ
cord-335140-njg0ln33	47	11	tumour	tumour	NN
cord-335140-njg0ln33	47	12	burden	burden	NN
cord-335140-njg0ln33	47	13	,	,	,
cord-335140-njg0ln33	47	14	temporarily	temporarily	RB
cord-335140-njg0ln33	47	15	decreasing	decrease	VBG
cord-335140-njg0ln33	47	16	the	the	DT
cord-335140-njg0ln33	47	17	frequency	frequency	NN
cord-335140-njg0ln33	47	18	of	of	IN
cord-335140-njg0ln33	47	19	administration	administration	NN
cord-335140-njg0ln33	47	20	to	to	IN
cord-335140-njg0ln33	47	21	every	every	DT
cord-335140-njg0ln33	47	22	second	second	JJ
cord-335140-njg0ln33	47	23	week	week	NN
cord-335140-njg0ln33	47	24	could	could	MD
cord-335140-njg0ln33	47	25	be	be	VB
cord-335140-njg0ln33	47	26	a	a	DT
cord-335140-njg0ln33	47	27	potential	potential	JJ
cord-335140-njg0ln33	47	28	option	option	NN
cord-335140-njg0ln33	47	29	(	(	-LRB-
cord-335140-njg0ln33	48	1	22	22	LS
cord-335140-njg0ln33	48	2	)	)	-RRB-
cord-335140-njg0ln33	48	3	Delay	delay	NN
cord-335140-njg0ln33	48	4	or	or	CC
cord-335140-njg0ln33	48	5	cancellation	cancellation	NN
cord-335140-njg0ln33	48	6	of	of	IN
cord-335140-njg0ln33	48	7	autologous	autologous	JJ
cord-335140-njg0ln33	48	8	stem	stem	NN
cord-335140-njg0ln33	48	9	cell	cell	NN
cord-335140-njg0ln33	48	10	transplantation	transplantation	NN
cord-335140-njg0ln33	48	11	(	(	-LRB-
cord-335140-njg0ln33	48	12	ASCT	ASCT	NNP
cord-335140-njg0ln33	48	13	)	)	-RRB-
cord-335140-njg0ln33	48	14	has	have	VBZ
cord-335140-njg0ln33	48	15	been	be	VBN
cord-335140-njg0ln33	48	16	recommended	recommend	VBN
cord-335140-njg0ln33	48	17	wherever	wherever	WRB
cord-335140-njg0ln33	48	18	possible	possible	JJ
cord-335140-njg0ln33	48	19	given	give	VBN
cord-335140-njg0ln33	48	20	its	-PRON-	PRP$
cord-335140-njg0ln33	48	21	significant	significant	JJ
cord-335140-njg0ln33	48	22	and	and	CC
cord-335140-njg0ln33	48	23	prolonged	prolonged	JJ
cord-335140-njg0ln33	48	24	immunosuppression	immunosuppression	NN
cord-335140-njg0ln33	48	25	in	in	IN
cord-335140-njg0ln33	48	26	the	the	DT
cord-335140-njg0ln33	48	27	current	current	JJ
cord-335140-njg0ln33	48	28	landscape	landscape	NN
cord-335140-njg0ln33	48	29	(	(	-LRB-
cord-335140-njg0ln33	48	30	23	23	CD
cord-335140-njg0ln33	48	31	,	,	,
cord-335140-njg0ln33	48	32	24	24	CD
cord-335140-njg0ln33	48	33	)	)	-RRB-
cord-335140-njg0ln33	48	34	.	.	.
cord-335140-njg0ln33	49	1	For	for	IN
cord-335140-njg0ln33	49	2	those	those	DT
cord-335140-njg0ln33	49	3	patients	patient	NNS
cord-335140-njg0ln33	49	4	in	in	IN
cord-335140-njg0ln33	49	5	whom	whom	WP
cord-335140-njg0ln33	49	6	proceeding	proceed	VBG
cord-335140-njg0ln33	49	7	with	with	IN
cord-335140-njg0ln33	49	8	ASCT	ASCT	NNP
cord-335140-njg0ln33	49	9	has	have	VBZ
cord-335140-njg0ln33	49	10	been	be	VBN
cord-335140-njg0ln33	49	11	deemed	deem	VBN
cord-335140-njg0ln33	49	12	absolutely	absolutely	RB
cord-335140-njg0ln33	49	13	necessary	necessary	JJ
cord-335140-njg0ln33	49	14	,	,	,
cord-335140-njg0ln33	49	15	increased	increase	VBN
cord-335140-njg0ln33	49	16	vigilance	vigilance	NN
cord-335140-njg0ln33	49	17	will	will	MD
cord-335140-njg0ln33	49	18	be	be	VB
cord-335140-njg0ln33	49	19	required	require	VBN
cord-335140-njg0ln33	49	20	in	in	IN
cord-335140-njg0ln33	49	21	the	the	DT
cord-335140-njg0ln33	49	22	short	short	JJ
cord-335140-njg0ln33	49	23	-	-	HYPH
cord-335140-njg0ln33	49	24	and	and	CC
cord-335140-njg0ln33	49	25	longerterm	longerterm	NN
cord-335140-njg0ln33	49	26	,	,	,
cord-335140-njg0ln33	49	27	given	give	VBN
cord-335140-njg0ln33	49	28	the	the	DT
cord-335140-njg0ln33	49	29	increased	increase	VBN
cord-335140-njg0ln33	49	30	susceptibility	susceptibility	NN
cord-335140-njg0ln33	49	31	to	to	IN
cord-335140-njg0ln33	49	32	viral	viral	JJ
cord-335140-njg0ln33	49	33	infection	infection	NN
cord-335140-njg0ln33	49	34	that	that	WDT
cord-335140-njg0ln33	49	35	will	will	MD
cord-335140-njg0ln33	49	36	persist	persist	VB
cord-335140-njg0ln33	49	37	beyond	beyond	IN
cord-335140-njg0ln33	49	38	the	the	DT
cord-335140-njg0ln33	49	39	initial	initial	JJ
cord-335140-njg0ln33	49	40	post	post	JJ
cord-335140-njg0ln33	49	41	-	-	JJ
cord-335140-njg0ln33	49	42	transplant	transplant	JJ
cord-335140-njg0ln33	49	43	period	period	NN
cord-335140-njg0ln33	49	44	(	(	-LRB-
cord-335140-njg0ln33	49	45	25	25	CD
cord-335140-njg0ln33	49	46	)	)	-RRB-
cord-335140-njg0ln33	49	47	(	(	-LRB-
cord-335140-njg0ln33	49	48	26	26	CD
cord-335140-njg0ln33	49	49	)	)	-RRB-
cord-335140-njg0ln33	49	50	(	(	-LRB-
cord-335140-njg0ln33	49	51	27	27	CD
cord-335140-njg0ln33	49	52	)	)	-RRB-
cord-335140-njg0ln33	49	53	.	.	.
cord-335140-njg0ln33	50	1	Until	until	IN
cord-335140-njg0ln33	50	2	herd	herd	NN
cord-335140-njg0ln33	50	3	immunity	immunity	NN
cord-335140-njg0ln33	50	4	is	be	VBZ
cord-335140-njg0ln33	50	5	established	establish	VBN
cord-335140-njg0ln33	50	6	,	,	,
cord-335140-njg0ln33	50	7	the	the	DT
cord-335140-njg0ln33	50	8	threat	threat	NN
cord-335140-njg0ln33	50	9	of	of	IN
cord-335140-njg0ln33	50	10	COVID-19	covid-19	JJ
cord-335140-njg0ln33	50	11	infection	infection	NN
cord-335140-njg0ln33	50	12	for	for	IN
cord-335140-njg0ln33	50	13	this	this	DT
cord-335140-njg0ln33	50	14	at	at	IN
cord-335140-njg0ln33	50	15	-	-	HYPH
cord-335140-njg0ln33	50	16	risk	risk	NN
cord-335140-njg0ln33	50	17	population	population	NN
cord-335140-njg0ln33	50	18	will	will	MD
cord-335140-njg0ln33	50	19	very	very	RB
cord-335140-njg0ln33	50	20	likely	likely	RB
cord-335140-njg0ln33	50	21	persist	persist	VB
cord-335140-njg0ln33	50	22	beyond	beyond	IN
cord-335140-njg0ln33	50	23	the	the	DT
cord-335140-njg0ln33	50	24	immediate	immediate	JJ
cord-335140-njg0ln33	50	25	crisis	crisis	NN
cord-335140-njg0ln33	50	26	and	and	CC
cord-335140-njg0ln33	50	27	may	may	MD
cord-335140-njg0ln33	50	28	change	change	VB
cord-335140-njg0ln33	50	29	our	-PRON-	PRP$
cord-335140-njg0ln33	50	30	recommendations	recommendation	NNS
cord-335140-njg0ln33	50	31	for	for	IN
cord-335140-njg0ln33	50	32	surveillance	surveillance	NN
cord-335140-njg0ln33	50	33	and	and	CC
cord-335140-njg0ln33	50	34	prevention	prevention	NN
cord-335140-njg0ln33	50	35	in	in	IN
cord-335140-njg0ln33	50	36	the	the	DT
cord-335140-njg0ln33	50	37	post	post	JJ
cord-335140-njg0ln33	50	38	-	-	JJ
cord-335140-njg0ln33	50	39	transplant	transplant	JJ
cord-335140-njg0ln33	50	40	period	period	NN
cord-335140-njg0ln33	50	41	indefinitely	indefinitely	RB
cord-335140-njg0ln33	50	42	(	(	-LRB-
cord-335140-njg0ln33	50	43	28	28	CD
cord-335140-njg0ln33	50	44	)	)	-RRB-
cord-335140-njg0ln33	50	45	(	(	-LRB-
cord-335140-njg0ln33	50	46	29	29	CD
cord-335140-njg0ln33	50	47	)	)	-RRB-
cord-335140-njg0ln33	50	48	(	(	-LRB-
cord-335140-njg0ln33	50	49	30	30	CD
cord-335140-njg0ln33	50	50	)	)	-RRB-
cord-335140-njg0ln33	50	51	.	.	.
cord-335140-njg0ln33	51	1	Switching	switch	VBG
cord-335140-njg0ln33	51	2	to	to	IN
cord-335140-njg0ln33	51	3	subcutaneous	subcutaneous	JJ
cord-335140-njg0ln33	51	4	rather	rather	RB
cord-335140-njg0ln33	51	5	than	than	IN
cord-335140-njg0ln33	51	6	intravenous	intravenous	JJ
cord-335140-njg0ln33	51	7	preparations	preparation	NNS
cord-335140-njg0ln33	51	8	(	(	-LRB-
cord-335140-njg0ln33	51	9	e.g.	e.g.	RB
cord-335140-njg0ln33	51	10	bortezomib	bortezomib	NNP
cord-335140-njg0ln33	51	11	,	,	,
cord-335140-njg0ln33	51	12	daratumumab	daratumumab	NNP
cord-335140-njg0ln33	51	13	,	,	,
cord-335140-njg0ln33	51	14	denosumab	denosumab	NNP
cord-335140-njg0ln33	51	15	)	)	-RRB-
cord-335140-njg0ln33	51	16	can	can	MD
cord-335140-njg0ln33	51	17	reduce	reduce	VB
cord-335140-njg0ln33	51	18	time	time	NN
cord-335140-njg0ln33	51	19	spent	spend	VBN
cord-335140-njg0ln33	51	20	"	"	''
cord-335140-njg0ln33	51	21	in	in	IN
cord-335140-njg0ln33	51	22	chair	chair	NN
cord-335140-njg0ln33	51	23	"	"	''
cord-335140-njg0ln33	51	24	and	and	CC
cord-335140-njg0ln33	51	25	associated	associate	VBD
cord-335140-njg0ln33	51	26	exposure	exposure	NN
cord-335140-njg0ln33	51	27	risk	risk	NN
cord-335140-njg0ln33	51	28	for	for	IN
cord-335140-njg0ln33	51	29	those	those	DT
cord-335140-njg0ln33	51	30	patients	patient	NNS
cord-335140-njg0ln33	51	31	needing	need	VBG
cord-335140-njg0ln33	51	32	to	to	TO
cord-335140-njg0ln33	51	33	remain	remain	VB
cord-335140-njg0ln33	51	34	on	on	IN
cord-335140-njg0ln33	51	35	parenteral	parenteral	JJ
cord-335140-njg0ln33	51	36	treatment	treatment	NN
cord-335140-njg0ln33	51	37	(	(	-LRB-
cord-335140-njg0ln33	51	38	31	31	CD
cord-335140-njg0ln33	51	39	)	)	-RRB-
cord-335140-njg0ln33	51	40	(	(	-LRB-
cord-335140-njg0ln33	51	41	32	32	CD
cord-335140-njg0ln33	51	42	)	)	-RRB-
cord-335140-njg0ln33	51	43	(	(	-LRB-
cord-335140-njg0ln33	51	44	33	33	CD
cord-335140-njg0ln33	51	45	)	)	-RRB-
cord-335140-njg0ln33	51	46	.	.	.
cord-335140-njg0ln33	52	1	Reports	report	NNS
cord-335140-njg0ln33	52	2	of	of	IN
cord-335140-njg0ln33	52	3	patient	patient	JJ
cord-335140-njg0ln33	52	4	selfadministration	selfadministration	NN
cord-335140-njg0ln33	52	5	of	of	IN
cord-335140-njg0ln33	52	6	subcutaneous	subcutaneous	JJ
cord-335140-njg0ln33	52	7	agents	agent	NNS
cord-335140-njg0ln33	52	8	at	at	IN
cord-335140-njg0ln33	52	9	home	home	NN
cord-335140-njg0ln33	52	10	suggest	suggest	VBP
cord-335140-njg0ln33	52	11	this	this	DT
cord-335140-njg0ln33	52	12	could	could	MD
cord-335140-njg0ln33	52	13	be	be	VB
cord-335140-njg0ln33	52	14	feasible	feasible	JJ
cord-335140-njg0ln33	52	15	in	in	IN
cord-335140-njg0ln33	52	16	appropriately	appropriately	RB
cord-335140-njg0ln33	52	17	trained	train	VBN
cord-335140-njg0ln33	52	18	and	and	CC
cord-335140-njg0ln33	52	19	educated	educate	VBN
cord-335140-njg0ln33	52	20	patients	patient	NNS
cord-335140-njg0ln33	52	21	(	(	-LRB-
cord-335140-njg0ln33	52	22	34	34	CD
cord-335140-njg0ln33	52	23	)	)	-RRB-
cord-335140-njg0ln33	52	24	(	(	-LRB-
cord-335140-njg0ln33	52	25	35	35	CD
cord-335140-njg0ln33	52	26	)	)	-RRB-
cord-335140-njg0ln33	52	27	(	(	-LRB-
cord-335140-njg0ln33	52	28	36	36	CD
cord-335140-njg0ln33	52	29	)	)	-RRB-
cord-335140-njg0ln33	52	30	(	(	-LRB-
cord-335140-njg0ln33	52	31	37	37	CD
cord-335140-njg0ln33	52	32	)	)	-RRB-
cord-335140-njg0ln33	52	33	.	.	.
cord-335140-njg0ln33	53	1	Courier	courier	NN
cord-335140-njg0ln33	53	2	services	service	NNS
cord-335140-njg0ln33	53	3	can	can	MD
cord-335140-njg0ln33	53	4	be	be	VB
cord-335140-njg0ln33	53	5	utilised	utilise	VBN
cord-335140-njg0ln33	53	6	to	to	TO
cord-335140-njg0ln33	53	7	deliver	deliver	VB
cord-335140-njg0ln33	53	8	medications	medication	NNS
cord-335140-njg0ln33	53	9	or	or	CC
cord-335140-njg0ln33	53	10	"	"	``
cord-335140-njg0ln33	53	11	drive	drive	VB
cord-335140-njg0ln33	53	12	through	through	IN
cord-335140-njg0ln33	53	13	"	"	''
cord-335140-njg0ln33	53	14	collection	collection	NN
cord-335140-njg0ln33	53	15	of	of	IN
cord-335140-njg0ln33	53	16	treatment	treatment	NN
cord-335140-njg0ln33	53	17	facilitated	facilitate	VBN
cord-335140-njg0ln33	53	18	.	.	.
cord-335140-njg0ln33	54	1	In	in	IN
cord-335140-njg0ln33	54	2	addition	addition	NN
cord-335140-njg0ln33	54	3	,	,	,
cord-335140-njg0ln33	54	4	reasonable	reasonable	JJ
cord-335140-njg0ln33	54	5	modifications	modification	NNS
cord-335140-njg0ln33	54	6	to	to	IN
cord-335140-njg0ln33	54	7	supportive	supportive	JJ
cord-335140-njg0ln33	54	8	care	care	NN
cord-335140-njg0ln33	54	9	such	such	JJ
cord-335140-njg0ln33	54	10	as	as	IN
cord-335140-njg0ln33	54	11	reducing	reduce	VBG
cord-335140-njg0ln33	54	12	the	the	DT
cord-335140-njg0ln33	54	13	frequency	frequency	NN
cord-335140-njg0ln33	54	14	of	of	IN
cord-335140-njg0ln33	54	15	zoledronic	zoledronic	NNP
cord-335140-njg0ln33	54	16	acid	acid	NN
cord-335140-njg0ln33	54	17	to	to	IN
cord-335140-njg0ln33	54	18	every	every	DT
cord-335140-njg0ln33	54	19	3	3	CD
cord-335140-njg0ln33	54	20	months	month	NNS
cord-335140-njg0ln33	54	21	rather	rather	RB
cord-335140-njg0ln33	54	22	than	than	IN
cord-335140-njg0ln33	54	23	every	every	DT
cord-335140-njg0ln33	54	24	4	4	CD
cord-335140-njg0ln33	54	25	weeks	week	NNS
cord-335140-njg0ln33	54	26	can	can	MD
cord-335140-njg0ln33	54	27	further	further	RB
cord-335140-njg0ln33	54	28	reduce	reduce	VB
cord-335140-njg0ln33	54	29	the	the	DT
cord-335140-njg0ln33	54	30	risk	risk	NN
cord-335140-njg0ln33	54	31	of	of	IN
cord-335140-njg0ln33	54	32	in	in	IN
cord-335140-njg0ln33	54	33	-	-	HYPH
cord-335140-njg0ln33	54	34	person	person	NN
cord-335140-njg0ln33	54	35	interactions	interaction	NNS
cord-335140-njg0ln33	54	36	without	without	IN
cord-335140-njg0ln33	54	37	significantly	significantly	RB
cord-335140-njg0ln33	54	38	impacting	impact	VBG
cord-335140-njg0ln33	54	39	outcome	outcome	NN
cord-335140-njg0ln33	54	40	(	(	-LRB-
cord-335140-njg0ln33	54	41	38	38	CD
cord-335140-njg0ln33	54	42	)	)	-RRB-
cord-335140-njg0ln33	54	43	.	.	.
cord-335140-njg0ln33	55	1	The	the	DT
cord-335140-njg0ln33	55	2	very	very	RB
cord-335140-njg0ln33	55	3	real	real	JJ
cord-335140-njg0ln33	55	4	risk	risk	NN
cord-335140-njg0ln33	55	5	of	of	IN
cord-335140-njg0ln33	55	6	hospitalisation	hospitalisation	NN
cord-335140-njg0ln33	55	7	posed	pose	VBN
cord-335140-njg0ln33	55	8	by	by	IN
cord-335140-njg0ln33	55	9	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	55	10	has	have	VBZ
cord-335140-njg0ln33	55	11	increasingly	increasingly	RB
cord-335140-njg0ln33	55	12	motivated	motivate	VBN
cord-335140-njg0ln33	55	13	both	both	DT
cord-335140-njg0ln33	55	14	patients	patient	NNS
cord-335140-njg0ln33	55	15	and	and	CC
cord-335140-njg0ln33	55	16	treating	treat	VBG
cord-335140-njg0ln33	55	17	physicians	physician	NNS
cord-335140-njg0ln33	55	18	to	to	TO
cord-335140-njg0ln33	55	19	actively	actively	RB
cord-335140-njg0ln33	55	20	engage	engage	VB
cord-335140-njg0ln33	55	21	in	in	IN
cord-335140-njg0ln33	55	22	conversations	conversation	NNS
cord-335140-njg0ln33	55	23	regarding	regard	VBG
cord-335140-njg0ln33	55	24	advance	advance	NN
cord-335140-njg0ln33	55	25	directives	directive	NNS
cord-335140-njg0ln33	55	26	,	,	,
cord-335140-njg0ln33	55	27	goals	goal	NNS
cord-335140-njg0ln33	55	28	of	of	IN
cord-335140-njg0ln33	55	29	care	care	NN
cord-335140-njg0ln33	55	30	and	and	CC
cord-335140-njg0ln33	55	31	end	end	NN
cord-335140-njg0ln33	55	32	-	-	HYPH
cord-335140-njg0ln33	55	33	of	of	IN
cord-335140-njg0ln33	55	34	-	-	HYPH
cord-335140-njg0ln33	55	35	life	life	NN
cord-335140-njg0ln33	55	36	planning	planning	NN
cord-335140-njg0ln33	55	37	-and	-and	:
cord-335140-njg0ln33	55	38	to	to	TO
cord-335140-njg0ln33	55	39	document	document	VB
cord-335140-njg0ln33	55	40	these	these	DT
cord-335140-njg0ln33	55	41	clearly	clearly	RB
cord-335140-njg0ln33	55	42	(	(	-LRB-
cord-335140-njg0ln33	55	43	39	39	CD
cord-335140-njg0ln33	55	44	,	,	,
cord-335140-njg0ln33	55	45	40	40	CD
cord-335140-njg0ln33	55	46	)	)	-RRB-
cord-335140-njg0ln33	55	47	.	.	.
cord-335140-njg0ln33	56	1	This	this	DT
cord-335140-njg0ln33	56	2	open	open	JJ
cord-335140-njg0ln33	56	3	communication	communication	NN
cord-335140-njg0ln33	56	4	is	be	VBZ
cord-335140-njg0ln33	56	5	crucial	crucial	JJ
cord-335140-njg0ln33	56	6	to	to	TO
cord-335140-njg0ln33	56	7	ensure	ensure	VB
cord-335140-njg0ln33	56	8	the	the	DT
cord-335140-njg0ln33	56	9	development	development	NN
cord-335140-njg0ln33	56	10	of	of	IN
cord-335140-njg0ln33	56	11	a	a	DT
cord-335140-njg0ln33	56	12	treatment	treatment	NN
cord-335140-njg0ln33	56	13	plan	plan	NN
cord-335140-njg0ln33	56	14	for	for	IN
cord-335140-njg0ln33	56	15	each	each	DT
cord-335140-njg0ln33	56	16	patient	patient	NN
cord-335140-njg0ln33	56	17	that	that	WDT
cord-335140-njg0ln33	56	18	is	be	VBZ
cord-335140-njg0ln33	56	19	medically	medically	RB
cord-335140-njg0ln33	56	20	appropriate	appropriate	JJ
cord-335140-njg0ln33	56	21	and	and	CC
cord-335140-njg0ln33	56	22	concordant	concordant	JJ
cord-335140-njg0ln33	56	23	with	with	IN
cord-335140-njg0ln33	56	24	the	the	DT
cord-335140-njg0ln33	56	25	patient	patient	NN
cord-335140-njg0ln33	56	26	's	's	POS
cord-335140-njg0ln33	56	27	wishes	wish	NNS
cord-335140-njg0ln33	56	28	(	(	-LRB-
cord-335140-njg0ln33	56	29	41	41	CD
cord-335140-njg0ln33	56	30	)	)	-RRB-
cord-335140-njg0ln33	56	31	.	.	.
cord-335140-njg0ln33	57	1	Despite	despite	IN
cord-335140-njg0ln33	57	2	the	the	DT
cord-335140-njg0ln33	57	3	fact	fact	NN
cord-335140-njg0ln33	57	4	that	that	IN
cord-335140-njg0ln33	57	5	at	at	IN
cord-335140-njg0ln33	57	6	the	the	DT
cord-335140-njg0ln33	57	7	time	time	NN
cord-335140-njg0ln33	57	8	of	of	IN
cord-335140-njg0ln33	57	9	writing	writing	NN
cord-335140-njg0ln33	57	10	there	there	EX
cord-335140-njg0ln33	57	11	are	be	VBP
cord-335140-njg0ln33	57	12	over	over	IN
cord-335140-njg0ln33	57	13	3000	3000	CD
cord-335140-njg0ln33	57	14	published	publish	VBN
cord-335140-njg0ln33	57	15	articles	article	NNS
cord-335140-njg0ln33	57	16	on	on	IN
cord-335140-njg0ln33	57	17	COVID	COVID	NNP
cord-335140-njg0ln33	57	18	,	,	,
cord-335140-njg0ln33	57	19	the	the	DT
cord-335140-njg0ln33	57	20	data	datum	NNS
cord-335140-njg0ln33	57	21	on	on	IN
cord-335140-njg0ln33	57	22	the	the	DT
cord-335140-njg0ln33	57	23	true	true	JJ
cord-335140-njg0ln33	57	24	risk	risk	NN
cord-335140-njg0ln33	57	25	posed	pose	VBN
cord-335140-njg0ln33	57	26	by	by	IN
cord-335140-njg0ln33	57	27	this	this	DT
cord-335140-njg0ln33	57	28	virus	virus	NN
cord-335140-njg0ln33	57	29	to	to	IN
cord-335140-njg0ln33	57	30	myeloma	myeloma	NN
cord-335140-njg0ln33	57	31	patients	patient	NNS
cord-335140-njg0ln33	57	32	remains	remain	VBZ
cord-335140-njg0ln33	57	33	immature	immature	JJ
cord-335140-njg0ln33	57	34	.	.	.
cord-335140-njg0ln33	58	1	Early	early	JJ
cord-335140-njg0ln33	58	2	reports	report	NNS
cord-335140-njg0ln33	58	3	there	there	EX
cord-335140-njg0ln33	58	4	are	be	VBP
cord-335140-njg0ln33	58	5	suggest	suggest	VBP
cord-335140-njg0ln33	58	6	that	that	IN
cord-335140-njg0ln33	58	7	patients	patient	NNS
cord-335140-njg0ln33	58	8	with	with	IN
cord-335140-njg0ln33	58	9	underlying	underlying	JJ
cord-335140-njg0ln33	58	10	malignancy	malignancy	NN
cord-335140-njg0ln33	58	11	are	be	VBP
cord-335140-njg0ln33	58	12	at	at	IN
cord-335140-njg0ln33	58	13	increased	increase	VBN
cord-335140-njg0ln33	58	14	risk	risk	NN
cord-335140-njg0ln33	58	15	of	of	IN
cord-335140-njg0ln33	58	16	both	both	CC
cord-335140-njg0ln33	58	17	serious	serious	JJ
cord-335140-njg0ln33	58	18	morbidity	morbidity	NN
cord-335140-njg0ln33	58	19	and	and	CC
cord-335140-njg0ln33	58	20	death	death	NN
cord-335140-njg0ln33	58	21	(	(	-LRB-
cord-335140-njg0ln33	58	22	42	42	CD
cord-335140-njg0ln33	58	23	,	,	,
cord-335140-njg0ln33	58	24	43	43	CD
cord-335140-njg0ln33	58	25	)	)	-RRB-
cord-335140-njg0ln33	58	26	.	.	.
cord-335140-njg0ln33	59	1	Given	give	VBN
cord-335140-njg0ln33	59	2	the	the	DT
cord-335140-njg0ln33	59	3	existing	exist	VBG
cord-335140-njg0ln33	59	4	pre	pre	JJ
cord-335140-njg0ln33	59	5	-	-	NN
cord-335140-njg0ln33	59	6	disposition	disposition	NN
cord-335140-njg0ln33	59	7	of	of	IN
cord-335140-njg0ln33	59	8	myeloma	myeloma	NN
cord-335140-njg0ln33	59	9	patients	patient	NNS
cord-335140-njg0ln33	59	10	to	to	IN
cord-335140-njg0ln33	59	11	infection	infection	NN
cord-335140-njg0ln33	59	12	generally	generally	RB
cord-335140-njg0ln33	59	13	,	,	,
cord-335140-njg0ln33	59	14	in	in	IN
cord-335140-njg0ln33	59	15	particular	particular	JJ
cord-335140-njg0ln33	59	16	viral	viral	JJ
cord-335140-njg0ln33	59	17	respiratory	respiratory	JJ
cord-335140-njg0ln33	59	18	infections	infection	NNS
cord-335140-njg0ln33	59	19	,	,	,
cord-335140-njg0ln33	59	20	it	-PRON-	PRP
cord-335140-njg0ln33	59	21	seems	seem	VBZ
cord-335140-njg0ln33	59	22	reasonable	reasonable	JJ
cord-335140-njg0ln33	59	23	to	to	TO
cord-335140-njg0ln33	59	24	conclude	conclude	VB
cord-335140-njg0ln33	59	25	in	in	IN
cord-335140-njg0ln33	59	26	the	the	DT
cord-335140-njg0ln33	59	27	short	short	JJ
cord-335140-njg0ln33	59	28	-	-	HYPH
cord-335140-njg0ln33	59	29	term	term	NN
cord-335140-njg0ln33	59	30	that	that	WDT
cord-335140-njg0ln33	59	31	their	-PRON-	PRP$
cord-335140-njg0ln33	59	32	risk	risk	NN
cord-335140-njg0ln33	59	33	of	of	IN
cord-335140-njg0ln33	59	34	serious	serious	JJ
cord-335140-njg0ln33	59	35	complications	complication	NNS
cord-335140-njg0ln33	59	36	is	be	VBZ
cord-335140-njg0ln33	59	37	increased	increase	VBN
cord-335140-njg0ln33	59	38	.	.	.
cord-335140-njg0ln33	60	1	However	however	RB
cord-335140-njg0ln33	60	2	,	,	,
cord-335140-njg0ln33	60	3	there	there	EX
cord-335140-njg0ln33	60	4	are	be	VBP
cord-335140-njg0ln33	60	5	early	early	JJ
cord-335140-njg0ln33	60	6	suggestions	suggestion	NNS
cord-335140-njg0ln33	60	7	that	that	IN
cord-335140-njg0ln33	60	8	certain	certain	JJ
cord-335140-njg0ln33	60	9	agents	agent	NNS
cord-335140-njg0ln33	60	10	used	use	VBN
cord-335140-njg0ln33	60	11	in	in	IN
cord-335140-njg0ln33	60	12	the	the	DT
cord-335140-njg0ln33	60	13	treatment	treatment	NN
cord-335140-njg0ln33	60	14	of	of	IN
cord-335140-njg0ln33	60	15	myeloma	myeloma	NN
cord-335140-njg0ln33	60	16	could	could	MD
cord-335140-njg0ln33	60	17	be	be	VB
cord-335140-njg0ln33	60	18	useful	useful	JJ
cord-335140-njg0ln33	60	19	against	against	IN
cord-335140-njg0ln33	60	20	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	60	21	,	,	,
cord-335140-njg0ln33	60	22	including	include	VBG
cord-335140-njg0ln33	60	23	selinexor	selinexor	NN
cord-335140-njg0ln33	60	24	and	and	CC
cord-335140-njg0ln33	60	25	ixazomib	ixazomib	NNP
cord-335140-njg0ln33	60	26	(	(	-LRB-
cord-335140-njg0ln33	60	27	44	44	CD
cord-335140-njg0ln33	60	28	)	)	-RRB-
cord-335140-njg0ln33	60	29	(	(	-LRB-
cord-335140-njg0ln33	60	30	45	45	CD
cord-335140-njg0ln33	60	31	)	)	-RRB-
cord-335140-njg0ln33	60	32	(	(	-LRB-
cord-335140-njg0ln33	60	33	46	46	CD
cord-335140-njg0ln33	60	34	)	)	-RRB-
cord-335140-njg0ln33	60	35	.	.	.
cord-335140-njg0ln33	61	1	Angiotensinconverting	angiotensinconverting	NN
cord-335140-njg0ln33	61	2	enzyme	enzyme	NN
cord-335140-njg0ln33	61	3	2	2	CD
cord-335140-njg0ln33	61	4	(	(	-LRB-
cord-335140-njg0ln33	61	5	ACE2	ACE2	NNP
cord-335140-njg0ln33	61	6	)	)	-RRB-
cord-335140-njg0ln33	61	7	is	be	VBZ
cord-335140-njg0ln33	61	8	a	a	DT
cord-335140-njg0ln33	61	9	co	co	NN
cord-335140-njg0ln33	61	10	-	-	NN
cord-335140-njg0ln33	61	11	receptor	receptor	NN
cord-335140-njg0ln33	61	12	for	for	IN
cord-335140-njg0ln33	61	13	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	61	14	,	,	,
cord-335140-njg0ln33	61	15	but	but	CC
cord-335140-njg0ln33	61	16	it	-PRON-	PRP
cord-335140-njg0ln33	61	17	remains	remain	VBZ
cord-335140-njg0ln33	61	18	unclear	unclear	JJ
cord-335140-njg0ln33	61	19	whether	whether	IN
cord-335140-njg0ln33	61	20	angiotensin	angiotensin	NN
cord-335140-njg0ln33	61	21	-	-	HYPH
cord-335140-njg0ln33	61	22	converting	convert	VBG
cord-335140-njg0ln33	61	23	enzyme	enzyme	NN
cord-335140-njg0ln33	61	24	inhibitors	inhibitor	NNS
cord-335140-njg0ln33	61	25	or	or	CC
cord-335140-njg0ln33	61	26	receptor	receptor	NN
cord-335140-njg0ln33	61	27	blockers	blocker	NNS
cord-335140-njg0ln33	61	28	,	,	,
cord-335140-njg0ln33	61	29	which	which	WDT
cord-335140-njg0ln33	61	30	are	be	VBP
cord-335140-njg0ln33	61	31	commonly	commonly	RB
cord-335140-njg0ln33	61	32	coprescribed	coprescribe	VBN
cord-335140-njg0ln33	61	33	for	for	IN
cord-335140-njg0ln33	61	34	myeloma	myeloma	NN
cord-335140-njg0ln33	61	35	patients	patient	NNS
cord-335140-njg0ln33	61	36	,	,	,
cord-335140-njg0ln33	61	37	could	could	MD
cord-335140-njg0ln33	61	38	either	either	CC
cord-335140-njg0ln33	61	39	aggravate	aggravate	VB
cord-335140-njg0ln33	61	40	or	or	CC
cord-335140-njg0ln33	61	41	ameliorate	ameliorate	VB
cord-335140-njg0ln33	61	42	the	the	DT
cord-335140-njg0ln33	61	43	disease	disease	NN
cord-335140-njg0ln33	61	44	(	(	-LRB-
cord-335140-njg0ln33	61	45	47	47	CD
cord-335140-njg0ln33	61	46	)	)	-RRB-
cord-335140-njg0ln33	61	47	(	(	-LRB-
cord-335140-njg0ln33	61	48	48	48	CD
cord-335140-njg0ln33	61	49	)	)	-RRB-
cord-335140-njg0ln33	61	50	(	(	-LRB-
cord-335140-njg0ln33	61	51	49	49	CD
cord-335140-njg0ln33	61	52	)	)	-RRB-
cord-335140-njg0ln33	61	53	.	.	.
cord-335140-njg0ln33	62	1	In	in	IN
cord-335140-njg0ln33	62	2	addition	addition	NN
cord-335140-njg0ln33	62	3	,	,	,
cord-335140-njg0ln33	62	4	if	if	IN
cord-335140-njg0ln33	62	5	a	a	DT
cord-335140-njg0ln33	62	6	vaccine	vaccine	NN
cord-335140-njg0ln33	62	7	is	be	VBZ
cord-335140-njg0ln33	62	8	ultimately	ultimately	RB
cord-335140-njg0ln33	62	9	developed	develop	VBN
cord-335140-njg0ln33	62	10	,	,	,
cord-335140-njg0ln33	62	11	it	-PRON-	PRP
cord-335140-njg0ln33	62	12	will	will	MD
cord-335140-njg0ln33	62	13	need	need	VB
cord-335140-njg0ln33	62	14	to	to	TO
cord-335140-njg0ln33	62	15	be	be	VB
cord-335140-njg0ln33	62	16	ascertained	ascertain	VBN
cord-335140-njg0ln33	62	17	if	if	IN
cord-335140-njg0ln33	62	18	myeloma	myeloma	NN
cord-335140-njg0ln33	62	19	patients	patient	NNS
cord-335140-njg0ln33	62	20	can	can	MD
cord-335140-njg0ln33	62	21	mount	mount	VB
cord-335140-njg0ln33	62	22	effective	effective	JJ
cord-335140-njg0ln33	62	23	responses	response	NNS
cord-335140-njg0ln33	62	24	or	or	CC
cord-335140-njg0ln33	62	25	if	if	IN
cord-335140-njg0ln33	62	26	additional	additional	JJ
cord-335140-njg0ln33	62	27	booster	booster	NN
cord-335140-njg0ln33	62	28	doses	dose	NNS
cord-335140-njg0ln33	62	29	are	be	VBP
cord-335140-njg0ln33	62	30	needed	need	VBN
cord-335140-njg0ln33	62	31	to	to	TO
cord-335140-njg0ln33	62	32	confer	confer	VB
cord-335140-njg0ln33	62	33	sufficient	sufficient	JJ
cord-335140-njg0ln33	62	34	protection	protection	NN
cord-335140-njg0ln33	62	35	(	(	-LRB-
cord-335140-njg0ln33	62	36	50	50	CD
cord-335140-njg0ln33	62	37	,	,	,
cord-335140-njg0ln33	62	38	51	51	CD
cord-335140-njg0ln33	62	39	)	)	-RRB-
cord-335140-njg0ln33	62	40	.	.	.
cord-335140-njg0ln33	63	1	Will	Will	MD
cord-335140-njg0ln33	63	2	anti	anti	JJ
cord-335140-njg0ln33	63	3	-	-	JJ
cord-335140-njg0ln33	63	4	viral	viral	JJ
cord-335140-njg0ln33	63	5	prophylaxis	prophylaxis	NN
cord-335140-njg0ln33	63	6	(	(	-LRB-
cord-335140-njg0ln33	63	7	once	once	RB
cord-335140-njg0ln33	63	8	available	available	JJ
cord-335140-njg0ln33	63	9	)	)	-RRB-
cord-335140-njg0ln33	63	10	be	be	VB
cord-335140-njg0ln33	63	11	required	require	VBN
cord-335140-njg0ln33	63	12	for	for	IN
cord-335140-njg0ln33	63	13	certain	certain	JJ
cord-335140-njg0ln33	63	14	at	at	IN
cord-335140-njg0ln33	63	15	-	-	HYPH
cord-335140-njg0ln33	63	16	risk	risk	NN
cord-335140-njg0ln33	63	17	groups	group	NNS
cord-335140-njg0ln33	63	18	?	?	.
cord-335140-njg0ln33	64	1	Only	only	JJ
cord-335140-njg0ln33	64	2	time	time	NN
cord-335140-njg0ln33	64	3	,	,	,
cord-335140-njg0ln33	64	4	and	and	CC
cord-335140-njg0ln33	64	5	the	the	DT
cord-335140-njg0ln33	64	6	emergence	emergence	NN
cord-335140-njg0ln33	64	7	of	of	IN
cord-335140-njg0ln33	64	8	more	more	JJR
cord-335140-njg0ln33	64	9	data	datum	NNS
cord-335140-njg0ln33	64	10	,	,	,
cord-335140-njg0ln33	64	11	will	will	MD
cord-335140-njg0ln33	64	12	tell	tell	VB
cord-335140-njg0ln33	64	13	.	.	.
cord-335140-njg0ln33	65	1	It	-PRON-	PRP
cord-335140-njg0ln33	65	2	is	be	VBZ
cord-335140-njg0ln33	65	3	hard	hard	JJ
cord-335140-njg0ln33	65	4	to	to	TO
cord-335140-njg0ln33	65	5	conceive	conceive	VB
cord-335140-njg0ln33	65	6	that	that	IN
cord-335140-njg0ln33	65	7	things	thing	NNS
cord-335140-njg0ln33	65	8	will	will	MD
cord-335140-njg0ln33	65	9	return	return	VB
cord-335140-njg0ln33	65	10	completely	completely	RB
cord-335140-njg0ln33	65	11	to	to	IN
cord-335140-njg0ln33	65	12	how	how	WRB
cord-335140-njg0ln33	65	13	they	-PRON-	PRP
cord-335140-njg0ln33	65	14	were	be	VBD
cord-335140-njg0ln33	65	15	in	in	IN
cord-335140-njg0ln33	65	16	the	the	DT
cord-335140-njg0ln33	65	17	wake	wake	NN
cord-335140-njg0ln33	65	18	of	of	IN
cord-335140-njg0ln33	65	19	the	the	DT
cord-335140-njg0ln33	65	20	immediate	immediate	JJ
cord-335140-njg0ln33	65	21	crisis	crisis	NN
cord-335140-njg0ln33	65	22	.	.	.
cord-335140-njg0ln33	66	1	One	one	CD
cord-335140-njg0ln33	66	2	myeloma	myeloma	NN
cord-335140-njg0ln33	66	3	physician	physician	NN
cord-335140-njg0ln33	66	4	has	have	VBZ
cord-335140-njg0ln33	66	5	suggested	suggest	VBN
cord-335140-njg0ln33	66	6	things	thing	NNS
cord-335140-njg0ln33	66	7	will	will	MD
cord-335140-njg0ln33	66	8	now	now	RB
cord-335140-njg0ln33	66	9	be	be	VB
cord-335140-njg0ln33	66	10	considered	consider	VBN
cord-335140-njg0ln33	66	11	in	in	IN
cord-335140-njg0ln33	66	12	terms	term	NNS
cord-335140-njg0ln33	66	13	of	of	IN
cord-335140-njg0ln33	66	14	whether	whether	IN
cord-335140-njg0ln33	66	15	they	-PRON-	PRP
cord-335140-njg0ln33	66	16	were	be	VBD
cord-335140-njg0ln33	66	17	"	"	``
cord-335140-njg0ln33	66	18	BC	BC	NNP
cord-335140-njg0ln33	66	19	"	"	''
cord-335140-njg0ln33	66	20	(	(	-LRB-
cord-335140-njg0ln33	66	21	Before	before	IN
cord-335140-njg0ln33	66	22	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	66	23	)	)	-RRB-
cord-335140-njg0ln33	66	24	or	or	CC
cord-335140-njg0ln33	66	25	"	"	``
cord-335140-njg0ln33	66	26	AC	ac	NN
cord-335140-njg0ln33	66	27	"	"	''
cord-335140-njg0ln33	66	28	(	(	-LRB-
cord-335140-njg0ln33	66	29	After	after	IN
cord-335140-njg0ln33	66	30	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	66	31	)	)	-RRB-
cord-335140-njg0ln33	66	32	(	(	-LRB-
cord-335140-njg0ln33	66	33	52	52	CD
cord-335140-njg0ln33	66	34	)	)	-RRB-
cord-335140-njg0ln33	66	35	.	.	.
cord-335140-njg0ln33	67	1	One	one	CD
cord-335140-njg0ln33	67	2	major	major	JJ
cord-335140-njg0ln33	67	3	benefit	benefit	NN
cord-335140-njg0ln33	67	4	to	to	IN
cord-335140-njg0ln33	67	5	myeloma	myeloma	NN
cord-335140-njg0ln33	67	6	patients	patient	NNS
cord-335140-njg0ln33	67	7	arising	arise	VBG
cord-335140-njg0ln33	67	8	from	from	IN
cord-335140-njg0ln33	67	9	this	this	DT
cord-335140-njg0ln33	67	10	pandemic	pandemic	NN
cord-335140-njg0ln33	67	11	will	will	MD
cord-335140-njg0ln33	67	12	be	be	VB
cord-335140-njg0ln33	67	13	the	the	DT
cord-335140-njg0ln33	67	14	ongoing	ongoing	JJ
cord-335140-njg0ln33	67	15	expansion	expansion	NN
cord-335140-njg0ln33	67	16	of	of	IN
cord-335140-njg0ln33	67	17	virtual	virtual	JJ
cord-335140-njg0ln33	67	18	healthcare	healthcare	NN
cord-335140-njg0ln33	67	19	.	.	.
cord-335140-njg0ln33	68	1	It	-PRON-	PRP
cord-335140-njg0ln33	68	2	has	have	VBZ
cord-335140-njg0ln33	68	3	significant	significant	JJ
cord-335140-njg0ln33	68	4	advantages	advantage	NNS
cord-335140-njg0ln33	68	5	for	for	IN
cord-335140-njg0ln33	68	6	both	both	DT
cord-335140-njg0ln33	68	7	patients	patient	NNS
cord-335140-njg0ln33	68	8	and	and	CC
cord-335140-njg0ln33	68	9	healthcare	healthcare	NN
cord-335140-njg0ln33	68	10	systems	system	NNS
cord-335140-njg0ln33	68	11	-it	-it	:
cord-335140-njg0ln33	68	12	is	be	VBZ
cord-335140-njg0ln33	68	13	convenient	convenient	JJ
cord-335140-njg0ln33	68	14	,	,	,
cord-335140-njg0ln33	68	15	liberates	liberate	VBZ
cord-335140-njg0ln33	68	16	resources	resource	NNS
cord-335140-njg0ln33	68	17	on	on	IN
cord-335140-njg0ln33	68	18	site	site	NN
cord-335140-njg0ln33	68	19	(	(	-LRB-
cord-335140-njg0ln33	68	20	frees	free	VBZ
cord-335140-njg0ln33	68	21	up	up	RP
cord-335140-njg0ln33	68	22	in	in	IN
cord-335140-njg0ln33	68	23	-	-	HYPH
cord-335140-njg0ln33	68	24	person	person	NN
cord-335140-njg0ln33	68	25	clinic	clinic	NN
cord-335140-njg0ln33	68	26	space	space	NN
cord-335140-njg0ln33	68	27	)	)	-RRB-
cord-335140-njg0ln33	68	28	,	,	,
cord-335140-njg0ln33	68	29	but	but	CC
cord-335140-njg0ln33	68	30	more	more	RBR
cord-335140-njg0ln33	68	31	This	this	DT
cord-335140-njg0ln33	68	32	article	article	NN
cord-335140-njg0ln33	68	33	is	be	VBZ
cord-335140-njg0ln33	68	34	protected	protect	VBN
cord-335140-njg0ln33	68	35	by	by	IN
cord-335140-njg0ln33	68	36	copyright	copyright	NN
cord-335140-njg0ln33	68	37	.	.	.
cord-335140-njg0ln33	69	1	All	all	DT
cord-335140-njg0ln33	69	2	rights	right	NNS
cord-335140-njg0ln33	69	3	reserved	reserve	VBN
cord-335140-njg0ln33	69	4	importantly	importantly	RB
cord-335140-njg0ln33	69	5	saves	save	VBZ
cord-335140-njg0ln33	69	6	patients	patient	NNS
cord-335140-njg0ln33	69	7	the	the	DT
cord-335140-njg0ln33	69	8	cost	cost	NN
cord-335140-njg0ln33	69	9	and	and	CC
cord-335140-njg0ln33	69	10	inconvenience	inconvenience	NN
cord-335140-njg0ln33	69	11	of	of	IN
cord-335140-njg0ln33	69	12	travel	travel	NN
cord-335140-njg0ln33	69	13	(	(	-LRB-
cord-335140-njg0ln33	69	14	10	10	CD
cord-335140-njg0ln33	69	15	)	)	-RRB-
cord-335140-njg0ln33	69	16	.	.	.
cord-335140-njg0ln33	70	1	Shared	share	VBN
cord-335140-njg0ln33	70	2	virtual	virtual	JJ
cord-335140-njg0ln33	70	3	care	care	NN
cord-335140-njg0ln33	70	4	with	with	IN
cord-335140-njg0ln33	70	5	comprehensive	comprehensive	JJ
cord-335140-njg0ln33	70	6	myeloma	myeloma	NN
cord-335140-njg0ln33	70	7	centres	centre	NNS
cord-335140-njg0ln33	70	8	could	could	MD
cord-335140-njg0ln33	70	9	become	become	VB
cord-335140-njg0ln33	70	10	an	an	DT
cord-335140-njg0ln33	70	11	option	option	NN
cord-335140-njg0ln33	70	12	for	for	IN
cord-335140-njg0ln33	70	13	patients	patient	NNS
cord-335140-njg0ln33	70	14	regardless	regardless	RB
cord-335140-njg0ln33	70	15	of	of	IN
cord-335140-njg0ln33	70	16	their	-PRON-	PRP$
cord-335140-njg0ln33	70	17	geographical	geographical	JJ
cord-335140-njg0ln33	70	18	location	location	NN
cord-335140-njg0ln33	70	19	-with	-with	:
cord-335140-njg0ln33	70	20	potential	potential	JJ
cord-335140-njg0ln33	70	21	benefits	benefit	NNS
cord-335140-njg0ln33	70	22	including	include	VBG
cord-335140-njg0ln33	70	23	improved	improve	VBN
cord-335140-njg0ln33	70	24	survival	survival	NN
cord-335140-njg0ln33	70	25	(	(	-LRB-
cord-335140-njg0ln33	70	26	53	53	CD
cord-335140-njg0ln33	70	27	)	)	-RRB-
cord-335140-njg0ln33	70	28	.	.	.
cord-335140-njg0ln33	71	1	Virtual	virtual	JJ
cord-335140-njg0ln33	71	2	visits	visit	NNS
cord-335140-njg0ln33	71	3	and	and	CC
cord-335140-njg0ln33	71	4	treatment	treatment	NN
cord-335140-njg0ln33	71	5	could	could	MD
cord-335140-njg0ln33	71	6	also	also	RB
cord-335140-njg0ln33	71	7	increase	increase	VB
cord-335140-njg0ln33	71	8	access	access	NN
cord-335140-njg0ln33	71	9	to	to	IN
cord-335140-njg0ln33	71	10	clinical	clinical	JJ
cord-335140-njg0ln33	71	11	trials	trial	NNS
cord-335140-njg0ln33	71	12	for	for	IN
cord-335140-njg0ln33	71	13	those	those	DT
cord-335140-njg0ln33	71	14	living	live	VBG
cord-335140-njg0ln33	71	15	at	at	IN
cord-335140-njg0ln33	71	16	a	a	DT
cord-335140-njg0ln33	71	17	distance	distance	NN
cord-335140-njg0ln33	71	18	from	from	IN
cord-335140-njg0ln33	71	19	investigative	investigative	JJ
cord-335140-njg0ln33	71	20	centres	centre	NNS
cord-335140-njg0ln33	71	21	(	(	-LRB-
cord-335140-njg0ln33	71	22	10	10	CD
cord-335140-njg0ln33	71	23	)	)	-RRB-
cord-335140-njg0ln33	71	24	.	.	.
cord-335140-njg0ln33	72	1	Which	which	WDT
cord-335140-njg0ln33	72	2	patients	patient	NNS
cord-335140-njg0ln33	72	3	can	can	MD
cord-335140-njg0ln33	72	4	be	be	VB
cord-335140-njg0ln33	72	5	considered	consider	VBN
cord-335140-njg0ln33	72	6	best	best	RB
cord-335140-njg0ln33	72	7	served	serve	VBN
cord-335140-njg0ln33	72	8	by	by	IN
cord-335140-njg0ln33	72	9	telemedicine	telemedicine	NN
cord-335140-njg0ln33	72	10	will	will	MD
cord-335140-njg0ln33	72	11	vary	vary	VB
cord-335140-njg0ln33	72	12	,	,	,
cord-335140-njg0ln33	72	13	but	but	CC
cord-335140-njg0ln33	72	14	could	could	MD
cord-335140-njg0ln33	72	15	include	include	VB
cord-335140-njg0ln33	72	16	those	those	DT
cord-335140-njg0ln33	72	17	under	under	IN
cord-335140-njg0ln33	72	18	surveillance	surveillance	NN
cord-335140-njg0ln33	72	19	,	,	,
cord-335140-njg0ln33	72	20	stable	stable	JJ
cord-335140-njg0ln33	72	21	on	on	IN
cord-335140-njg0ln33	72	22	maintenance	maintenance	NN
cord-335140-njg0ln33	72	23	therapy	therapy	NN
cord-335140-njg0ln33	72	24	or	or	CC
cord-335140-njg0ln33	72	25	every	every	DT
cord-335140-njg0ln33	72	26	other	other	JJ
cord-335140-njg0ln33	72	27	cycle	cycle	NN
cord-335140-njg0ln33	72	28	for	for	IN
cord-335140-njg0ln33	72	29	those	those	DT
cord-335140-njg0ln33	72	30	on	on	IN
cord-335140-njg0ln33	72	31	prolonged	prolong	VBN
cord-335140-njg0ln33	72	32	treatment	treatment	NN
cord-335140-njg0ln33	72	33	regimens	regimen	NNS
cord-335140-njg0ln33	72	34	.	.	.
cord-335140-njg0ln33	73	1	Whether	whether	IN
cord-335140-njg0ln33	73	2	a	a	DT
cord-335140-njg0ln33	73	3	patient	patient	NN
cord-335140-njg0ln33	73	4	can	can	MD
cord-335140-njg0ln33	73	5	be	be	VB
cord-335140-njg0ln33	73	6	followed	follow	VBN
cord-335140-njg0ln33	73	7	up	up	RP
cord-335140-njg0ln33	73	8	"	"	``
cord-335140-njg0ln33	73	9	virtually	virtually	RB
cord-335140-njg0ln33	73	10	"	"	''
cord-335140-njg0ln33	73	11	will	will	MD
cord-335140-njg0ln33	73	12	always	always	RB
cord-335140-njg0ln33	73	13	be	be	VB
cord-335140-njg0ln33	73	14	a	a	DT
cord-335140-njg0ln33	73	15	judgement	judgement	NN
cord-335140-njg0ln33	73	16	call	call	NN
cord-335140-njg0ln33	73	17	,	,	,
cord-335140-njg0ln33	73	18	but	but	CC
cord-335140-njg0ln33	73	19	for	for	IN
cord-335140-njg0ln33	73	20	those	those	DT
cord-335140-njg0ln33	73	21	well	well	RB
cord-335140-njg0ln33	73	22	-	-	HYPH
cord-335140-njg0ln33	73	23	served	serve	VBN
cord-335140-njg0ln33	73	24	by	by	IN
cord-335140-njg0ln33	73	25	this	this	DT
cord-335140-njg0ln33	73	26	approach	approach	NN
cord-335140-njg0ln33	73	27	the	the	DT
cord-335140-njg0ln33	73	28	technology	technology	NN
cord-335140-njg0ln33	73	29	(	(	-LRB-
cord-335140-njg0ln33	73	30	and	and	CC
cord-335140-njg0ln33	73	31	reimbursement	reimbursement	NN
cord-335140-njg0ln33	73	32	)	)	-RRB-
cord-335140-njg0ln33	73	33	can	can	MD
cord-335140-njg0ln33	73	34	,	,	,
cord-335140-njg0ln33	73	35	and	and	CC
cord-335140-njg0ln33	73	36	should	should	MD
cord-335140-njg0ln33	73	37	,	,	,
cord-335140-njg0ln33	73	38	support	support	VB
cord-335140-njg0ln33	73	39	its	-PRON-	PRP$
cord-335140-njg0ln33	73	40	use	use	NN
cord-335140-njg0ln33	73	41	.	.	.
cord-335140-njg0ln33	74	1	A	a	DT
cord-335140-njg0ln33	74	2	global	global	JJ
cord-335140-njg0ln33	74	3	recession	recession	NN
cord-335140-njg0ln33	74	4	in	in	IN
cord-335140-njg0ln33	74	5	the	the	DT
cord-335140-njg0ln33	74	6	wake	wake	NN
cord-335140-njg0ln33	74	7	of	of	IN
cord-335140-njg0ln33	74	8	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	74	9	seems	seem	VBZ
cord-335140-njg0ln33	74	10	undeniable	undeniable	JJ
cord-335140-njg0ln33	74	11	and	and	CC
cord-335140-njg0ln33	74	12	will	will	MD
cord-335140-njg0ln33	74	13	undoubtedly	undoubtedly	RB
cord-335140-njg0ln33	74	14	have	have	VB
cord-335140-njg0ln33	74	15	a	a	DT
cord-335140-njg0ln33	74	16	significant	significant	JJ
cord-335140-njg0ln33	74	17	impact	impact	NN
cord-335140-njg0ln33	74	18	on	on	IN
cord-335140-njg0ln33	74	19	healthcare	healthcare	NN
cord-335140-njg0ln33	74	20	spending	spending	NN
cord-335140-njg0ln33	74	21	regardless	regardless	RB
cord-335140-njg0ln33	74	22	of	of	IN
cord-335140-njg0ln33	74	23	the	the	DT
cord-335140-njg0ln33	74	24	underlying	underlying	JJ
cord-335140-njg0ln33	74	25	revenue	revenue	NN
cord-335140-njg0ln33	74	26	source	source	NN
cord-335140-njg0ln33	74	27	and	and	CC
cord-335140-njg0ln33	74	28	infrastructure	infrastructure	NN
cord-335140-njg0ln33	74	29	(	(	-LRB-
cord-335140-njg0ln33	74	30	54	54	CD
cord-335140-njg0ln33	74	31	)	)	-RRB-
cord-335140-njg0ln33	74	32	.	.	.
cord-335140-njg0ln33	75	1	In	in	IN
cord-335140-njg0ln33	75	2	an	an	DT
cord-335140-njg0ln33	75	3	analysis	analysis	NN
cord-335140-njg0ln33	75	4	of	of	IN
cord-335140-njg0ln33	75	5	European	european	JJ
cord-335140-njg0ln33	75	6	countries	country	NNS
cord-335140-njg0ln33	75	7	,	,	,
cord-335140-njg0ln33	75	8	fiscal	fiscal	JJ
cord-335140-njg0ln33	75	9	pressure	pressure	NN
cord-335140-njg0ln33	75	10	resulting	result	VBG
cord-335140-njg0ln33	75	11	from	from	IN
cord-335140-njg0ln33	75	12	increased	increase	VBN
cord-335140-njg0ln33	75	13	unemployment	unemployment	NN
cord-335140-njg0ln33	75	14	prompted	prompt	VBD
cord-335140-njg0ln33	75	15	significant	significant	JJ
cord-335140-njg0ln33	75	16	reductions	reduction	NNS
cord-335140-njg0ln33	75	17	in	in	IN
cord-335140-njg0ln33	75	18	public	public	JJ
cord-335140-njg0ln33	75	19	spending	spending	NN
cord-335140-njg0ln33	75	20	on	on	IN
cord-335140-njg0ln33	75	21	health	health	NN
cord-335140-njg0ln33	75	22	(	(	-LRB-
cord-335140-njg0ln33	75	23	55	55	CD
cord-335140-njg0ln33	75	24	)	)	-RRB-
cord-335140-njg0ln33	75	25	.	.	.
cord-335140-njg0ln33	76	1	At	at	IN
cord-335140-njg0ln33	76	2	the	the	DT
cord-335140-njg0ln33	76	3	time	time	NN
cord-335140-njg0ln33	76	4	of	of	IN
cord-335140-njg0ln33	76	5	writing	writing	NN
cord-335140-njg0ln33	76	6	,	,	,
cord-335140-njg0ln33	76	7	estimates	estimate	NNS
cord-335140-njg0ln33	76	8	suggest	suggest	VBP
cord-335140-njg0ln33	76	9	that	that	IN
cord-335140-njg0ln33	76	10	in	in	IN
cord-335140-njg0ln33	76	11	the	the	DT
cord-335140-njg0ln33	76	12	United	United	NNP
cord-335140-njg0ln33	76	13	States	States	NNP
cord-335140-njg0ln33	76	14	alone	alone	RB
cord-335140-njg0ln33	76	15	,	,	,
cord-335140-njg0ln33	76	16	unemployment	unemployment	NN
cord-335140-njg0ln33	76	17	resulting	result	VBG
cord-335140-njg0ln33	76	18	from	from	IN
cord-335140-njg0ln33	76	19	the	the	DT
cord-335140-njg0ln33	76	20	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	76	21	pandemic	pandemic	NN
cord-335140-njg0ln33	76	22	could	could	MD
cord-335140-njg0ln33	76	23	reach	reach	VB
cord-335140-njg0ln33	76	24	levels	level	NNS
cord-335140-njg0ln33	76	25	of	of	IN
cord-335140-njg0ln33	76	26	to	to	IN
cord-335140-njg0ln33	76	27	52.8	52.8	CD
cord-335140-njg0ln33	76	28	million	million	CD
cord-335140-njg0ln33	76	29	,	,	,
cord-335140-njg0ln33	76	30	more	more	JJR
cord-335140-njg0ln33	76	31	than	than	IN
cord-335140-njg0ln33	76	32	three	three	CD
cord-335140-njg0ln33	76	33	times	time	NNS
cord-335140-njg0ln33	76	34	worse	bad	JJR
cord-335140-njg0ln33	76	35	than	than	IN
cord-335140-njg0ln33	76	36	the	the	DT
cord-335140-njg0ln33	76	37	peak	peak	NN
cord-335140-njg0ln33	76	38	of	of	IN
cord-335140-njg0ln33	76	39	the	the	DT
cord-335140-njg0ln33	76	40	Great	great	JJ
cord-335140-njg0ln33	76	41	Recession	recession	NN
cord-335140-njg0ln33	76	42	(	(	-LRB-
cord-335140-njg0ln33	76	43	56	56	CD
cord-335140-njg0ln33	76	44	)	)	-RRB-
cord-335140-njg0ln33	76	45	.	.	.
cord-335140-njg0ln33	77	1	In	in	IN
cord-335140-njg0ln33	77	2	the	the	DT
cord-335140-njg0ln33	77	3	aftermath	aftermath	NN
cord-335140-njg0ln33	77	4	of	of	IN
cord-335140-njg0ln33	77	5	that	that	DT
cord-335140-njg0ln33	77	6	recession	recession	NN
cord-335140-njg0ln33	77	7	there	there	EX
cord-335140-njg0ln33	77	8	was	be	VBD
cord-335140-njg0ln33	77	9	a	a	DT
cord-335140-njg0ln33	77	10	significant	significant	JJ
cord-335140-njg0ln33	77	11	decrease	decrease	NN
cord-335140-njg0ln33	77	12	in	in	IN
cord-335140-njg0ln33	77	13	the	the	DT
cord-335140-njg0ln33	77	14	number	number	NN
cord-335140-njg0ln33	77	15	of	of	IN
cord-335140-njg0ln33	77	16	employer	employer	NN
cord-335140-njg0ln33	77	17	-	-	HYPH
cord-335140-njg0ln33	77	18	sponsored	sponsor	VBN
cord-335140-njg0ln33	77	19	and	and	CC
cord-335140-njg0ln33	77	20	privately	privately	RB
cord-335140-njg0ln33	77	21	-	-	HYPH
cord-335140-njg0ln33	77	22	insured	insure	VBN
cord-335140-njg0ln33	77	23	patients	patient	NNS
cord-335140-njg0ln33	77	24	seen	see	VBN
cord-335140-njg0ln33	77	25	by	by	IN
cord-335140-njg0ln33	77	26	physicians	physician	NNS
cord-335140-njg0ln33	77	27	(	(	-LRB-
cord-335140-njg0ln33	77	28	57	57	CD
cord-335140-njg0ln33	77	29	)	)	-RRB-
cord-335140-njg0ln33	77	30	.	.	.
cord-335140-njg0ln33	78	1	With	with	IN
cord-335140-njg0ln33	78	2	fewer	few	JJR
cord-335140-njg0ln33	78	3	privately	privately	RB
cord-335140-njg0ln33	78	4	-	-	HYPH
cord-335140-njg0ln33	78	5	insured	insure	VBN
cord-335140-njg0ln33	78	6	patients	patient	NNS
cord-335140-njg0ln33	78	7	,	,	,
cord-335140-njg0ln33	78	8	governments	government	NNS
cord-335140-njg0ln33	78	9	will	will	MD
cord-335140-njg0ln33	78	10	be	be	VB
cord-335140-njg0ln33	78	11	increasingly	increasingly	RB
cord-335140-njg0ln33	78	12	facing	face	VBG
cord-335140-njg0ln33	78	13	the	the	DT
cord-335140-njg0ln33	78	14	bill	bill	NN
cord-335140-njg0ln33	78	15	for	for	IN
cord-335140-njg0ln33	78	16	antimyeloma	antimyeloma	NNP
cord-335140-njg0ln33	78	17	drug	drug	NN
cord-335140-njg0ln33	78	18	costs	cost	NNS
cord-335140-njg0ln33	78	19	.	.	.
cord-335140-njg0ln33	79	1	Commonly	commonly	RB
cord-335140-njg0ln33	79	2	employed	employ	VBN
cord-335140-njg0ln33	79	3	triplet	triplet	NN
cord-335140-njg0ln33	79	4	regimens	regimen	NNS
cord-335140-njg0ln33	79	5	have	have	VBP
cord-335140-njg0ln33	79	6	a	a	DT
cord-335140-njg0ln33	79	7	price	price	NN
cord-335140-njg0ln33	79	8	tag	tag	NN
cord-335140-njg0ln33	79	9	that	that	WDT
cord-335140-njg0ln33	79	10	can	can	MD
cord-335140-njg0ln33	79	11	range	range	VB
cord-335140-njg0ln33	79	12	from	from	IN
cord-335140-njg0ln33	79	13	$	$	$
cord-335140-njg0ln33	79	14	60,000	60,000	CD
cord-335140-njg0ln33	80	1	-$590,000	-$590,000	NNP
cord-335140-njg0ln33	80	2	(	(	-LRB-
cord-335140-njg0ln33	80	3	USD	usd	NN
cord-335140-njg0ln33	80	4	)	)	-RRB-
cord-335140-njg0ln33	81	1	per	per	IN
cord-335140-njg0ln33	81	2	annum	annum	FW
cord-335140-njg0ln33	81	3	(	(	-LRB-
cord-335140-njg0ln33	81	4	58	58	CD
cord-335140-njg0ln33	81	5	)	)	-RRB-
cord-335140-njg0ln33	81	6	.	.	.
cord-335140-njg0ln33	82	1	Given	give	VBN
cord-335140-njg0ln33	82	2	that	that	IN
cord-335140-njg0ln33	82	3	myeloma	myeloma	NN
cord-335140-njg0ln33	82	4	accounts	account	VBZ
cord-335140-njg0ln33	82	5	for	for	IN
cord-335140-njg0ln33	82	6	only	only	RB
cord-335140-njg0ln33	82	7	1	1	CD
cord-335140-njg0ln33	82	8	%	%	NN
cord-335140-njg0ln33	82	9	of	of	IN
cord-335140-njg0ln33	82	10	all	all	DT
cord-335140-njg0ln33	82	11	malignancies	malignancy	NNS
cord-335140-njg0ln33	82	12	,	,	,
cord-335140-njg0ln33	82	13	patients	patient	NNS
cord-335140-njg0ln33	82	14	are	be	VBP
cord-335140-njg0ln33	82	15	treated	treat	VBN
cord-335140-njg0ln33	82	16	for	for	IN
cord-335140-njg0ln33	82	17	long	long	JJ
cord-335140-njg0ln33	82	18	periods	period	NNS
cord-335140-njg0ln33	82	19	of	of	IN
cord-335140-njg0ln33	82	20	time	time	NN
cord-335140-njg0ln33	82	21	and	and	CC
cord-335140-njg0ln33	82	22	it	-PRON-	PRP
cord-335140-njg0ln33	82	23	remains	remain	VBZ
cord-335140-njg0ln33	82	24	an	an	DT
cord-335140-njg0ln33	82	25	incurable	incurable	JJ
cord-335140-njg0ln33	82	26	entity	entity	NN
cord-335140-njg0ln33	82	27	,	,	,
cord-335140-njg0ln33	82	28	it	-PRON-	PRP
cord-335140-njg0ln33	82	29	would	would	MD
cord-335140-njg0ln33	82	30	seem	seem	VB
cord-335140-njg0ln33	82	31	inevitable	inevitable	JJ
cord-335140-njg0ln33	82	32	that	that	IN
cord-335140-njg0ln33	82	33	the	the	DT
cord-335140-njg0ln33	82	34	cost	cost	NN
cord-335140-njg0ln33	82	35	of	of	IN
cord-335140-njg0ln33	82	36	treatment	treatment	NN
cord-335140-njg0ln33	82	37	will	will	MD
cord-335140-njg0ln33	82	38	become	become	VB
cord-335140-njg0ln33	82	39	a	a	DT
cord-335140-njg0ln33	82	40	fundamental	fundamental	JJ
cord-335140-njg0ln33	82	41	issueregardless	issueregardless	NN
cord-335140-njg0ln33	82	42	of	of	IN
cord-335140-njg0ln33	82	43	payer	payer	NN
cord-335140-njg0ln33	82	44	,	,	,
cord-335140-njg0ln33	82	45	patient	patient	NN
cord-335140-njg0ln33	82	46	or	or	CC
cord-335140-njg0ln33	82	47	government	government	NN
cord-335140-njg0ln33	82	48	.	.	.
cord-335140-njg0ln33	83	1	The	the	DT
cord-335140-njg0ln33	83	2	cost	cost	NN
cord-335140-njg0ln33	83	3	of	of	IN
cord-335140-njg0ln33	83	4	medicines	medicine	NNS
cord-335140-njg0ln33	83	5	has	have	VBZ
cord-335140-njg0ln33	83	6	been	be	VBN
cord-335140-njg0ln33	83	7	highlighted	highlight	VBN
cord-335140-njg0ln33	83	8	by	by	IN
cord-335140-njg0ln33	83	9	the	the	DT
cord-335140-njg0ln33	83	10	WHO	WHO	NNP
cord-335140-njg0ln33	83	11	as	as	IN
cord-335140-njg0ln33	83	12	a	a	DT
cord-335140-njg0ln33	83	13	leading	lead	VBG
cord-335140-njg0ln33	83	14	source	source	NN
cord-335140-njg0ln33	83	15	of	of	IN
cord-335140-njg0ln33	83	16	inefficiency	inefficiency	NN
cord-335140-njg0ln33	83	17	in	in	IN
cord-335140-njg0ln33	83	18	health	health	NN
cord-335140-njg0ln33	83	19	systems	system	NNS
cord-335140-njg0ln33	83	20	.	.	.
cord-335140-njg0ln33	84	1	Savings	saving	NNS
cord-335140-njg0ln33	84	2	could	could	MD
cord-335140-njg0ln33	84	3	be	be	VB
cord-335140-njg0ln33	84	4	substantial	substantial	JJ
cord-335140-njg0ln33	84	5	This	this	DT
cord-335140-njg0ln33	84	6	article	article	NN
cord-335140-njg0ln33	84	7	is	be	VBZ
cord-335140-njg0ln33	84	8	protected	protect	VBN
cord-335140-njg0ln33	84	9	by	by	IN
cord-335140-njg0ln33	84	10	copyright	copyright	NN
cord-335140-njg0ln33	84	11	.	.	.
cord-335140-njg0ln33	85	1	All	all	DT
cord-335140-njg0ln33	85	2	rights	right	NNS
cord-335140-njg0ln33	85	3	reserved	reserve	VBN
cord-335140-njg0ln33	85	4	if	if	IN
cord-335140-njg0ln33	85	5	how	how	WRB
cord-335140-njg0ln33	85	6	myeloma	myeloma	NN
cord-335140-njg0ln33	85	7	drugs	drug	NNS
cord-335140-njg0ln33	85	8	are	be	VBP
cord-335140-njg0ln33	85	9	developed	develop	VBN
cord-335140-njg0ln33	85	10	,	,	,
cord-335140-njg0ln33	85	11	regulated	regulate	VBN
cord-335140-njg0ln33	85	12	and	and	CC
cord-335140-njg0ln33	85	13	priced	price	VBN
cord-335140-njg0ln33	85	14	can	can	MD
cord-335140-njg0ln33	85	15	be	be	VB
cord-335140-njg0ln33	85	16	better	well	RBR
cord-335140-njg0ln33	85	17	addressed	address	VBN
cord-335140-njg0ln33	85	18	(	(	-LRB-
cord-335140-njg0ln33	85	19	55	55	CD
cord-335140-njg0ln33	85	20	,	,	,
cord-335140-njg0ln33	85	21	(	(	-LRB-
cord-335140-njg0ln33	85	22	58	58	CD
cord-335140-njg0ln33	85	23	)	)	-RRB-
cord-335140-njg0ln33	85	24	(	(	-LRB-
cord-335140-njg0ln33	85	25	59	59	CD
cord-335140-njg0ln33	85	26	)	)	-RRB-
cord-335140-njg0ln33	86	1	(	(	-LRB-
cord-335140-njg0ln33	86	2	60	60	CD
cord-335140-njg0ln33	86	3	)	)	-RRB-
cord-335140-njg0ln33	86	4	.	.	.
cord-335140-njg0ln33	87	1	In	in	IN
cord-335140-njg0ln33	87	2	this	this	DT
cord-335140-njg0ln33	87	3	post	post	JJ
cord-335140-njg0ln33	87	4	-	-	JJ
cord-335140-njg0ln33	87	5	COVID	covid	JJ
cord-335140-njg0ln33	87	6	,	,	,
cord-335140-njg0ln33	87	7	resource	resource	NN
cord-335140-njg0ln33	87	8	constrained	constrain	VBN
cord-335140-njg0ln33	87	9	,	,	,
cord-335140-njg0ln33	87	10	global	global	JJ
cord-335140-njg0ln33	87	11	health	health	NN
cord-335140-njg0ln33	87	12	economy	economy	NN
cord-335140-njg0ln33	87	13	,	,	,
cord-335140-njg0ln33	87	14	we	-PRON-	PRP
cord-335140-njg0ln33	87	15	will	will	MD
cord-335140-njg0ln33	87	16	increasingly	increasingly	RB
cord-335140-njg0ln33	87	17	need	need	VB
cord-335140-njg0ln33	87	18	to	to	TO
cord-335140-njg0ln33	87	19	focus	focus	VB
cord-335140-njg0ln33	87	20	our	-PRON-	PRP$
cord-335140-njg0ln33	87	21	attention	attention	NN
cord-335140-njg0ln33	87	22	on	on	IN
cord-335140-njg0ln33	87	23	optimising	optimise	VBG
cord-335140-njg0ln33	87	24	outcomes	outcome	NNS
cord-335140-njg0ln33	87	25	and	and	CC
cord-335140-njg0ln33	87	26	providing	provide	VBG
cord-335140-njg0ln33	87	27	the	the	DT
cord-335140-njg0ln33	87	28	greatest	great	JJS
cord-335140-njg0ln33	87	29	value	value	NN
cord-335140-njg0ln33	87	30	possible	possible	JJ
cord-335140-njg0ln33	87	31	for	for	IN
cord-335140-njg0ln33	87	32	each	each	DT
cord-335140-njg0ln33	87	33	and	and	CC
cord-335140-njg0ln33	87	34	every	every	DT
cord-335140-njg0ln33	87	35	patient	patient	NN
cord-335140-njg0ln33	87	36	.	.	.
cord-335140-njg0ln33	88	1	How	how	WRB
cord-335140-njg0ln33	88	2	might	may	MD
cord-335140-njg0ln33	88	3	this	this	DT
cord-335140-njg0ln33	88	4	be	be	VB
cord-335140-njg0ln33	88	5	achieved	achieve	VBN
cord-335140-njg0ln33	88	6	in	in	IN
cord-335140-njg0ln33	88	7	myeloma	myeloma	NN
cord-335140-njg0ln33	88	8	?	?	.
cord-335140-njg0ln33	89	1	There	there	EX
cord-335140-njg0ln33	89	2	are	be	VBP
cord-335140-njg0ln33	89	3	many	many	JJ
cord-335140-njg0ln33	89	4	potential	potential	JJ
cord-335140-njg0ln33	89	5	strategies	strategy	NNS
cord-335140-njg0ln33	89	6	that	that	WDT
cord-335140-njg0ln33	89	7	could	could	MD
cord-335140-njg0ln33	89	8	be	be	VB
cord-335140-njg0ln33	89	9	employed	employ	VBN
cord-335140-njg0ln33	89	10	.	.	.
cord-335140-njg0ln33	90	1	Some	some	DT
cord-335140-njg0ln33	90	2	possibilities	possibility	NNS
cord-335140-njg0ln33	90	3	include	include	VBP
cord-335140-njg0ln33	90	4	:	:	:
cord-335140-njg0ln33	90	5			.
cord-335140-njg0ln33	91	1	Conducting	conduct	VBG
cord-335140-njg0ln33	91	2	appropriately	appropriately	RB
cord-335140-njg0ln33	91	3	designed	design	VBN
cord-335140-njg0ln33	91	4	trials	trial	NNS
cord-335140-njg0ln33	91	5	that	that	WDT
cord-335140-njg0ln33	91	6	identify	identify	VBP
cord-335140-njg0ln33	91	7	those	those	DT
cord-335140-njg0ln33	91	8	who	who	WP
cord-335140-njg0ln33	91	9	can	can	MD
cord-335140-njg0ln33	91	10	safely	safely	RB
cord-335140-njg0ln33	91	11	stop	stop	VB
cord-335140-njg0ln33	91	12	therapy	therapy	NN
cord-335140-njg0ln33	91	13	(	(	-LRB-
cord-335140-njg0ln33	91	14	e.g.	e.g.	DT
cord-335140-njg0ln33	91	15	NCT04221178	NCT04221178	NNP
cord-335140-njg0ln33	91	16	)	)	-RRB-
cord-335140-njg0ln33	91	17			.
cord-335140-njg0ln33	92	1	Using	use	VBG
cord-335140-njg0ln33	92	2	genomic	genomic	JJ
cord-335140-njg0ln33	92	3	information	information	NN
cord-335140-njg0ln33	92	4	a	a	DT
cord-335140-njg0ln33	92	5	priori	priori	FW
cord-335140-njg0ln33	92	6	to	to	TO
cord-335140-njg0ln33	92	7	predict	predict	VB
cord-335140-njg0ln33	92	8	treatment	treatment	NN
cord-335140-njg0ln33	92	9	benefit	benefit	NN
cord-335140-njg0ln33	92	10	(	(	-LRB-
cord-335140-njg0ln33	92	11	61	61	CD
cord-335140-njg0ln33	92	12	,	,	,
cord-335140-njg0ln33	92	13	62	62	CD
cord-335140-njg0ln33	93	1	)	)	-RRB-
cord-335140-njg0ln33	93	2			NFP
cord-335140-njg0ln33	93	3	Establishing	establish	VBG
cord-335140-njg0ln33	93	4	drug	drug	NN
cord-335140-njg0ln33	93	5	sensitivity	sensitivity	NN
cord-335140-njg0ln33	93	6	of	of	IN
cord-335140-njg0ln33	93	7	plasma	plasma	NN
cord-335140-njg0ln33	93	8	cells	cell	NNS
cord-335140-njg0ln33	93	9	upfront	upfront	JJ
cord-335140-njg0ln33	93	10	with	with	IN
cord-335140-njg0ln33	93	11	the	the	DT
cord-335140-njg0ln33	93	12	aim	aim	NN
cord-335140-njg0ln33	93	13	of	of	IN
cord-335140-njg0ln33	93	14	selecting	select	VBG
cord-335140-njg0ln33	93	15	more	more	JJR
cord-335140-njg0ln33	93	16	cost	cost	NN
cord-335140-njg0ln33	93	17	-	-	HYPH
cord-335140-njg0ln33	93	18	effective	effective	JJ
cord-335140-njg0ln33	93	19	regimens	regimen	NNS
cord-335140-njg0ln33	93	20	(	(	-LRB-
cord-335140-njg0ln33	93	21	63	63	CD
cord-335140-njg0ln33	93	22	)	)	-RRB-
cord-335140-njg0ln33	94	1	(	(	-LRB-
cord-335140-njg0ln33	94	2	64	64	CD
cord-335140-njg0ln33	94	3	)	)	-RRB-
cord-335140-njg0ln33	95	1	(	(	-LRB-
cord-335140-njg0ln33	95	2	65	65	CD
cord-335140-njg0ln33	95	3	)	)	-RRB-
cord-335140-njg0ln33	95	4			.
cord-335140-njg0ln33	96	1	Integrating	integrate	VBG
cord-335140-njg0ln33	96	2	a	a	DT
cord-335140-njg0ln33	96	3	team	team	NN
cord-335140-njg0ln33	96	4	-	-	HYPH
cord-335140-njg0ln33	96	5	based	base	VBN
cord-335140-njg0ln33	96	6	approach	approach	NN
cord-335140-njg0ln33	96	7	to	to	TO
cord-335140-njg0ln33	96	8	care	care	VB
cord-335140-njg0ln33	96	9	,	,	,
cord-335140-njg0ln33	96	10	with	with	IN
cord-335140-njg0ln33	96	11	increased	increase	VBN
cord-335140-njg0ln33	96	12	utilisation	utilisation	NN
cord-335140-njg0ln33	96	13	of	of	IN
cord-335140-njg0ln33	96	14	allied	allied	JJ
cord-335140-njg0ln33	96	15	health	health	NN
cord-335140-njg0ln33	96	16	professionals	professional	NNS
cord-335140-njg0ln33	96	17	,	,	,
cord-335140-njg0ln33	96	18	pharmacists	pharmacist	NNS
cord-335140-njg0ln33	96	19	and	and	CC
cord-335140-njg0ln33	96	20	nurse	nurse	NN
cord-335140-njg0ln33	96	21	-	-	HYPH
cord-335140-njg0ln33	96	22	practitioners	practitioner	NNS
cord-335140-njg0ln33	96	23	(	(	-LRB-
cord-335140-njg0ln33	96	24	66	66	CD
cord-335140-njg0ln33	96	25	)	)	-RRB-
cord-335140-njg0ln33	97	1	(	(	-LRB-
cord-335140-njg0ln33	97	2	67	67	CD
cord-335140-njg0ln33	97	3	)	)	-RRB-
cord-335140-njg0ln33	98	1	(	(	-LRB-
cord-335140-njg0ln33	98	2	68	68	CD
cord-335140-njg0ln33	98	3	)	)	-RRB-
cord-335140-njg0ln33	98	4			.
cord-335140-njg0ln33	99	1	Minimizing	minimize	VBG
cord-335140-njg0ln33	99	2	waste	waste	NN
cord-335140-njg0ln33	99	3	with	with	IN
cord-335140-njg0ln33	99	4	"	"	``
cord-335140-njg0ln33	99	5	LEAN	lean	JJ
cord-335140-njg0ln33	99	6	"	"	''
cord-335140-njg0ln33	99	7	approaches	approach	NNS
cord-335140-njg0ln33	99	8	to	to	IN
cord-335140-njg0ln33	99	9	myeloma	myeloma	NN
cord-335140-njg0ln33	99	10	care	care	NN
cord-335140-njg0ln33	99	11	-process	-process	NN
cord-335140-njg0ln33	99	12	simplification	simplification	NN
cord-335140-njg0ln33	99	13	,	,	,
cord-335140-njg0ln33	99	14	streamlining	streamline	VBG
cord-335140-njg0ln33	99	15	drug	drug	NN
cord-335140-njg0ln33	99	16	treatment	treatment	NN
cord-335140-njg0ln33	99	17	,	,	,
cord-335140-njg0ln33	99	18	standardised	standardised	JJ
cord-335140-njg0ln33	99	19	and	and	CC
cord-335140-njg0ln33	99	20	uniform	uniform	JJ
cord-335140-njg0ln33	99	21	protocols	protocol	NNS
cord-335140-njg0ln33	99	22	for	for	IN
cord-335140-njg0ln33	99	23	therapy	therapy	NN
cord-335140-njg0ln33	99	24	and	and	CC
cord-335140-njg0ln33	99	25	surveillance	surveillance	NN
cord-335140-njg0ln33	99	26	(	(	-LRB-
cord-335140-njg0ln33	99	27	69	69	CD
cord-335140-njg0ln33	99	28	,	,	,
cord-335140-njg0ln33	99	29	70	70	CD
cord-335140-njg0ln33	99	30	)	)	-RRB-
cord-335140-njg0ln33	99	31			NFP
cord-335140-njg0ln33	100	1	Reforming	reform	VBG
cord-335140-njg0ln33	100	2	the	the	DT
cord-335140-njg0ln33	100	3	way	way	NN
cord-335140-njg0ln33	100	4	anti	anti	JJ
cord-335140-njg0ln33	100	5	-	-	JJ
cord-335140-njg0ln33	100	6	myeloma	myeloma	JJ
cord-335140-njg0ln33	100	7	medicines	medicine	NNS
cord-335140-njg0ln33	100	8	are	be	VBP
cord-335140-njg0ln33	100	9	valued	value	VBN
cord-335140-njg0ln33	100	10	and	and	CC
cord-335140-njg0ln33	100	11	paid	pay	VBN
cord-335140-njg0ln33	100	12	for	for	IN
cord-335140-njg0ln33	100	13	-advocating	-advocate	VBG
cord-335140-njg0ln33	100	14	for	for	IN
cord-335140-njg0ln33	100	15	better	well	JJR
cord-335140-njg0ln33	100	16	access	access	NN
cord-335140-njg0ln33	100	17	and	and	CC
cord-335140-njg0ln33	100	18	fairness	fairness	NN
cord-335140-njg0ln33	100	19	for	for	IN
cord-335140-njg0ln33	100	20	our	-PRON-	PRP$
cord-335140-njg0ln33	100	21	patients	patient	NNS
cord-335140-njg0ln33	100	22	around	around	IN
cord-335140-njg0ln33	100	23	the	the	DT
cord-335140-njg0ln33	100	24	globe	globe	NN
cord-335140-njg0ln33	100	25	(	(	-LRB-
cord-335140-njg0ln33	100	26	58	58	CD
cord-335140-njg0ln33	100	27	,	,	,
cord-335140-njg0ln33	100	28	(	(	-LRB-
cord-335140-njg0ln33	100	29	71	71	CD
cord-335140-njg0ln33	100	30	)	)	-RRB-
cord-335140-njg0ln33	101	1	(	(	-LRB-
cord-335140-njg0ln33	101	2	72	72	CD
cord-335140-njg0ln33	101	3	)	)	-RRB-
cord-335140-njg0ln33	102	1	(	(	-LRB-
cord-335140-njg0ln33	102	2	73	73	CD
cord-335140-njg0ln33	102	3	)	)	-RRB-
cord-335140-njg0ln33	103	1	(	(	-LRB-
cord-335140-njg0ln33	103	2	74	74	CD
cord-335140-njg0ln33	103	3	)	)	-RRB-
cord-335140-njg0ln33	104	1	(	(	-LRB-
cord-335140-njg0ln33	104	2	75	75	CD
cord-335140-njg0ln33	104	3	)	)	-RRB-
cord-335140-njg0ln33	105	1	The	the	DT
cord-335140-njg0ln33	105	2	importance	importance	NN
cord-335140-njg0ln33	105	3	of	of	IN
cord-335140-njg0ln33	105	4	these	these	DT
cord-335140-njg0ln33	105	5	(	(	-LRB-
cord-335140-njg0ln33	105	6	or	or	CC
cord-335140-njg0ln33	105	7	any	any	DT
cord-335140-njg0ln33	105	8	)	)	-RRB-
cord-335140-njg0ln33	105	9	approaches	approach	VBZ
cord-335140-njg0ln33	105	10	to	to	TO
cord-335140-njg0ln33	105	11	improve	improve	VB
cord-335140-njg0ln33	105	12	the	the	DT
cord-335140-njg0ln33	105	13	value	value	NN
cord-335140-njg0ln33	105	14	delivered	deliver	VBN
cord-335140-njg0ln33	105	15	to	to	IN
cord-335140-njg0ln33	105	16	myeloma	myeloma	NN
cord-335140-njg0ln33	105	17	patients	patient	NNS
cord-335140-njg0ln33	105	18	can	can	MD
cord-335140-njg0ln33	105	19	not	not	RB
cord-335140-njg0ln33	105	20	be	be	VB
cord-335140-njg0ln33	105	21	emphasized	emphasize	VBN
cord-335140-njg0ln33	105	22	enough	enough	RB
cord-335140-njg0ln33	105	23	.	.	.
cord-335140-njg0ln33	106	1	In	in	IN
cord-335140-njg0ln33	106	2	the	the	DT
cord-335140-njg0ln33	106	3	grim	grim	JJ
cord-335140-njg0ln33	106	4	reality	reality	NN
cord-335140-njg0ln33	106	5	that	that	WDT
cord-335140-njg0ln33	106	6	could	could	MD
cord-335140-njg0ln33	106	7	emerge	emerge	VB
cord-335140-njg0ln33	106	8	from	from	IN
cord-335140-njg0ln33	106	9	this	this	DT
cord-335140-njg0ln33	106	10	pandemic	pandemic	NN
cord-335140-njg0ln33	106	11	,	,	,
cord-335140-njg0ln33	106	12	resources	resource	NNS
cord-335140-njg0ln33	106	13	will	will	MD
cord-335140-njg0ln33	106	14	be	be	VB
cord-335140-njg0ln33	106	15	tighter	tight	JJR
cord-335140-njg0ln33	106	16	than	than	IN
cord-335140-njg0ln33	106	17	ever	ever	RB
cord-335140-njg0ln33	106	18	before	before	RB
cord-335140-njg0ln33	106	19	for	for	IN
cord-335140-njg0ln33	106	20	patient	patient	NN
cord-335140-njg0ln33	106	21	and	and	CC
cord-335140-njg0ln33	106	22	payers	payer	NNS
cord-335140-njg0ln33	106	23	alike	alike	RB
cord-335140-njg0ln33	106	24	and	and	CC
cord-335140-njg0ln33	106	25	rationing	rationing	NN
cord-335140-njg0ln33	106	26	care	care	NN
cord-335140-njg0ln33	106	27	could	could	MD
cord-335140-njg0ln33	106	28	become	become	VB
cord-335140-njg0ln33	106	29	an	an	DT
cord-335140-njg0ln33	106	30	even	even	RB
cord-335140-njg0ln33	106	31	more	more	RBR
cord-335140-njg0ln33	106	32	commonplace	commonplace	JJ
cord-335140-njg0ln33	106	33	reality	reality	NN
cord-335140-njg0ln33	106	34	.	.	.
cord-335140-njg0ln33	107	1	This	this	DT
cord-335140-njg0ln33	107	2	article	article	NN
cord-335140-njg0ln33	107	3	is	be	VBZ
cord-335140-njg0ln33	107	4	protected	protect	VBN
cord-335140-njg0ln33	107	5	by	by	IN
cord-335140-njg0ln33	107	6	copyright	copyright	NN
cord-335140-njg0ln33	107	7	.	.	.
cord-335140-njg0ln33	108	1	All	all	DT
cord-335140-njg0ln33	108	2	rights	right	NNS
cord-335140-njg0ln33	108	3	reserved	reserve	VBD
cord-335140-njg0ln33	108	4	The	the	DT
cord-335140-njg0ln33	108	5	need	need	NN
cord-335140-njg0ln33	108	6	to	to	TO
cord-335140-njg0ln33	108	7	triumph	triumph	VB
cord-335140-njg0ln33	108	8	over	over	IN
cord-335140-njg0ln33	108	9	adversity	adversity	NN
cord-335140-njg0ln33	108	10	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	108	11	has	have	VBZ
cord-335140-njg0ln33	108	12	challenged	challenge	VBN
cord-335140-njg0ln33	108	13	the	the	DT
cord-335140-njg0ln33	108	14	global	global	JJ
cord-335140-njg0ln33	108	15	population	population	NN
cord-335140-njg0ln33	108	16	in	in	IN
cord-335140-njg0ln33	108	17	ways	way	NNS
cord-335140-njg0ln33	108	18	we	-PRON-	PRP
cord-335140-njg0ln33	108	19	could	could	MD
cord-335140-njg0ln33	108	20	not	not	RB
cord-335140-njg0ln33	108	21	possibly	possibly	RB
cord-335140-njg0ln33	108	22	have	have	VB
cord-335140-njg0ln33	108	23	imagined	imagine	VBN
cord-335140-njg0ln33	108	24	.	.	.
cord-335140-njg0ln33	109	1	In	in	IN
cord-335140-njg0ln33	109	2	the	the	DT
cord-335140-njg0ln33	109	3	short	short	JJ
cord-335140-njg0ln33	109	4	term	term	NN
cord-335140-njg0ln33	109	5	,	,	,
cord-335140-njg0ln33	109	6	our	-PRON-	PRP$
cord-335140-njg0ln33	109	7	focus	focus	NN
cord-335140-njg0ln33	109	8	as	as	IN
cord-335140-njg0ln33	109	9	myeloma	myeloma	NN
cord-335140-njg0ln33	109	10	treaters	treater	NNS
cord-335140-njg0ln33	109	11	is	be	VBZ
cord-335140-njg0ln33	109	12	on	on	IN
cord-335140-njg0ln33	109	13	minimising	minimise	VBG
cord-335140-njg0ln33	109	14	risk	risk	NN
cord-335140-njg0ln33	109	15	and	and	CC
cord-335140-njg0ln33	109	16	keeping	keep	VBG
cord-335140-njg0ln33	109	17	our	-PRON-	PRP$
cord-335140-njg0ln33	109	18	patients	patient	NNS
cord-335140-njg0ln33	109	19	,	,	,
cord-335140-njg0ln33	109	20	wherever	wherever	WRB
cord-335140-njg0ln33	109	21	possible	possible	JJ
cord-335140-njg0ln33	109	22	,	,	,
cord-335140-njg0ln33	109	23	out	out	IN
cord-335140-njg0ln33	109	24	of	of	IN
cord-335140-njg0ln33	109	25	harm	harm	NN
cord-335140-njg0ln33	109	26	's	's	POS
cord-335140-njg0ln33	109	27	way	way	NN
cord-335140-njg0ln33	109	28	.	.	.
cord-335140-njg0ln33	110	1	In	in	IN
cord-335140-njg0ln33	110	2	the	the	DT
cord-335140-njg0ln33	110	3	longer	long	JJR
cord-335140-njg0ln33	110	4	term	term	NN
cord-335140-njg0ln33	110	5	,	,	,
cord-335140-njg0ln33	110	6	we	-PRON-	PRP
cord-335140-njg0ln33	110	7	will	will	MD
cord-335140-njg0ln33	110	8	need	need	VB
cord-335140-njg0ln33	110	9	to	to	TO
cord-335140-njg0ln33	110	10	rise	rise	VB
cord-335140-njg0ln33	110	11	to	to	IN
cord-335140-njg0ln33	110	12	the	the	DT
cord-335140-njg0ln33	110	13	challenges	challenge	NNS
cord-335140-njg0ln33	110	14	posed	pose	VBN
cord-335140-njg0ln33	110	15	by	by	IN
cord-335140-njg0ln33	110	16	the	the	DT
cord-335140-njg0ln33	110	17	post	post	JJ
cord-335140-njg0ln33	110	18	-	-	JJ
cord-335140-njg0ln33	110	19	pandemic	pandemic	JJ
cord-335140-njg0ln33	110	20	environment	environment	NN
cord-335140-njg0ln33	110	21	.	.	.
cord-335140-njg0ln33	111	1	We	-PRON-	PRP
cord-335140-njg0ln33	111	2	will	will	MD
cord-335140-njg0ln33	111	3	need	need	VB
cord-335140-njg0ln33	111	4	to	to	TO
cord-335140-njg0ln33	111	5	find	find	VB
cord-335140-njg0ln33	111	6	leaner	lean	JJR
cord-335140-njg0ln33	111	7	and	and	CC
cord-335140-njg0ln33	111	8	smarter	smart	JJR
cord-335140-njg0ln33	111	9	ways	way	NNS
cord-335140-njg0ln33	111	10	to	to	TO
cord-335140-njg0ln33	111	11	deliver	deliver	VB
cord-335140-njg0ln33	111	12	the	the	DT
cord-335140-njg0ln33	111	13	best	good	JJS
cord-335140-njg0ln33	111	14	care	care	NN
cord-335140-njg0ln33	111	15	possible	possible	JJ
cord-335140-njg0ln33	111	16	to	to	IN
cord-335140-njg0ln33	111	17	our	-PRON-	PRP$
cord-335140-njg0ln33	111	18	patients	patient	NNS
cord-335140-njg0ln33	111	19	.	.	.
cord-335140-njg0ln33	112	1	We	-PRON-	PRP
cord-335140-njg0ln33	112	2	will	will	MD
cord-335140-njg0ln33	112	3	need	need	VB
cord-335140-njg0ln33	112	4	to	to	TO
cord-335140-njg0ln33	112	5	advocate	advocate	VB
cord-335140-njg0ln33	112	6	with	with	IN
cord-335140-njg0ln33	112	7	a	a	DT
cord-335140-njg0ln33	112	8	united	united	JJ
cord-335140-njg0ln33	112	9	voice	voice	NN
cord-335140-njg0ln33	112	10	for	for	IN
cord-335140-njg0ln33	112	11	better	well	JJR
cord-335140-njg0ln33	112	12	value	value	NN
cord-335140-njg0ln33	112	13	therapy	therapy	NN
cord-335140-njg0ln33	112	14	and	and	CC
cord-335140-njg0ln33	112	15	use	use	VB
cord-335140-njg0ln33	112	16	innovative	innovative	JJ
cord-335140-njg0ln33	112	17	technology	technology	NN
cord-335140-njg0ln33	112	18	and	and	CC
cord-335140-njg0ln33	112	19	science	science	NN
cord-335140-njg0ln33	112	20	to	to	IN
cord-335140-njg0ln33	112	21	the	the	DT
cord-335140-njg0ln33	112	22	best	good	JJS
cord-335140-njg0ln33	112	23	of	of	IN
cord-335140-njg0ln33	112	24	their	-PRON-	PRP$
cord-335140-njg0ln33	112	25	advantage	advantage	NN
cord-335140-njg0ln33	112	26	.	.	.
cord-335140-njg0ln33	113	1	What	what	WP
cord-335140-njg0ln33	113	2	started	start	VBD
cord-335140-njg0ln33	113	3	with	with	IN
cord-335140-njg0ln33	113	4	adversity	adversity	NN
cord-335140-njg0ln33	113	5	can	can	MD
cord-335140-njg0ln33	113	6	,	,	,
cord-335140-njg0ln33	113	7	with	with	IN
cord-335140-njg0ln33	113	8	the	the	DT
cord-335140-njg0ln33	113	9	right	right	JJ
cord-335140-njg0ln33	113	10	mindset	mindset	NN
cord-335140-njg0ln33	113	11	,	,	,
cord-335140-njg0ln33	113	12	evolve	evolve	VB
cord-335140-njg0ln33	113	13	into	into	IN
cord-335140-njg0ln33	113	14	great	great	JJ
cord-335140-njg0ln33	113	15	opportunity	opportunity	NN
cord-335140-njg0ln33	113	16	.	.	.
cord-335140-njg0ln33	114	1	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	114	2	Dashboard	Dashboard	NNP
cord-335140-njg0ln33	114	3	by	by	IN
cord-335140-njg0ln33	114	4	the	the	DT
cord-335140-njg0ln33	114	5	Center	Center	NNP
cord-335140-njg0ln33	114	6	for	for	IN
cord-335140-njg0ln33	114	7	Systems	Systems	NNP
cord-335140-njg0ln33	114	8	Science	Science	NNP
cord-335140-njg0ln33	114	9	and	and	CC
cord-335140-njg0ln33	114	10	Engineering	Engineering	NNP
cord-335140-njg0ln33	114	11	Managing	Managing	NNP
cord-335140-njg0ln33	114	12	Cancer	Cancer	NNP
cord-335140-njg0ln33	114	13	Care	Care	NNP
cord-335140-njg0ln33	114	14	During	during	IN
cord-335140-njg0ln33	114	15	the	the	DT
cord-335140-njg0ln33	114	16	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	114	17	Pandemic	Pandemic	NNP
cord-335140-njg0ln33	114	18	:	:	:
cord-335140-njg0ln33	114	19	Agility	Agility	NNP
cord-335140-njg0ln33	114	20	and	and	CC
cord-335140-njg0ln33	114	21	Collaboration	Collaboration	NNP
cord-335140-njg0ln33	114	22	Toward	toward	IN
cord-335140-njg0ln33	114	23	a	a	DT
cord-335140-njg0ln33	114	24	Common	Common	NNP
cord-335140-njg0ln33	114	25	Goal	Goal	NNP
cord-335140-njg0ln33	114	26	A	A	NNP
cord-335140-njg0ln33	114	27	Practical	Practical	NNP
cord-335140-njg0ln33	114	28	Approach	Approach	NNP
cord-335140-njg0ln33	114	29	to	to	IN
cord-335140-njg0ln33	114	30	the	the	DT
cord-335140-njg0ln33	114	31	Management	Management	NNP
cord-335140-njg0ln33	114	32	of	of	IN
cord-335140-njg0ln33	114	33	Cancer	Cancer	NNP
cord-335140-njg0ln33	114	34	Patients	patient	NNS
cord-335140-njg0ln33	114	35	During	during	IN
cord-335140-njg0ln33	114	36	the	the	DT
cord-335140-njg0ln33	114	37	Novel	Novel	NNP
cord-335140-njg0ln33	114	38	Coronavirus	Coronavirus	NNP
cord-335140-njg0ln33	114	39	Disease	Disease	NNP
cord-335140-njg0ln33	114	40	2019	2019	CD
cord-335140-njg0ln33	115	1	(	(	-LRB-
cord-335140-njg0ln33	115	2	COVID-19	covid-19	VB
cord-335140-njg0ln33	115	3	)	)	-RRB-
cord-335140-njg0ln33	115	4	Pandemic	pandemic	NN
cord-335140-njg0ln33	115	5	:	:	:
cord-335140-njg0ln33	116	1	An	an	DT
cord-335140-njg0ln33	116	2	International	International	NNP
cord-335140-njg0ln33	116	3	Collaborative	Collaborative	NNP
cord-335140-njg0ln33	116	4	Group	Group	NNP
cord-335140-njg0ln33	116	5	Interim	Interim	NNP
cord-335140-njg0ln33	116	6	Infection	Infection	NNP
cord-335140-njg0ln33	116	7	Prevention	Prevention	NNP
cord-335140-njg0ln33	116	8	and	and	CC
cord-335140-njg0ln33	116	9	Control	Control	NNP
cord-335140-njg0ln33	116	10	Recommendations	Recommendations	NNPS
cord-335140-njg0ln33	116	11	for	for	IN
cord-335140-njg0ln33	116	12	Patients	patient	NNS
cord-335140-njg0ln33	116	13	with	with	IN
cord-335140-njg0ln33	116	14	Suspected	Suspected	NNP
cord-335140-njg0ln33	116	15	or	or	CC
cord-335140-njg0ln33	116	16	Confirmed	confirm	VBN
cord-335140-njg0ln33	116	17	Coronavirus	Coronavirus	NNP
cord-335140-njg0ln33	116	18	Disease	Disease	NNP
cord-335140-njg0ln33	116	19	2019	2019	CD
cord-335140-njg0ln33	116	20	(	(	-LRB-
cord-335140-njg0ln33	116	21	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	116	22	)	)	-RRB-
cord-335140-njg0ln33	116	23	in	in	IN
cord-335140-njg0ln33	116	24	Healthcare	Healthcare	NNP
cord-335140-njg0ln33	116	25	Settings	Settings	NNPS
cord-335140-njg0ln33	116	26	:	:	:
cord-335140-njg0ln33	116	27	Centres	centre	NNS
cord-335140-njg0ln33	116	28	for	for	IN
cord-335140-njg0ln33	116	29	Disease	Disease	NNP
cord-335140-njg0ln33	116	30	Control	Control	NNP
cord-335140-njg0ln33	116	31	and	and	CC
cord-335140-njg0ln33	116	32	Prevention	Prevention	NNP
cord-335140-njg0ln33	116	33	2F2019-ncov%2Finfection	2F2019-ncov%2Finfection	NNP
cord-335140-njg0ln33	116	34	-	-	HYPH
cord-335140-njg0ln33	116	35	control%2Fcontrol	control%2fcontrol	POS
cord-335140-njg0ln33	116	36	-	-	HYPH
cord-335140-njg0ln33	116	37	recommendations.html	recommendations.html	VBG
cord-335140-njg0ln33	116	38	Coronavirus	Coronavirus	NNP
cord-335140-njg0ln33	116	39	disease	disease	NN
cord-335140-njg0ln33	116	40	(	(	-LRB-
cord-335140-njg0ln33	116	41	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	116	42	)	)	-RRB-
cord-335140-njg0ln33	116	43	technical	technical	JJ
cord-335140-njg0ln33	116	44	guidance	guidance	NN
cord-335140-njg0ln33	116	45	:	:	:
cord-335140-njg0ln33	116	46	Infection	infection	NN
cord-335140-njg0ln33	116	47	prevention	prevention	NN
cord-335140-njg0ln33	116	48	and	and	CC
cord-335140-njg0ln33	116	49	control	control	NN
cord-335140-njg0ln33	116	50	:	:	:
cord-335140-njg0ln33	116	51	WHO.int	who.int	NN
cord-335140-njg0ln33	116	52	;	;	.
cord-335140-njg0ln33	117	1	2020	2020	CD
cord-335140-njg0ln33	117	2	[	[	-LRB-
cord-335140-njg0ln33	117	3	Available	available	JJ
cord-335140-njg0ln33	117	4	from	from	IN
cord-335140-njg0ln33	117	5	:	:	:
cord-335140-njg0ln33	117	6	Accepted	Accepted	NNP
cord-335140-njg0ln33	117	7	Article	Article	NNP
cord-335140-njg0ln33	118	1	This	this	DT
cord-335140-njg0ln33	118	2	article	article	NN
cord-335140-njg0ln33	118	3	is	be	VBZ
cord-335140-njg0ln33	118	4	protected	protect	VBN
cord-335140-njg0ln33	118	5	by	by	IN
cord-335140-njg0ln33	118	6	copyright	copyright	NN
cord-335140-njg0ln33	118	7	Virtually	virtually	RB
cord-335140-njg0ln33	118	8	Perfect	perfect	JJ
cord-335140-njg0ln33	118	9	?	?	.
cord-335140-njg0ln33	119	1	Telemedicine	telemedicine	NN
cord-335140-njg0ln33	119	2	for	for	IN
cord-335140-njg0ln33	119	3	Covid-19	covid-19	NN
cord-335140-njg0ln33	120	1	How	how	WRB
cord-335140-njg0ln33	120	2	I	-PRON-	PRP
cord-335140-njg0ln33	120	3	treat	treat	VBP
cord-335140-njg0ln33	120	4	fragile	fragile	JJ
cord-335140-njg0ln33	120	5	myeloma	myeloma	NN
cord-335140-njg0ln33	120	6	patients	patient	NNS
cord-335140-njg0ln33	120	7	A	a	DT
cord-335140-njg0ln33	120	8	simplified	simplified	JJ
cord-335140-njg0ln33	120	9	frailty	frailty	NN
cord-335140-njg0ln33	120	10	scale	scale	NN
cord-335140-njg0ln33	120	11	predicts	predict	VBZ
cord-335140-njg0ln33	120	12	outcomes	outcome	NNS
cord-335140-njg0ln33	120	13	in	in	IN
cord-335140-njg0ln33	120	14	transplant	transplant	NN
cord-335140-njg0ln33	120	15	-	-	HYPH
cord-335140-njg0ln33	120	16	ineligible	ineligible	JJ
cord-335140-njg0ln33	120	17	patients	patient	NNS
cord-335140-njg0ln33	120	18	with	with	IN
cord-335140-njg0ln33	120	19	newly	newly	RB
cord-335140-njg0ln33	120	20	diagnosed	diagnose	VBN
cord-335140-njg0ln33	120	21	multiple	multiple	JJ
cord-335140-njg0ln33	120	22	myeloma	myeloma	NN
cord-335140-njg0ln33	120	23	treated	treat	VBN
cord-335140-njg0ln33	120	24	in	in	IN
cord-335140-njg0ln33	120	25	the	the	DT
cord-335140-njg0ln33	120	26	FIRST	FIRST	NNP
cord-335140-njg0ln33	120	27	(	(	-LRB-
cord-335140-njg0ln33	120	28	MM-020	mm-020	NN
cord-335140-njg0ln33	120	29	)	)	-RRB-
cord-335140-njg0ln33	120	30	trial	trial	NN
cord-335140-njg0ln33	120	31	Myeloma	Myeloma	NNP
cord-335140-njg0ln33	120	32	in	in	IN
cord-335140-njg0ln33	120	33	Elderly	Elderly	NNP
cord-335140-njg0ln33	120	34	Patients	patient	NNS
cord-335140-njg0ln33	120	35	:	:	:
cord-335140-njg0ln33	120	36	When	when	WRB
cord-335140-njg0ln33	120	37	Less	Less	JJR
cord-335140-njg0ln33	120	38	Is	be	VBZ
cord-335140-njg0ln33	120	39	More	More	JJR
cord-335140-njg0ln33	120	40	and	and	CC
cord-335140-njg0ln33	120	41	More	More	JJR
cord-335140-njg0ln33	120	42	Is	be	VBZ
cord-335140-njg0ln33	120	43	More	More	JJR
cord-335140-njg0ln33	120	44	Telemedicine	telemedicine	NN
cord-335140-njg0ln33	120	45	in	in	IN
cord-335140-njg0ln33	121	1	Cancer	Cancer	NNP
cord-335140-njg0ln33	121	2	Care	Care	NNP
cord-335140-njg0ln33	121	3	Covid-19	Covid-19	NNP
cord-335140-njg0ln33	121	4	and	and	CC
cord-335140-njg0ln33	121	5	Health	Health	NNP
cord-335140-njg0ln33	121	6	Care	Care	NNP
cord-335140-njg0ln33	121	7	's	's	POS
cord-335140-njg0ln33	121	8	Digital	Digital	NNP
cord-335140-njg0ln33	121	9	Revolution	Revolution	NNP
cord-335140-njg0ln33	121	10	Multiple	multiple	JJ
cord-335140-njg0ln33	121	11	myeloma	myeloma	NN
cord-335140-njg0ln33	121	12	and	and	CC
cord-335140-njg0ln33	121	13	infections	infection	NNS
cord-335140-njg0ln33	121	14	:	:	:
cord-335140-njg0ln33	121	15	a	a	DT
cord-335140-njg0ln33	121	16	population	population	NN
cord-335140-njg0ln33	121	17	-	-	HYPH
cord-335140-njg0ln33	121	18	based	base	VBN
cord-335140-njg0ln33	121	19	study	study	NN
cord-335140-njg0ln33	121	20	on	on	IN
cord-335140-njg0ln33	121	21	9253	9253	CD
cord-335140-njg0ln33	121	22	multiple	multiple	JJ
cord-335140-njg0ln33	121	23	myeloma	myeloma	NN
cord-335140-njg0ln33	121	24	patients	patient	NNS
cord-335140-njg0ln33	121	25	Risks	risk	NNS
cord-335140-njg0ln33	121	26	,	,	,
cord-335140-njg0ln33	121	27	severity	severity	NN
cord-335140-njg0ln33	121	28	and	and	CC
cord-335140-njg0ln33	121	29	timing	timing	NN
cord-335140-njg0ln33	121	30	of	of	IN
cord-335140-njg0ln33	121	31	infections	infection	NNS
cord-335140-njg0ln33	121	32	in	in	IN
cord-335140-njg0ln33	121	33	patients	patient	NNS
cord-335140-njg0ln33	121	34	with	with	IN
cord-335140-njg0ln33	121	35	multiple	multiple	JJ
cord-335140-njg0ln33	121	36	myeloma	myeloma	NN
cord-335140-njg0ln33	121	37	:	:	:
cord-335140-njg0ln33	121	38	a	a	DT
cord-335140-njg0ln33	121	39	longitudinal	longitudinal	JJ
cord-335140-njg0ln33	121	40	cohort	cohort	NN
cord-335140-njg0ln33	121	41	study	study	NN
cord-335140-njg0ln33	121	42	in	in	IN
cord-335140-njg0ln33	121	43	the	the	DT
cord-335140-njg0ln33	121	44	era	era	NN
cord-335140-njg0ln33	121	45	of	of	IN
cord-335140-njg0ln33	121	46	immunomodulatory	immunomodulatory	JJ
cord-335140-njg0ln33	121	47	drug	drug	NN
cord-335140-njg0ln33	121	48	therapy	therapy	NN
cord-335140-njg0ln33	121	49	Accepted	Accepted	NNP
cord-335140-njg0ln33	121	50	Article	Article	NNP
cord-335140-njg0ln33	121	51	This	this	DT
cord-335140-njg0ln33	121	52	article	article	NN
cord-335140-njg0ln33	121	53	is	be	VBZ
cord-335140-njg0ln33	121	54	protected	protect	VBN
cord-335140-njg0ln33	121	55	by	by	IN
cord-335140-njg0ln33	121	56	copyright	copyright	NN
cord-335140-njg0ln33	121	57	.	.	.
cord-335140-njg0ln33	122	1	All	all	DT
cord-335140-njg0ln33	122	2	rights	right	NNS
cord-335140-njg0ln33	122	3	reserved	reserve	VBD
cord-335140-njg0ln33	122	4	15	15	CD
cord-335140-njg0ln33	122	5	How	how	WRB
cord-335140-njg0ln33	122	6	to	to	TO
cord-335140-njg0ln33	122	7	Manage	manage	VB
cord-335140-njg0ln33	122	8	Neutropenia	neutropenia	NN
cord-335140-njg0ln33	122	9	in	in	IN
cord-335140-njg0ln33	122	10	Multiple	multiple	JJ
cord-335140-njg0ln33	122	11	Myeloma	Myeloma	NNP
cord-335140-njg0ln33	123	1	Four	four	CD
cord-335140-njg0ln33	123	2	phase	phase	NN
cord-335140-njg0ln33	123	3	3	3	CD
cord-335140-njg0ln33	123	4	studies	study	NNS
cord-335140-njg0ln33	123	5	of	of	IN
cord-335140-njg0ln33	123	6	the	the	DT
cord-335140-njg0ln33	123	7	oral	oral	JJ
cord-335140-njg0ln33	123	8	proteasome	proteasome	VBN
cord-335140-njg0ln33	123	9	inhibitor	inhibitor	NN
cord-335140-njg0ln33	123	10	(	(	-LRB-
cord-335140-njg0ln33	123	11	PI	PI	NNP
cord-335140-njg0ln33	123	12	)	)	-RRB-
cord-335140-njg0ln33	123	13	ixazomib	ixazomib	NNP
cord-335140-njg0ln33	123	14	for	for	IN
cord-335140-njg0ln33	123	15	multiple	multiple	JJ
cord-335140-njg0ln33	123	16	myeloma	myeloma	NN
cord-335140-njg0ln33	123	17	in	in	IN
cord-335140-njg0ln33	123	18	the	the	DT
cord-335140-njg0ln33	123	19	newly	newly	RB
cord-335140-njg0ln33	123	20	-	-	HYPH
cord-335140-njg0ln33	123	21	diagnosed	diagnose	VBN
cord-335140-njg0ln33	123	22	,	,	,
cord-335140-njg0ln33	123	23	relapsed	relapse	VBN
cord-335140-njg0ln33	123	24	/	/	SYM
cord-335140-njg0ln33	123	25	refractory	refractory	NN
cord-335140-njg0ln33	123	26	,	,	,
cord-335140-njg0ln33	123	27	and	and	CC
cord-335140-njg0ln33	123	28	maintenance	maintenance	NN
cord-335140-njg0ln33	123	29	settings	setting	NNS
cord-335140-njg0ln33	123	30	:	:	:
cord-335140-njg0ln33	123	31	TOURMALINE	TOURMALINE	NNP
cord-335140-njg0ln33	123	32	-	-	HYPH
cord-335140-njg0ln33	123	33	MM1	MM1	NNP
cord-335140-njg0ln33	123	34	,	,	,
cord-335140-njg0ln33	123	35	-MM2	-MM2	NNP
cord-335140-njg0ln33	123	36	,	,	,
cord-335140-njg0ln33	123	37	-MM3	-MM3	NNP
cord-335140-njg0ln33	123	38	,	,	,
cord-335140-njg0ln33	123	39	and	and	CC
cord-335140-njg0ln33	123	40	-MM4	-MM4	:
cord-335140-njg0ln33	123	41	Pharmacokinetics	Pharmacokinetics	NNP
cord-335140-njg0ln33	123	42	of	of	IN
cord-335140-njg0ln33	123	43	Daratumumab	Daratumumab	NNP
cord-335140-njg0ln33	124	1	Following	follow	VBG
cord-335140-njg0ln33	124	2	Intravenous	Intravenous	NNP
cord-335140-njg0ln33	124	3	Infusion	Infusion	NNP
cord-335140-njg0ln33	124	4	in	in	IN
cord-335140-njg0ln33	124	5	Relapsed	Relapsed	NNP
cord-335140-njg0ln33	124	6	or	or	CC
cord-335140-njg0ln33	124	7	Refractory	refractory	JJ
cord-335140-njg0ln33	124	8	Multiple	multiple	JJ
cord-335140-njg0ln33	124	9	Myeloma	myeloma	NN
cord-335140-njg0ln33	125	1	After	after	IN
cord-335140-njg0ln33	125	2	Prior	Prior	NNP
cord-335140-njg0ln33	125	3	Proteasome	Proteasome	NNP
cord-335140-njg0ln33	125	4	Inhibitor	Inhibitor	NNP
cord-335140-njg0ln33	125	5	and	and	CC
cord-335140-njg0ln33	125	6	Immunomodulatory	Immunomodulatory	NNP
cord-335140-njg0ln33	125	7	Drug	Drug	NNP
cord-335140-njg0ln33	125	8	Treatment	Treatment	NNP
cord-335140-njg0ln33	125	9	Once	once	RB
cord-335140-njg0ln33	125	10	-	-	HYPH
cord-335140-njg0ln33	125	11	weekly	weekly	NN
cord-335140-njg0ln33	125	12	versus	versus	IN
cord-335140-njg0ln33	125	13	twice	twice	RB
cord-335140-njg0ln33	125	14	-	-	HYPH
cord-335140-njg0ln33	125	15	weekly	weekly	JJ
cord-335140-njg0ln33	125	16	carfilzomib	carfilzomib	NN
cord-335140-njg0ln33	125	17	in	in	IN
cord-335140-njg0ln33	125	18	patients	patient	NNS
cord-335140-njg0ln33	125	19	with	with	IN
cord-335140-njg0ln33	125	20	newly	newly	RB
cord-335140-njg0ln33	125	21	diagnosed	diagnose	VBN
cord-335140-njg0ln33	125	22	multiple	multiple	JJ
cord-335140-njg0ln33	125	23	myeloma	myeloma	NN
cord-335140-njg0ln33	125	24	:	:	:
cord-335140-njg0ln33	125	25	a	a	DT
cord-335140-njg0ln33	125	26	pooled	pool	VBN
cord-335140-njg0ln33	125	27	analysis	analysis	NN
cord-335140-njg0ln33	125	28	of	of	IN
cord-335140-njg0ln33	125	29	two	two	CD
cord-335140-njg0ln33	125	30	phase	phase	NN
cord-335140-njg0ln33	125	31	1/2	1/2	CD
cord-335140-njg0ln33	125	32	studies	study	NNS
cord-335140-njg0ln33	125	33	.	.	.
cord-335140-njg0ln33	126	1	Haematologica	Haematologica	NNP
cord-335140-njg0ln33	126	2	.	.	.
cord-335140-njg0ln33	127	1	2019	2019	CD
cord-335140-njg0ln33	127	2	:	:	:
cord-335140-njg0ln33	128	1	haematol	haematol	NNP
cord-335140-njg0ln33	129	1	Once	once	RB
cord-335140-njg0ln33	129	2	-	-	HYPH
cord-335140-njg0ln33	129	3	versus	versus	FW
cord-335140-njg0ln33	129	4	twice	twice	RB
cord-335140-njg0ln33	129	5	-	-	HYPH
cord-335140-njg0ln33	129	6	weekly	weekly	JJ
cord-335140-njg0ln33	129	7	carfilzomib	carfilzomib	NN
cord-335140-njg0ln33	129	8	in	in	IN
cord-335140-njg0ln33	129	9	relapsed	relapsed	JJ
cord-335140-njg0ln33	129	10	and	and	CC
cord-335140-njg0ln33	129	11	refractory	refractory	JJ
cord-335140-njg0ln33	129	12	multiple	multiple	JJ
cord-335140-njg0ln33	129	13	myeloma	myeloma	NN
cord-335140-njg0ln33	129	14	by	by	IN
cord-335140-njg0ln33	129	15	select	select	JJ
cord-335140-njg0ln33	129	16	patient	patient	NN
cord-335140-njg0ln33	129	17	characteristics	characteristic	NNS
cord-335140-njg0ln33	129	18	:	:	:
cord-335140-njg0ln33	129	19	phase	phase	NN
cord-335140-njg0ln33	129	20	3	3	CD
cord-335140-njg0ln33	130	1	A.R.R.O.W.	a.r.r.o.w.	CD
cord-335140-njg0ln33	130	2	study	study	NN
cord-335140-njg0ln33	130	3	subgroup	subgroup	NN
cord-335140-njg0ln33	130	4	analysis	analysis	NN
cord-335140-njg0ln33	130	5	INTERIM	INTERIM	NNP
cord-335140-njg0ln33	130	6	GUIDELINES	GUIDELINES	NNP
cord-335140-njg0ln33	130	7	FOR	for	IN
cord-335140-njg0ln33	130	8	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	130	9	MANAGEMENT	MANAGEMENT	NNP
cord-335140-njg0ln33	130	10	IN	in	IN
cord-335140-njg0ln33	130	11	HEMATOPOIETIC	HEMATOPOIETIC	NNP
cord-335140-njg0ln33	130	12	CELL	cell	NN
cord-335140-njg0ln33	130	13	TRANSPLANT	transplant	NN
cord-335140-njg0ln33	130	14	AND	and	CC
cord-335140-njg0ln33	130	15	CELLULAR	cellular	NN
cord-335140-njg0ln33	130	16	THERAPY	therapy	NN
cord-335140-njg0ln33	130	17	PATIENTS	patient	NNS
cord-335140-njg0ln33	131	1	Accepted	Accepted	NNP
cord-335140-njg0ln33	131	2	Article	Article	NNP
cord-335140-njg0ln33	132	1	This	this	DT
cord-335140-njg0ln33	132	2	article	article	NN
cord-335140-njg0ln33	132	3	is	be	VBZ
cord-335140-njg0ln33	132	4	protected	protect	VBN
cord-335140-njg0ln33	132	5	by	by	IN
cord-335140-njg0ln33	132	6	copyright	copyright	NN
cord-335140-njg0ln33	132	7	.	.	.
cord-335140-njg0ln33	133	1	All	all	DT
cord-335140-njg0ln33	133	2	rights	right	NNS
cord-335140-njg0ln33	133	3	reserved	reserve	VBD
cord-335140-njg0ln33	133	4	Version	version	NN
cord-335140-njg0ln33	133	5	1.2	1.2	CD
cord-335140-njg0ln33	133	6	:	:	:
cord-335140-njg0ln33	133	7	ASTCT	ASTCT	NNS
cord-335140-njg0ln33	133	8	;	;	:
cord-335140-njg0ln33	134	1	2020	2020	CD
cord-335140-njg0ln33	134	2	Management	management	NN
cord-335140-njg0ln33	134	3	of	of	IN
cord-335140-njg0ln33	134	4	respiratory	respiratory	JJ
cord-335140-njg0ln33	134	5	viral	viral	JJ
cord-335140-njg0ln33	134	6	infections	infection	NNS
cord-335140-njg0ln33	134	7	in	in	IN
cord-335140-njg0ln33	134	8	hematopoietic	hematopoietic	JJ
cord-335140-njg0ln33	134	9	cell	cell	NN
cord-335140-njg0ln33	134	10	transplant	transplant	NN
cord-335140-njg0ln33	134	11	recipients	recipient	NNS
cord-335140-njg0ln33	135	1	Coronavirus	Coronavirus	NNP
cord-335140-njg0ln33	135	2	229E	229e	CD
cord-335140-njg0ln33	135	3	-	-	HYPH
cord-335140-njg0ln33	135	4	Related	relate	VBN
cord-335140-njg0ln33	135	5	Pneumonia	Pneumonia	NNP
cord-335140-njg0ln33	135	6	in	in	IN
cord-335140-njg0ln33	135	7	Immunocompromised	Immunocompromised	NNP
cord-335140-njg0ln33	135	8	Patients	Patients	NNP
cord-335140-njg0ln33	135	9	Respiratory	Respiratory	NNP
cord-335140-njg0ln33	135	10	Virus	Virus	NNP
cord-335140-njg0ln33	135	11	Infections	infection	NNS
cord-335140-njg0ln33	135	12	of	of	IN
cord-335140-njg0ln33	135	13	the	the	DT
cord-335140-njg0ln33	135	14	Stem	Stem	NNP
cord-335140-njg0ln33	135	15	Cell	Cell	NNP
cord-335140-njg0ln33	135	16	Transplant	Transplant	NNP
cord-335140-njg0ln33	135	17	Recipient	Recipient	NNP
cord-335140-njg0ln33	135	18	and	and	CC
cord-335140-njg0ln33	135	19	the	the	DT
cord-335140-njg0ln33	135	20	Hematologic	Hematologic	NNP
cord-335140-njg0ln33	135	21	Malignancy	Malignancy	NNP
cord-335140-njg0ln33	135	22	Patient	Patient	NNP
cord-335140-njg0ln33	135	23	Herd	Herd	NNP
cord-335140-njg0ln33	135	24	immunity	immunity	NN
cord-335140-njg0ln33	135	25	:	:	:
cord-335140-njg0ln33	136	1	Understanding	understand	VBG
cord-335140-njg0ln33	136	2	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	136	3	How	how	WRB
cord-335140-njg0ln33	136	4	I	-PRON-	PRP
cord-335140-njg0ln33	136	5	vaccinate	vaccinate	VBP
cord-335140-njg0ln33	136	6	blood	blood	NN
cord-335140-njg0ln33	136	7	and	and	CC
cord-335140-njg0ln33	136	8	marrow	marrow	NN
cord-335140-njg0ln33	136	9	transplant	transplant	NN
cord-335140-njg0ln33	136	10	recipients	recipient	NNS
cord-335140-njg0ln33	136	11	Respiratory	respiratory	JJ
cord-335140-njg0ln33	136	12	virus	virus	NN
cord-335140-njg0ln33	136	13	infections	infection	NNS
cord-335140-njg0ln33	136	14	after	after	IN
cord-335140-njg0ln33	136	15	stem	stem	NN
cord-335140-njg0ln33	136	16	cell	cell	NN
cord-335140-njg0ln33	136	17	transplantation	transplantation	NN
cord-335140-njg0ln33	136	18	:	:	:
cord-335140-njg0ln33	136	19	a	a	DT
cord-335140-njg0ln33	136	20	prospective	prospective	JJ
cord-335140-njg0ln33	136	21	study	study	NN
cord-335140-njg0ln33	136	22	from	from	IN
cord-335140-njg0ln33	136	23	the	the	DT
cord-335140-njg0ln33	136	24	Infectious	Infectious	NNP
cord-335140-njg0ln33	136	25	Diseases	Diseases	NNPS
cord-335140-njg0ln33	136	26	Working	Working	NNP
cord-335140-njg0ln33	136	27	Party	Party	NNP
cord-335140-njg0ln33	136	28	of	of	IN
cord-335140-njg0ln33	136	29	the	the	DT
cord-335140-njg0ln33	136	30	European	European	NNP
cord-335140-njg0ln33	136	31	Group	Group	NNP
cord-335140-njg0ln33	136	32	for	for	IN
cord-335140-njg0ln33	136	33	Blood	Blood	NNP
cord-335140-njg0ln33	136	34	and	and	CC
cord-335140-njg0ln33	136	35	Marrow	marrow	NN
cord-335140-njg0ln33	136	36	Transplantation	transplantation	NN
cord-335140-njg0ln33	137	1	Treating	treat	VBG
cord-335140-njg0ln33	137	2	Multiple	multiple	JJ
cord-335140-njg0ln33	137	3	Myeloma	myeloma	NN
cord-335140-njg0ln33	137	4	Patients	patient	NNS
cord-335140-njg0ln33	137	5	With	with	IN
cord-335140-njg0ln33	137	6	Oral	oral	JJ
cord-335140-njg0ln33	137	7	Therapies	Therapies	NNPS
cord-335140-njg0ln33	137	8	Subcutaneous	subcutaneous	JJ
cord-335140-njg0ln33	137	9	versus	versus	IN
cord-335140-njg0ln33	137	10	intravenous	intravenous	JJ
cord-335140-njg0ln33	137	11	daratumumab	daratumumab	VBD
cord-335140-njg0ln33	137	12	in	in	IN
cord-335140-njg0ln33	137	13	patients	patient	NNS
cord-335140-njg0ln33	137	14	with	with	IN
cord-335140-njg0ln33	137	15	relapsed	relapsed	JJ
cord-335140-njg0ln33	137	16	or	or	CC
cord-335140-njg0ln33	137	17	refractory	refractory	JJ
cord-335140-njg0ln33	137	18	multiple	multiple	JJ
cord-335140-njg0ln33	137	19	myeloma	myeloma	NN
cord-335140-njg0ln33	137	20	(	(	-LRB-
cord-335140-njg0ln33	137	21	COLUMBA	COLUMBA	NNP
cord-335140-njg0ln33	137	22	)	)	-RRB-
cord-335140-njg0ln33	137	23	:	:	:
cord-335140-njg0ln33	137	24	a	a	DT
cord-335140-njg0ln33	137	25	multicentre	multicentre	NNP
cord-335140-njg0ln33	137	26	,	,	,
cord-335140-njg0ln33	137	27	open	open	JJ
cord-335140-njg0ln33	137	28	-	-	HYPH
cord-335140-njg0ln33	137	29	label	label	NN
cord-335140-njg0ln33	137	30	,	,	,
cord-335140-njg0ln33	137	31	non	non	JJ
cord-335140-njg0ln33	137	32	-	-	JJ
cord-335140-njg0ln33	137	33	inferiority	inferiority	JJ
cord-335140-njg0ln33	137	34	,	,	,
cord-335140-njg0ln33	137	35	randomised	randomised	JJ
cord-335140-njg0ln33	137	36	,	,	,
cord-335140-njg0ln33	137	37	phase	phase	NN
cord-335140-njg0ln33	137	38	3	3	CD
cord-335140-njg0ln33	137	39	trial	trial	NN
cord-335140-njg0ln33	137	40	.	.	.
cord-335140-njg0ln33	138	1	The	the	DT
cord-335140-njg0ln33	138	2	Lancet	Lancet	NNP
cord-335140-njg0ln33	138	3	Haematology	Haematology	NNP
cord-335140-njg0ln33	138	4	Accepted	Accepted	NNP
cord-335140-njg0ln33	138	5	Article	Article	NNP
cord-335140-njg0ln33	138	6	This	this	DT
cord-335140-njg0ln33	138	7	article	article	NN
cord-335140-njg0ln33	138	8	is	be	VBZ
cord-335140-njg0ln33	138	9	protected	protect	VBN
cord-335140-njg0ln33	138	10	by	by	IN
cord-335140-njg0ln33	138	11	copyright	copyright	NN
cord-335140-njg0ln33	138	12	.	.	.
cord-335140-njg0ln33	139	1	All	all	DT
cord-335140-njg0ln33	139	2	rights	right	NNS
cord-335140-njg0ln33	139	3	reserved	reserve	VBD
cord-335140-njg0ln33	139	4	33	33	CD
cord-335140-njg0ln33	139	5	Denosumab	Denosumab	NNP
cord-335140-njg0ln33	139	6	versus	versus	IN
cord-335140-njg0ln33	139	7	zoledronic	zoledronic	NNP
cord-335140-njg0ln33	139	8	acid	acid	NN
cord-335140-njg0ln33	139	9	in	in	IN
cord-335140-njg0ln33	139	10	bone	bone	NN
cord-335140-njg0ln33	139	11	disease	disease	NN
cord-335140-njg0ln33	139	12	treatment	treatment	NN
cord-335140-njg0ln33	139	13	of	of	IN
cord-335140-njg0ln33	139	14	newly	newly	RB
cord-335140-njg0ln33	139	15	diagnosed	diagnose	VBN
cord-335140-njg0ln33	139	16	multiple	multiple	JJ
cord-335140-njg0ln33	139	17	myeloma	myeloma	NN
cord-335140-njg0ln33	139	18	:	:	:
cord-335140-njg0ln33	139	19	an	an	DT
cord-335140-njg0ln33	139	20	international	international	JJ
cord-335140-njg0ln33	139	21	,	,	,
cord-335140-njg0ln33	139	22	double	double	JJ
cord-335140-njg0ln33	139	23	-	-	HYPH
cord-335140-njg0ln33	139	24	blind	blind	JJ
cord-335140-njg0ln33	139	25	,	,	,
cord-335140-njg0ln33	139	26	double	double	JJ
cord-335140-njg0ln33	139	27	-	-	HYPH
cord-335140-njg0ln33	139	28	dummy	dummy	JJ
cord-335140-njg0ln33	139	29	,	,	,
cord-335140-njg0ln33	139	30	randomised	randomised	JJ
cord-335140-njg0ln33	139	31	,	,	,
cord-335140-njg0ln33	139	32	controlled	control	VBN
cord-335140-njg0ln33	139	33	,	,	,
cord-335140-njg0ln33	139	34	phase	phase	NN
cord-335140-njg0ln33	139	35	3	3	CD
cord-335140-njg0ln33	139	36	study	study	NN
cord-335140-njg0ln33	139	37	Home	Home	NNP
cord-335140-njg0ln33	139	38	administration	administration	NN
cord-335140-njg0ln33	139	39	of	of	IN
cord-335140-njg0ln33	139	40	bortezomib	bortezomib	NNP
cord-335140-njg0ln33	139	41	in	in	IN
cord-335140-njg0ln33	139	42	multiple	multiple	JJ
cord-335140-njg0ln33	139	43	myeloma	myeloma	NN
cord-335140-njg0ln33	139	44	is	be	VBZ
cord-335140-njg0ln33	139	45	cost	cost	NN
cord-335140-njg0ln33	139	46	-	-	HYPH
cord-335140-njg0ln33	139	47	effective	effective	JJ
cord-335140-njg0ln33	139	48	and	and	CC
cord-335140-njg0ln33	139	49	is	be	VBZ
cord-335140-njg0ln33	139	50	preferred	prefer	VBN
cord-335140-njg0ln33	139	51	by	by	IN
cord-335140-njg0ln33	139	52	patients	patient	NNS
cord-335140-njg0ln33	139	53	compared	compare	VBN
cord-335140-njg0ln33	139	54	with	with	IN
cord-335140-njg0ln33	139	55	hospital	hospital	NN
cord-335140-njg0ln33	139	56	administration	administration	NN
cord-335140-njg0ln33	139	57	:	:	:
cord-335140-njg0ln33	139	58	results	result	NNS
cord-335140-njg0ln33	139	59	of	of	IN
cord-335140-njg0ln33	139	60	a	a	DT
cord-335140-njg0ln33	139	61	prospective	prospective	JJ
cord-335140-njg0ln33	139	62	single	single	JJ
cord-335140-njg0ln33	139	63	-	-	HYPH
cord-335140-njg0ln33	139	64	center	center	NN
cord-335140-njg0ln33	139	65	study	study	NN
cord-335140-njg0ln33	139	66	Bortezomib	Bortezomib	NNP
cord-335140-njg0ln33	139	67	selfinjection	selfinjection	NN
cord-335140-njg0ln33	139	68	is	be	VBZ
cord-335140-njg0ln33	139	69	time	time	NN
cord-335140-njg0ln33	139	70	-	-	HYPH
cord-335140-njg0ln33	139	71	saving	save	VBG
cord-335140-njg0ln33	139	72	,	,	,
cord-335140-njg0ln33	139	73	cost	cost	NN
cord-335140-njg0ln33	139	74	-	-	HYPH
cord-335140-njg0ln33	139	75	neutral	neutral	JJ
cord-335140-njg0ln33	139	76	and	and	CC
cord-335140-njg0ln33	139	77	well	well	RB
cord-335140-njg0ln33	139	78	received	receive	VBN
cord-335140-njg0ln33	139	79	by	by	IN
cord-335140-njg0ln33	139	80	patients	patient	NNS
cord-335140-njg0ln33	139	81	with	with	IN
cord-335140-njg0ln33	139	82	myeloma	myeloma	NN
cord-335140-njg0ln33	139	83	or	or	CC
cord-335140-njg0ln33	139	84	AL	AL	NNP
cord-335140-njg0ln33	139	85	amyloidosis	amyloidosis	NN
cord-335140-njg0ln33	139	86	:	:	:
cord-335140-njg0ln33	140	1	Results	result	NNS
cord-335140-njg0ln33	140	2	from	from	IN
cord-335140-njg0ln33	140	3	the	the	DT
cord-335140-njg0ln33	140	4	"	"	``
cord-335140-njg0ln33	140	5	SUBLIME	sublime	JJ
cord-335140-njg0ln33	140	6	"	"	''
cord-335140-njg0ln33	140	7	study	study	NN
cord-335140-njg0ln33	140	8	Subcutaneous	Subcutaneous	NNP
cord-335140-njg0ln33	140	9	Administration	Administration	NNP
cord-335140-njg0ln33	140	10	of	of	IN
cord-335140-njg0ln33	140	11	Biotherapeutics	Biotherapeutics	NNPS
cord-335140-njg0ln33	140	12	:	:	:
cord-335140-njg0ln33	141	1	An	an	DT
cord-335140-njg0ln33	141	2	Overview	Overview	NNP
cord-335140-njg0ln33	141	3	of	of	IN
cord-335140-njg0ln33	141	4	Current	current	JJ
cord-335140-njg0ln33	141	5	Challenges	challenge	NNS
cord-335140-njg0ln33	141	6	and	and	CC
cord-335140-njg0ln33	141	7	Opportunities	Opportunities	NNPS
cord-335140-njg0ln33	141	8	Home	Home	NNP
cord-335140-njg0ln33	141	9	Administration	Administration	NNP
cord-335140-njg0ln33	141	10	of	of	IN
cord-335140-njg0ln33	141	11	Subcutaneous	Subcutaneous	NNP
cord-335140-njg0ln33	141	12	Rituximab	Rituximab	NNP
cord-335140-njg0ln33	141	13	Is	be	VBZ
cord-335140-njg0ln33	141	14	Safe	safe	JJ
cord-335140-njg0ln33	141	15	and	and	CC
cord-335140-njg0ln33	141	16	Associated	associate	VBN
cord-335140-njg0ln33	141	17	with	with	IN
cord-335140-njg0ln33	141	18	Significant	significant	JJ
cord-335140-njg0ln33	141	19	Cost	cost	NN
cord-335140-njg0ln33	141	20	Saving	saving	NN
cord-335140-njg0ln33	141	21	:	:	:
cord-335140-njg0ln33	142	1	A	a	DT
cord-335140-njg0ln33	142	2	Single	Single	NNP
cord-335140-njg0ln33	142	3	Center	Center	NNP
cord-335140-njg0ln33	142	4	Experience	experience	NN
cord-335140-njg0ln33	142	5	Effect	effect	NN
cord-335140-njg0ln33	142	6	of	of	IN
cord-335140-njg0ln33	142	7	Longer	Longer	NNP
cord-335140-njg0ln33	142	8	-	-	HYPH
cord-335140-njg0ln33	142	9	Interval	interval	NN
cord-335140-njg0ln33	142	10	vs	vs	IN
cord-335140-njg0ln33	142	11	Standard	Standard	NNP
cord-335140-njg0ln33	142	12	Dosing	Dosing	NNP
cord-335140-njg0ln33	142	13	of	of	IN
cord-335140-njg0ln33	142	14	Zoledronic	Zoledronic	NNP
cord-335140-njg0ln33	142	15	Acid	Acid	NNP
cord-335140-njg0ln33	142	16	on	on	IN
cord-335140-njg0ln33	142	17	Skeletal	skeletal	JJ
cord-335140-njg0ln33	142	18	Events	event	NNS
cord-335140-njg0ln33	142	19	in	in	IN
cord-335140-njg0ln33	142	20	Patients	patient	NNS
cord-335140-njg0ln33	142	21	With	with	IN
cord-335140-njg0ln33	142	22	Bone	Bone	NNP
cord-335140-njg0ln33	142	23	Metastases	Metastases	NNP
cord-335140-njg0ln33	143	1	The	the	DT
cord-335140-njg0ln33	143	2	impact	impact	NN
cord-335140-njg0ln33	143	3	of	of	IN
cord-335140-njg0ln33	143	4	disease	disease	NN
cord-335140-njg0ln33	143	5	-	-	HYPH
cord-335140-njg0ln33	143	6	related	relate	VBN
cord-335140-njg0ln33	143	7	symptoms	symptom	NNS
cord-335140-njg0ln33	143	8	and	and	CC
cord-335140-njg0ln33	143	9	palliative	palliative	JJ
cord-335140-njg0ln33	143	10	care	care	NN
cord-335140-njg0ln33	143	11	concerns	concern	NNS
cord-335140-njg0ln33	143	12	on	on	IN
cord-335140-njg0ln33	143	13	health	health	NN
cord-335140-njg0ln33	143	14	-	-	HYPH
cord-335140-njg0ln33	143	15	related	relate	VBN
cord-335140-njg0ln33	143	16	quality	quality	NN
cord-335140-njg0ln33	143	17	of	of	IN
cord-335140-njg0ln33	143	18	life	life	NN
cord-335140-njg0ln33	143	19	in	in	IN
cord-335140-njg0ln33	143	20	multiple	multiple	JJ
cord-335140-njg0ln33	143	21	myeloma	myeloma	NN
cord-335140-njg0ln33	143	22	:	:	:
cord-335140-njg0ln33	143	23	a	a	DT
cord-335140-njg0ln33	143	24	multi	multi	JJ
cord-335140-njg0ln33	143	25	-	-	JJ
cord-335140-njg0ln33	143	26	centre	centre	JJ
cord-335140-njg0ln33	143	27	study	study	NN
cord-335140-njg0ln33	143	28	Timeliness	timeliness	NN
cord-335140-njg0ln33	143	29	of	of	IN
cord-335140-njg0ln33	143	30	Endof	Endof	NNP
cord-335140-njg0ln33	143	31	-	-	HYPH
cord-335140-njg0ln33	143	32	Life	Life	NNP
cord-335140-njg0ln33	143	33	Discussions	discussion	NNS
cord-335140-njg0ln33	143	34	for	for	IN
cord-335140-njg0ln33	143	35	Blood	blood	NN
cord-335140-njg0ln33	143	36	Cancers	cancer	NNS
cord-335140-njg0ln33	143	37	Is	be	VBZ
cord-335140-njg0ln33	143	38	Early	early	JJ
cord-335140-njg0ln33	143	39	Palliative	Palliative	NNP
cord-335140-njg0ln33	143	40	Care	Care	NNP
cord-335140-njg0ln33	143	41	Feasible	feasible	JJ
cord-335140-njg0ln33	143	42	in	in	IN
cord-335140-njg0ln33	143	43	Patients	patient	NNS
cord-335140-njg0ln33	143	44	With	with	IN
cord-335140-njg0ln33	143	45	Multiple	multiple	JJ
cord-335140-njg0ln33	143	46	Myeloma	myeloma	NN
cord-335140-njg0ln33	143	47	?	?	.
cord-335140-njg0ln33	144	1	Accepted	Accepted	NNP
cord-335140-njg0ln33	144	2	Article	Article	NNP
cord-335140-njg0ln33	145	1	This	this	DT
cord-335140-njg0ln33	145	2	article	article	NN
cord-335140-njg0ln33	145	3	is	be	VBZ
cord-335140-njg0ln33	145	4	protected	protect	VBN
cord-335140-njg0ln33	145	5	by	by	IN
cord-335140-njg0ln33	145	6	copyright	copyright	NN
cord-335140-njg0ln33	145	7	.	.	.
cord-335140-njg0ln33	146	1	All	all	DT
cord-335140-njg0ln33	146	2	rights	right	NNS
cord-335140-njg0ln33	146	3	reserved	reserve	VBD
cord-335140-njg0ln33	146	4	42	42	CD
cord-335140-njg0ln33	146	5	Cancer	Cancer	NNP
cord-335140-njg0ln33	146	6	patients	patient	NNS
cord-335140-njg0ln33	146	7	in	in	IN
cord-335140-njg0ln33	146	8	SARS	SARS	NNP
cord-335140-njg0ln33	146	9	-	-	HYPH
cord-335140-njg0ln33	146	10	CoV-2	CoV-2	NNP
cord-335140-njg0ln33	146	11	infection	infection	NN
cord-335140-njg0ln33	146	12	:	:	:
cord-335140-njg0ln33	146	13	a	a	DT
cord-335140-njg0ln33	146	14	nationwide	nationwide	JJ
cord-335140-njg0ln33	146	15	analysis	analysis	NN
cord-335140-njg0ln33	146	16	in	in	IN
cord-335140-njg0ln33	146	17	China	China	NNP
cord-335140-njg0ln33	147	1	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	147	2	and	and	CC
cord-335140-njg0ln33	147	3	Cancer	Cancer	NNP
cord-335140-njg0ln33	147	4	:	:	:
cord-335140-njg0ln33	147	5	Lessons	lesson	NNS
cord-335140-njg0ln33	147	6	From	from	IN
cord-335140-njg0ln33	147	7	a	a	DT
cord-335140-njg0ln33	147	8	Pooled	pool	VBN
cord-335140-njg0ln33	147	9	Meta	Meta	NNP
cord-335140-njg0ln33	147	10	-	-	HYPH
cord-335140-njg0ln33	147	11	Analysis	Analysis	NNP
cord-335140-njg0ln33	147	12	CoV-2-Human	CoV-2-Human	NNP
cord-335140-njg0ln33	147	13	Protein	Protein	NNP
cord-335140-njg0ln33	147	14	-	-	HYPH
cord-335140-njg0ln33	147	15	Protein	Protein	NNP
cord-335140-njg0ln33	147	16	Interaction	Interaction	NNP
cord-335140-njg0ln33	147	17	Map	Map	NNP
cord-335140-njg0ln33	147	18	Reveals	reveal	VBZ
cord-335140-njg0ln33	147	19	Drug	Drug	NNP
cord-335140-njg0ln33	147	20	Targets	Targets	NNPS
cord-335140-njg0ln33	147	21	and	and	CC
cord-335140-njg0ln33	147	22	Potential	Potential	NNP
cord-335140-njg0ln33	147	23	Drug	Drug	NNP
cord-335140-njg0ln33	147	24	-	-	HYPH
cord-335140-njg0ln33	147	25	Repurposing	repurposing	NN
cord-335140-njg0ln33	147	26	AI	AI	NNP
cord-335140-njg0ln33	147	27	finds	find	VBZ
cord-335140-njg0ln33	147	28	potential	potential	JJ
cord-335140-njg0ln33	147	29	COVID-19	covid-19	JJ
cord-335140-njg0ln33	147	30	drugs	drug	NNS
cord-335140-njg0ln33	147	31	that	that	WDT
cord-335140-njg0ln33	147	32	can	can	MD
cord-335140-njg0ln33	147	33	be	be	VB
cord-335140-njg0ln33	147	34	used	use	VBN
cord-335140-njg0ln33	147	35	on	on	IN
cord-335140-njg0ln33	147	36	humans	human	NNS
cord-335140-njg0ln33	147	37	immediately	immediately	RB
cord-335140-njg0ln33	147	38	Karyopharm	Karyopharm	NNP
cord-335140-njg0ln33	147	39	to	to	TO
cord-335140-njg0ln33	147	40	Evaluate	evaluate	VB
cord-335140-njg0ln33	147	41	Low	Low	NNP
cord-335140-njg0ln33	147	42	Dose	Dose	NNP
cord-335140-njg0ln33	147	43	Selinexor	Selinexor	NNP
cord-335140-njg0ln33	147	44	as	as	IN
cord-335140-njg0ln33	147	45	a	a	DT
cord-335140-njg0ln33	147	46	Potential	Potential	NNP
cord-335140-njg0ln33	147	47	Treatment	treatment	NN
cord-335140-njg0ln33	147	48	for	for	IN
cord-335140-njg0ln33	147	49	Hospitalized	Hospitalized	NNP
cord-335140-njg0ln33	147	50	Patients	Patients	NNP
cord-335140-njg0ln33	147	51	with	with	IN
cord-335140-njg0ln33	147	52	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	147	53	A	a	DT
cord-335140-njg0ln33	147	54	pneumonia	pneumonia	NN
cord-335140-njg0ln33	147	55	outbreak	outbreak	NN
cord-335140-njg0ln33	147	56	associated	associate	VBN
cord-335140-njg0ln33	147	57	with	with	IN
cord-335140-njg0ln33	147	58	a	a	DT
cord-335140-njg0ln33	147	59	new	new	JJ
cord-335140-njg0ln33	147	60	coronavirus	coronavirus	NN
cord-335140-njg0ln33	147	61	of	of	IN
cord-335140-njg0ln33	147	62	probable	probable	JJ
cord-335140-njg0ln33	147	63	bat	bat	NN
cord-335140-njg0ln33	147	64	origin	origin	NN
cord-335140-njg0ln33	147	65	Antihypertensive	antihypertensive	JJ
cord-335140-njg0ln33	147	66	drugs	drug	NNS
cord-335140-njg0ln33	147	67	and	and	CC
cord-335140-njg0ln33	147	68	risk	risk	NN
cord-335140-njg0ln33	147	69	of	of	IN
cord-335140-njg0ln33	147	70	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	147	71	?	?	.
cord-335140-njg0ln33	148	1	-Authors	-author	NNS
cord-335140-njg0ln33	148	2	'	'	POS
cord-335140-njg0ln33	148	3	reply	reply	NN
cord-335140-njg0ln33	148	4	.	.	.
cord-335140-njg0ln33	149	1	The	the	DT
cord-335140-njg0ln33	149	2	Lancet	Lancet	NNP
cord-335140-njg0ln33	149	3	Respiratory	Respiratory	NNP
cord-335140-njg0ln33	149	4	Medicine	Medicine	NNP
cord-335140-njg0ln33	149	5	COVID-19	COVID-19	NNP
cord-335140-njg0ln33	149	6	and	and	CC
cord-335140-njg0ln33	149	7	Angiotensin	Angiotensin	NNP
cord-335140-njg0ln33	149	8	-	-	HYPH
cord-335140-njg0ln33	149	9	Converting	convert	VBG
cord-335140-njg0ln33	149	10	Enzyme	Enzyme	NNP
cord-335140-njg0ln33	149	11	Inhibitors	Inhibitors	NNP
cord-335140-njg0ln33	149	12	and	and	CC
cord-335140-njg0ln33	149	13	Angiotensin	Angiotensin	NNP
cord-335140-njg0ln33	149	14	Receptor	Receptor	NNP
cord-335140-njg0ln33	149	15	Blockers	Blockers	NNP
cord-335140-njg0ln33	149	16	Vaccination	Vaccination	NNP
cord-335140-njg0ln33	149	17	in	in	IN
cord-335140-njg0ln33	149	18	Multiple	Multiple	NNP
cord-335140-njg0ln33	149	19	Myeloma	Myeloma	NNP
cord-335140-njg0ln33	149	20	:	:	:
cord-335140-njg0ln33	149	21	Review	Review	NNP
cord-335140-njg0ln33	149	22	of	of	IN
cord-335140-njg0ln33	149	23	Current	Current	NNP
cord-335140-njg0ln33	149	24	Literature	Literature	NNP
cord-335140-njg0ln33	149	25	Efficacy	Efficacy	NNP
cord-335140-njg0ln33	149	26	of	of	IN
cord-335140-njg0ln33	149	27	single	single	JJ
cord-335140-njg0ln33	149	28	versus	versus	IN
cord-335140-njg0ln33	149	29	boost	boost	NN
cord-335140-njg0ln33	149	30	vaccination	vaccination	NN
cord-335140-njg0ln33	149	31	against	against	IN
cord-335140-njg0ln33	149	32	influenza	influenza	NN
cord-335140-njg0ln33	149	33	virus	virus	NN
cord-335140-njg0ln33	149	34	in	in	IN
cord-335140-njg0ln33	149	35	patients	patient	NNS
cord-335140-njg0ln33	149	36	with	with	IN
cord-335140-njg0ln33	149	37	multiple	multiple	JJ
cord-335140-njg0ln33	149	38	myeloma	myeloma	NN
cord-335140-njg0ln33	149	39	Association	Association	NNP
cord-335140-njg0ln33	149	40	Between	Between	NNP
cord-335140-njg0ln33	149	41	Treatment	Treatment	NNP
cord-335140-njg0ln33	149	42	Facility	Facility	NNP
cord-335140-njg0ln33	149	43	Volume	Volume	NNP
cord-335140-njg0ln33	149	44	and	and	CC
cord-335140-njg0ln33	149	45	Mortality	mortality	NN
cord-335140-njg0ln33	149	46	of	of	IN
cord-335140-njg0ln33	149	47	Patients	patient	NNS
cord-335140-njg0ln33	149	48	With	with	IN
cord-335140-njg0ln33	149	49	Multiple	Multiple	NNP
cord-335140-njg0ln33	149	50	Myeloma	Myeloma	NNP
cord-335140-njg0ln33	149	51	Economic	economic	JJ
cord-335140-njg0ln33	149	52	impacts	impact	NNS
cord-335140-njg0ln33	149	53	of	of	IN
cord-335140-njg0ln33	149	54	Wuhan	Wuhan	NNP
cord-335140-njg0ln33	149	55	2019-nCoV	2019-ncov	CD
cord-335140-njg0ln33	149	56	on	on	IN
cord-335140-njg0ln33	149	57	China	China	NNP
cord-335140-njg0ln33	149	58	and	and	CC
cord-335140-njg0ln33	149	59	the	the	DT
cord-335140-njg0ln33	149	60	world	world	NN
cord-335140-njg0ln33	149	61	Economic	economic	JJ
cord-335140-njg0ln33	149	62	crisis	crisis	NN
cord-335140-njg0ln33	149	63	,	,	,
cord-335140-njg0ln33	149	64	health	health	NN
cord-335140-njg0ln33	149	65	systems	system	NNS
cord-335140-njg0ln33	149	66	and	and	CC
cord-335140-njg0ln33	149	67	health	health	NN
cord-335140-njg0ln33	149	68	in	in	IN
cord-335140-njg0ln33	149	69	Europe	Europe	NNP
cord-335140-njg0ln33	149	70	:	:	:
cord-335140-njg0ln33	149	71	impact	impact	NN
cord-335140-njg0ln33	149	72	and	and	CC
cord-335140-njg0ln33	149	73	implications	implication	NNS
cord-335140-njg0ln33	149	74	for	for	IN
cord-335140-njg0ln33	149	75	policy	policy	NN
cord-335140-njg0ln33	149	76	On	on	IN
cord-335140-njg0ln33	149	77	the	the	DT
cord-335140-njg0ln33	149	78	Economy	Economy	NNP
cord-335140-njg0ln33	149	79	Blog	blog	NN
cord-335140-njg0ln33	149	80	:	:	:
cord-335140-njg0ln33	150	1	The	the	DT
cord-335140-njg0ln33	150	2	St.	St.	NNP
cord-335140-njg0ln33	150	3	Louis	Louis	NNP
cord-335140-njg0ln33	150	4	Federal	Federal	NNP
cord-335140-njg0ln33	150	5	Reserve	Reserve	NNP
cord-335140-njg0ln33	150	6	Bank	Bank	NNP
cord-335140-njg0ln33	151	1	How	how	WRB
cord-335140-njg0ln33	151	2	the	the	DT
cord-335140-njg0ln33	151	3	Recession	recession	NN
cord-335140-njg0ln33	151	4	is	be	VBZ
cord-335140-njg0ln33	151	5	Affecting	affect	VBG
cord-335140-njg0ln33	151	6	Health	Health	NNP
cord-335140-njg0ln33	151	7	Care	Care	NNP
cord-335140-njg0ln33	152	1	The	the	DT
cord-335140-njg0ln33	152	2	American	American	NNP
cord-335140-njg0ln33	152	3	Academy	Academy	NNP
cord-335140-njg0ln33	152	4	of	of	IN
cord-335140-njg0ln33	152	5	Family	Family	NNP
cord-335140-njg0ln33	152	6	Physicians	Physicians	NNP
cord-335140-njg0ln33	152	7	Value	Value	NNP
cord-335140-njg0ln33	152	8	and	and	CC
cord-335140-njg0ln33	152	9	Cost	Cost	NNP
cord-335140-njg0ln33	152	10	of	of	IN
cord-335140-njg0ln33	152	11	Myeloma	Myeloma	NNP
cord-335140-njg0ln33	152	12	Therapy	Therapy	NNP
cord-335140-njg0ln33	152	13	Government	Government	NNP
cord-335140-njg0ln33	152	14	becomes	become	VBZ
cord-335140-njg0ln33	152	15	Big	Big	NNP
cord-335140-njg0ln33	152	16	Pharma	Pharma	NNS
cord-335140-njg0ln33	152	17	.	.	.
cord-335140-njg0ln33	153	1	POLITICO	POLITICO	NNP
cord-335140-njg0ln33	153	2	.	.	.
cord-335140-njg0ln33	154	1	2020	2020	CD
cord-335140-njg0ln33	154	2	.	.	.
cord-335140-njg0ln33	155	1	60	60	CD
cord-335140-njg0ln33	155	2	.	.	.
cord-335140-njg0ln33	156	1	Bach	Bach	NNP
cord-335140-njg0ln33	156	2	PB	PB	NNP
cord-335140-njg0ln33	157	1	Predicting	predict	VBG
cord-335140-njg0ln33	157	2	treatment	treatment	NN
cord-335140-njg0ln33	157	3	benefit	benefit	NN
cord-335140-njg0ln33	157	4	in	in	IN
cord-335140-njg0ln33	157	5	multiple	multiple	JJ
cord-335140-njg0ln33	157	6	myeloma	myeloma	NN
cord-335140-njg0ln33	157	7	through	through	IN
cord-335140-njg0ln33	157	8	simulation	simulation	NN
cord-335140-njg0ln33	157	9	of	of	IN
cord-335140-njg0ln33	157	10	alternative	alternative	JJ
cord-335140-njg0ln33	157	11	treatment	treatment	NN
cord-335140-njg0ln33	157	12	effects	effect	NNS
cord-335140-njg0ln33	158	1	A	a	DT
cord-335140-njg0ln33	158	2	gene	gene	NN
cord-335140-njg0ln33	158	3	expression	expression	NN
cord-335140-njg0ln33	158	4	signature	signature	NN
cord-335140-njg0ln33	158	5	distinguishes	distinguish	VBZ
cord-335140-njg0ln33	158	6	innate	innate	JJ
cord-335140-njg0ln33	158	7	response	response	NN
cord-335140-njg0ln33	158	8	and	and	CC
cord-335140-njg0ln33	158	9	resistance	resistance	NN
cord-335140-njg0ln33	158	10	to	to	IN
cord-335140-njg0ln33	158	11	proteasome	proteasome	NN
cord-335140-njg0ln33	158	12	inhibitors	inhibitor	NNS
cord-335140-njg0ln33	158	13	in	in	IN
cord-335140-njg0ln33	158	14	multiple	multiple	JJ
cord-335140-njg0ln33	158	15	myeloma	myeloma	NN
cord-335140-njg0ln33	159	1	An	an	DT
cord-335140-njg0ln33	159	2	Ex	Ex	NNP
cord-335140-njg0ln33	159	3	Vivo	Vivo	NNP
cord-335140-njg0ln33	159	4	Platform	Platform	NNP
cord-335140-njg0ln33	159	5	for	for	IN
cord-335140-njg0ln33	159	6	the	the	DT
cord-335140-njg0ln33	159	7	Prediction	Prediction	NNP
cord-335140-njg0ln33	159	8	of	of	IN
cord-335140-njg0ln33	159	9	Clinical	Clinical	NNP
cord-335140-njg0ln33	159	10	Response	Response	NNP
cord-335140-njg0ln33	159	11	in	in	IN
cord-335140-njg0ln33	159	12	Multiple	Multiple	NNP
cord-335140-njg0ln33	159	13	Myeloma	Myeloma	NNP
cord-335140-njg0ln33	159	14	Accepted	Accepted	NNP
cord-335140-njg0ln33	159	15	Article	Article	NNP
cord-335140-njg0ln33	160	1	This	this	DT
cord-335140-njg0ln33	160	2	article	article	NN
cord-335140-njg0ln33	160	3	is	be	VBZ
cord-335140-njg0ln33	160	4	protected	protect	VBN
cord-335140-njg0ln33	160	5	by	by	IN
cord-335140-njg0ln33	160	6	copyright	copyright	NN
cord-335140-njg0ln33	160	7	.	.	.
cord-335140-njg0ln33	161	1	All	all	DT
cord-335140-njg0ln33	161	2	rights	right	NNS
cord-335140-njg0ln33	161	3	reserved	reserve	VBD
cord-335140-njg0ln33	161	4	64	64	CD
cord-335140-njg0ln33	161	5	Identification	identification	NN
cord-335140-njg0ln33	161	6	of	of	IN
cord-335140-njg0ln33	161	7	precision	precision	NN
cord-335140-njg0ln33	161	8	treatment	treatment	NN
cord-335140-njg0ln33	161	9	strategies	strategy	NNS
cord-335140-njg0ln33	161	10	for	for	IN
cord-335140-njg0ln33	161	11	relapsed/	relapsed/	NN
cord-335140-njg0ln33	161	12	refractory	refractory	JJ
cord-335140-njg0ln33	161	13	multiple	multiple	JJ
cord-335140-njg0ln33	161	14	myeloma	myeloma	NN
cord-335140-njg0ln33	161	15	by	by	IN
cord-335140-njg0ln33	161	16	functional	functional	JJ
cord-335140-njg0ln33	161	17	drug	drug	NN
cord-335140-njg0ln33	161	18	sensitivity	sensitivity	NN
cord-335140-njg0ln33	161	19	testing	testing	NN
cord-335140-njg0ln33	162	1	Determining	determine	VBG
cord-335140-njg0ln33	162	2	therapeutic	therapeutic	JJ
cord-335140-njg0ln33	162	3	susceptibility	susceptibility	NN
cord-335140-njg0ln33	162	4	in	in	IN
cord-335140-njg0ln33	162	5	multiple	multiple	JJ
cord-335140-njg0ln33	162	6	myeloma	myeloma	NN
cord-335140-njg0ln33	162	7	by	by	IN
cord-335140-njg0ln33	162	8	single	single	JJ
cord-335140-njg0ln33	162	9	-	-	HYPH
cord-335140-njg0ln33	162	10	cell	cell	NN
cord-335140-njg0ln33	162	11	mass	mass	NN
cord-335140-njg0ln33	162	12	accumulation	accumulation	NN
cord-335140-njg0ln33	162	13	Nurse	Nurse	NNP
cord-335140-njg0ln33	162	14	Practitioners	Practitioners	NNPS
cord-335140-njg0ln33	162	15	and	and	CC
cord-335140-njg0ln33	162	16	Physician	Physician	NNP
cord-335140-njg0ln33	162	17	Assistants	Assistants	NNPS
cord-335140-njg0ln33	162	18	in	in	IN
cord-335140-njg0ln33	162	19	Acute	Acute	NNP
cord-335140-njg0ln33	162	20	and	and	CC
cord-335140-njg0ln33	162	21	Critical	Critical	NNP
cord-335140-njg0ln33	162	22	Care	Care	NNP
cord-335140-njg0ln33	162	23	Impact	Impact	NNP
cord-335140-njg0ln33	162	24	of	of	IN
cord-335140-njg0ln33	162	25	an	an	DT
cord-335140-njg0ln33	162	26	integrated	integrated	JJ
cord-335140-njg0ln33	162	27	oral	oral	JJ
cord-335140-njg0ln33	162	28	chemotherapy	chemotherapy	NN
cord-335140-njg0ln33	162	29	program	program	NN
cord-335140-njg0ln33	162	30	on	on	IN
cord-335140-njg0ln33	162	31	patient	patient	JJ
cord-335140-njg0ln33	162	32	adherence	adherence	NN
cord-335140-njg0ln33	162	33	Collaborative	Collaborative	NNP
cord-335140-njg0ln33	162	34	Physician	Physician	NNP
cord-335140-njg0ln33	162	35	-	-	HYPH
cord-335140-njg0ln33	162	36	Pharmacist	Pharmacist	NNP
cord-335140-njg0ln33	162	37	-	-	HYPH
cord-335140-njg0ln33	162	38	Managed	manage	VBN
cord-335140-njg0ln33	162	39	Multiple	Multiple	NNP
cord-335140-njg0ln33	162	40	Myeloma	Myeloma	NNP
cord-335140-njg0ln33	162	41	Clinic	Clinic	NNP
cord-335140-njg0ln33	162	42	Improves	improve	VBZ
cord-335140-njg0ln33	162	43	Guideline	Guideline	NNP
cord-335140-njg0ln33	162	44	Adherence	Adherence	NNP
cord-335140-njg0ln33	162	45	and	and	CC
cord-335140-njg0ln33	162	46	Prevents	prevent	VBZ
cord-335140-njg0ln33	162	47	Treatment	treatment	NN
cord-335140-njg0ln33	162	48	Delays	delay	NNS
cord-335140-njg0ln33	162	49	Lean	lean	JJ
cord-335140-njg0ln33	162	50	oncology	oncology	NN
cord-335140-njg0ln33	162	51	:	:	:
cord-335140-njg0ln33	163	1	a	a	DT
cord-335140-njg0ln33	163	2	new	new	JJ
cord-335140-njg0ln33	163	3	model	model	NN
cord-335140-njg0ln33	163	4	for	for	IN
cord-335140-njg0ln33	163	5	oncologists	oncologist	NNS
cord-335140-njg0ln33	163	6	Technology	Technology	NNP
cord-335140-njg0ln33	163	7	integration	integration	NN
cord-335140-njg0ln33	163	8	performance	performance	NN
cord-335140-njg0ln33	163	9	assessment	assessment	NN
cord-335140-njg0ln33	163	10	using	use	VBG
cord-335140-njg0ln33	163	11	lean	lean	JJ
cord-335140-njg0ln33	163	12	principles	principle	NNS
cord-335140-njg0ln33	163	13	in	in	IN
cord-335140-njg0ln33	163	14	health	health	NN
cord-335140-njg0ln33	163	15	care	care	NN
cord-335140-njg0ln33	164	1	No	no	DT
cord-335140-njg0ln33	164	2	cure	cure	NN
cord-335140-njg0ln33	164	3	,	,	,
cord-335140-njg0ln33	164	4	no	no	DT
cord-335140-njg0ln33	164	5	cost	cost	NN
cord-335140-njg0ln33	164	6	Financial	financial	JJ
cord-335140-njg0ln33	164	7	toxicity	toxicity	NN
cord-335140-njg0ln33	164	8	in	in	IN
cord-335140-njg0ln33	164	9	insured	insure	VBN
cord-335140-njg0ln33	164	10	patients	patient	NNS
cord-335140-njg0ln33	164	11	with	with	IN
cord-335140-njg0ln33	164	12	multiple	multiple	JJ
cord-335140-njg0ln33	164	13	myeloma	myeloma	NN
cord-335140-njg0ln33	164	14	:	:	:
cord-335140-njg0ln33	164	15	a	a	DT
cord-335140-njg0ln33	164	16	cross	cross	JJ
cord-335140-njg0ln33	164	17	-	-	JJ
cord-335140-njg0ln33	164	18	sectional	sectional	JJ
cord-335140-njg0ln33	164	19	pilot	pilot	NN
cord-335140-njg0ln33	164	20	study	study	NN
cord-335140-njg0ln33	164	21	.	.	.
cord-335140-njg0ln33	165	1	The	the	DT
cord-335140-njg0ln33	165	2	Lancet	Lancet	NNP
cord-335140-njg0ln33	165	3	Haematology	Haematology	NNP
cord-335140-njg0ln33	165	4	Realigning	realign	VBG
cord-335140-njg0ln33	165	5	Incentives	incentive	NNS
cord-335140-njg0ln33	165	6	for	for	IN
cord-335140-njg0ln33	165	7	Developing	develop	VBG
cord-335140-njg0ln33	165	8	and	and	CC
cord-335140-njg0ln33	165	9	Pricing	price	VBG
cord-335140-njg0ln33	165	10	New	New	NNP
cord-335140-njg0ln33	165	11	Anticancer	Anticancer	NNP
cord-335140-njg0ln33	165	12	Treatments	Treatments	NNPS
cord-335140-njg0ln33	165	13	Controlling	control	VBG
cord-335140-njg0ln33	165	14	the	the	DT
cord-335140-njg0ln33	165	15	cost	cost	NN
cord-335140-njg0ln33	165	16	of	of	IN
cord-335140-njg0ln33	165	17	innovative	innovative	JJ
cord-335140-njg0ln33	165	18	cancer	cancer	NN
cord-335140-njg0ln33	165	19	therapeutics	therapeutic	NNS
cord-335140-njg0ln33	165	20	Accepted	Accepted	NNP
cord-335140-njg0ln33	165	21	Article	Article	NNP
cord-335140-njg0ln33	165	22	This	this	DT
cord-335140-njg0ln33	165	23	article	article	NN
cord-335140-njg0ln33	165	24	is	be	VBZ
cord-335140-njg0ln33	165	25	protected	protect	VBN
cord-335140-njg0ln33	165	26	by	by	IN
cord-335140-njg0ln33	165	27	copyright	copyright	NN
cord-335140-njg0ln33	165	28	.	.	.
cord-335140-njg0ln33	166	1	All	all	DT
cord-335140-njg0ln33	166	2	rights	right	NNS
cord-335140-njg0ln33	166	3	reserved	reserve	VBD
cord-335140-njg0ln33	166	4	75	75	CD
cord-335140-njg0ln33	166	5	A	a	DT
cord-335140-njg0ln33	166	6	global	global	JJ
cord-335140-njg0ln33	166	7	comparison	comparison	NN
cord-335140-njg0ln33	166	8	of	of	IN
cord-335140-njg0ln33	166	9	the	the	DT
cord-335140-njg0ln33	166	10	cost	cost	NN
cord-335140-njg0ln33	166	11	of	of	IN
cord-335140-njg0ln33	166	12	patented	patent	VBN
cord-335140-njg0ln33	166	13	cancer	cancer	NN
cord-335140-njg0ln33	166	14	drugs	drug	NNS
cord-335140-njg0ln33	166	15	in	in	IN
cord-335140-njg0ln33	166	16	relation	relation	NN
cord-335140-njg0ln33	166	17	to	to	IN
cord-335140-njg0ln33	166	18	global	global	JJ
cord-335140-njg0ln33	166	19	differences	difference	NNS
cord-335140-njg0ln33	166	20	in	in	IN
cord-335140-njg0ln33	166	21	wealth	wealth	NN
cord-335140-njg0ln33	167	1	Ciara	Ciara	NNP
cord-335140-njg0ln33	167	2	L	L	NNP
cord-335140-njg0ln33	167	3	Freeman	Freeman	NNP
cord-335140-njg0ln33	167	4	performed	perform	VBD
cord-335140-njg0ln33	167	5	the	the	DT
cord-335140-njg0ln33	167	6	literature	literature	NN
cord-335140-njg0ln33	167	7	search	search	NN
cord-335140-njg0ln33	167	8	,	,	,
cord-335140-njg0ln33	167	9	data	datum	NNS
cord-335140-njg0ln33	167	10	collection	collection	NN
cord-335140-njg0ln33	167	11	and	and	CC
cord-335140-njg0ln33	167	12	wrote	write	VBD
cord-335140-njg0ln33	167	13	the	the	DT
cord-335140-njg0ln33	167	14	manuscript	manuscript	NN
cord-335140-njg0ln33	167	15	Joseph	Joseph	NNP
cord-335140-njg0ln33	167	16	Mikhael	Mikhael	NNP
cord-335140-njg0ln33	167	17	reviewed	review	VBD
cord-335140-njg0ln33	167	18	and	and	CC
cord-335140-njg0ln33	167	19	wrote	write	VBD
cord-335140-njg0ln33	167	20	the	the	DT
cord-335140-njg0ln33	167	21	manuscript	manuscript	NN
cord-335140-njg0ln33	167	22	.	.	.
cord-335140-njg0ln33	168	1	Conflict	conflict	NN
cord-335140-njg0ln33	168	2	of	of	IN
cord-335140-njg0ln33	168	3	Interest	interest	NN
cord-335140-njg0ln33	168	4	Disclosures	disclosure	NNS
cord-335140-njg0ln33	168	5	:	:	:
cord-335140-njg0ln33	168	6	Freeman	freeman	NN
cord-335140-njg0ln33	168	7	:	:	:
cord-335140-njg0ln33	168	8	Honoraria	Honoraria	NNP
cord-335140-njg0ln33	168	9	from	from	IN
cord-335140-njg0ln33	168	10	Seattle	Seattle	NNP
cord-335140-njg0ln33	168	11	Genetics	Genetics	NNP
cord-335140-njg0ln33	168	12	,	,	,
cord-335140-njg0ln33	168	13	Janssen	Janssen	NNP
cord-335140-njg0ln33	168	14	,	,	,
cord-335140-njg0ln33	168	15	Amgen	Amgen	NNP
cord-335140-njg0ln33	168	16	,	,	,
cord-335140-njg0ln33	168	17	Celgene	Celgene	NNP
cord-335140-njg0ln33	168	18	and	and	CC
cord-335140-njg0ln33	168	19	Abbvie	Abbvie	NNP
cord-335140-njg0ln33	168	20	,	,	,
cord-335140-njg0ln33	168	21	and	and	CC
cord-335140-njg0ln33	168	22	research	research	NN
cord-335140-njg0ln33	168	23	funding	funding	NN
cord-335140-njg0ln33	168	24	from	from	IN
cord-335140-njg0ln33	168	25	Roche	Roche	NNP
cord-335140-njg0ln33	168	26	and	and	CC
cord-335140-njg0ln33	168	27	Teva	Teva	NNP